

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3132034 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **C 12 N 15/09 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2020-10-19**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-08-19**
- (86) Europæisk ansøgning nr.: **15718982.0**
- (86) Europæisk indleveringsdag: **2015-04-14**
- (87) Den europæiske ansøgnings publiceringsdag: **2017-02-22**
- (86) International ansøgning nr.: **GB2015051132**
- (87) Internationalt publikationsnr.: **WO2015159068**
- (30) Prioritet: **2014-04-14 GB 201406674** **2014-08-01 GB 201413719**
2014-10-17 GB 201418508
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Nemesis Bioscience Ltd., First Floor 12 St Johns Way , St Johns Business Estate , Downham Market , Norfolk, PE38 0QQ, Storbritannien**
- (72) Opfinder: **MIKAWA, Yoshikazu, c/o Nemesis Bioscience Ltd, First Floor, 12 St Johns Way, St Johns Business Estate, Downham Market, Norfolk PE38 0QQ, Storbritannien**
LICHTENSTEIN, Conrad, c/o Nemesis Bioscience Ltd, First Floor, 12 St Johns Way, St Johns Business Estate, Downham Market, Norfolk PE38 0QQ, Storbritannien
- (74) Fuldmægtig i Danmark: **Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S, Danmark**
- (54) Benævnelse: **Terapeutikum**
- (56) Fremdragne publikationer:
WO-A2-2010/075424
Huang: "E. curi: A way of deactivating antibiotic resistance genes in E. coli", , 1 April 2012 (2012-04-01), XP002742963, Retrieved from the Internet: URL:http://uscusj.weebly.com/uploads/4/9/5/1/4951238/jonathan__usj__v3.pdf [retrieved on 2015-08-03]
CITORI K ROBERT J ET AL: "Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases", NATURE BIOTECHNOLOGY, vol. 32, no. 11, 1 November 2014 (2014-11-01), pages 1141-1145+2PP, XP002742964,
BIKARD DAVID ET AL: "Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials", NATURE BIOTECHNOLOGY, vol. 32, no. 11, November 2014 (2014-11), pages 1146-1150, XP002742966,
YOSEF IDO ET AL: "Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 112, no. 23, 9 June 2015 (2015-06-09) , pages 7267-7272, XP002742965, ISSN: 1091-6490

DESCRIPTION

[0001] The invention relates to recombinant polynucleotides, compositions and methods for interfering with antibiotic resistance genes, and/or replicons carrying such genes, in microorganisms in order to disable antibiotic resistance in the microorganisms.

[0002] Antibiotics, originally isolated from microorganisms such as *Streptomyces*, are a powerful way to treat infectious disease. However, very quickly bacteria acquired anti-microbial resistance (AMR) to antibiotics in response to selection pressure. One common route to AMR has been the acquisition of resistance genes evolved in the original antibiotic-producing microorganisms, via horizontal transmission on plasmid vectors. Such plasmids have in some instances acquired multiple antibiotic resistance genes carried by transposable elements and integrons. Host-encoded mutations that modify the bacterial protein target or prevent entry of the antibiotic have also occurred.

[0003] Resistance to antibiotics by microorganisms such as bacterial pathogens is one of our most serious health threats. Infections from resistant bacteria, for example, are now not uncommon, and some pathogens have even become resistant to multiple types or classes of antibiotics. The loss of effective antibiotics undermines our ability to fight infectious diseases and manage the infectious complications common in vulnerable patients, for example those undergoing chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ transplantation, for which the ability to treat secondary infections is critical.

[0004] When first-line and second-line treatment options are limited by antibiotic resistance or are unavailable, healthcare providers are forced to use alternative antibiotics that may be more toxic to the patient, more expensive and less effective. Even when alternative treatments exist, patients with resistant infections are often more likely to die, while survivors may have significantly longer hospital stays, delayed recuperation, and long-term disability.

[0005] Many achievements of modern medicine are put at risk by AMR. Without effective antibiotics for care and prevention of infections, the success of treatments such as organ transplantation, cancer chemotherapy and major surgery would be compromised.

The growth of global trade and travel allows antibiotic resistant microorganisms to be spread rapidly through humans, other animals, and food.

[0006] Resistance mechanisms fall into four classes:

1. (1) enzymes that degrade antibiotics, including beta-lactamases that break the beta-lactam ring of the penicillin family of antibiotics;
2. (2) enzymes that modify antibiotics include aminoglycoside phosphotransferases that phosphorylate aminoglycoside antibiotics such as kanamycin; chloramphenicol acetyl-transferase (CAT) that acetylate chloramphenicol;
3. (3) efflux pumps that actively export antibiotics from cytoplasm out of the cell, such as the tetracycline efflux pump that is expressed in the presence of tetracycline, plus other pumps, conferring multidrug resistance, that are capable of exporting a range of antibiotics; and
4. (4) mutations that change the protein target of the antibiotic such that it is no longer inactivated by it; for example, beta-lactams are bactericidal because they inhibit penicillin-binding proteins (PBPs) that are required for peptidoglycan biosynthesis and bacterial cell wall integrity and PBP mutants with reduced binding to beta-lactams will not be inhibited.

[0007] Several approaches are currently being used or developed to address the problem of antibiotic resistance, including the following.

[0008] Firstly, new antibiotics, such as derivatives of existing drugs, have been developed. Fewer new antibiotic drugs have been developed, and many are more toxic so are used in the last resort. Microorganisms have acquired resistance to new antibiotics of both types.

[0009] Secondly, direct inhibition of resistance enzymes has been attempted. Examples include clavulanic acid, a beta-

lactamase inhibitor which is used in combination with amoxycillin, a beta-lactam antibiotic (also called Augmentin). Other beta-lactamase antibiotic inhibitors include the carbapenems. But even here resistance has appeared. Blueberry Therapeutics and Avacta are developing peptide affimers to target mechanisms of resistance. Development of new inhibitors of antibiotic resistance enzymes requires a long pipeline of drug development. An alternative approach has been adopted by Dr Eric Brown at McMaster University, Canada, who is screening known drugs (already approved for use) with unrelated targets, for cryptic activity in inactivating antibody resistance mechanisms.

[0010] Thirdly, non-antibiotic bactericides have been used. For example, infection by bacteriophage was developed in the 1920's and although largely discontinued with the discovery of antibiotics, has been retained in certain countries. Current approaches use virulent, lytic bacteriophage that kill bacteria, including antibiotic resistant bacteria, but this opens the way for selection of bacterial variants that are resistant to bacteriophage infection. To obviate this, preparations containing a mixture of different strains of bacteriophage are being used. Another disadvantage of the use of such lytic bacteriophage in patients suffering from sepsis is that cell lysis and death by lytic bacteriophage can release endotoxins from the cell into the blood and can cause endotoxin shock.

[0011] Further compositions and methods for combating antibiotic resistant microorganisms are required.

[0012] According to an aspect of the present invention, there is provided a delivery vehicle for introducing a polynucleotide into an antibiotic-resistant microorganism, wherein the delivery vehicle is selected from the group consisting of a plasmid (such as a conjugative plasmid or other plasmid replicon), a nucleotide vector, linear double-stranded DNA, a non-virulent bacteriophage and a lysogenic bacteriophage, and comprises a recombinant polynucleotide for inactivation of DNA carrying at least one antibiotic resistance gene encoding an enzyme which confers antibiotic resistance to a microorganism, wherein the recombinant polynucleotide comprises a clustered regularly interspaced short palindromic repeat (CRISPR) array nucleic acid sequence having or transcribing multiple RNA guide molecules, wherein each RNA guide molecule:

1. (i) is transcribed from its own promoter sequence;
2. (ii) mediates the binding of a CRISPR associated (Cas) DNA-binding polypeptide or its functional equivalent or its modified version thereof to the at least one antibiotic resistance gene(s); and
3. (iii) has a spacer sequence sufficiently complementary to a target DNA sequence of the at least one antibiotic resistance gene for the at least one antibiotic resistance gene to be targeted and inactivated in the presence of a CRISPR associated (Cas) DNA-binding polypeptide or a functional equivalent or a modified version thereof, and wherein:

either the Cas DNA-binding polypeptide or a functional equivalent or a modified version thereof is a modified Cas DNA-binding polypeptide which creates a deletion and reseals the target DNA sequence to inactivate the at least one antibiotic resistance gene to prevent double-strand break (DSB)-induced killing of the microorganism, such that the microorganism becomes sensitised to an antibiotic, or

the Cas DNA-binding polypeptide or a functional equivalent or a modified version thereof creates a DSB in the target DNA sequence to inactivate the at least one antibiotic resistance gene, and the delivery vehicle further comprises a nucleotide sequence encoding a gene product which prevents direct killing of the microorganism due to the generation of the DSB in the at least one antibiotic resistance gene, such that the microorganism becomes sensitised to an antibiotic.

[0013] The delivery vehicle of the invention may further comprise a nucleic acid sequence which encodes the Cas DNA-binding polypeptide or its functional equivalent or its modified version.

[0014] The Cas DNA-binding polypeptide may be Cas9 or a functional equivalent or a modified version thereof.

[0015] The delivery vehicle of the invention may comprise a further RNA guide molecule which targets a gene involved in pathogenicity or other aspects of microbial metabolism, for example a gene involved in bacterial metabolism for biofilm production.

[0016] The modified Cas DNA-binding polypeptide may comprise a recombinase catalytic domain to reseal target DNA

sequence.

[0017] The gene product that prevents direct killing of the microorganism may be a protein encoded by a replicon subject to degradation due to the DSB caused by the Cas DNA-binding polypeptide, or an antitoxin that neutralises the effect of a toxin or killer function carried by a replicon on which the target DNA sequence is located.

[0018] The CRISPR array nucleic acid sequence may have or transcribe one or more RNA guide molecules each comprising a spacer sequence sufficiently complementary to a target sequence of one or more beta-lactamase genes, for example one or more or all of the genes selected from the group consisting of : NDM, VIM, IMP, KPC, OXA, TEM, SHV, CTX, OKP, LEN, GES, MIR, ACT, ACC, CMY, LAT, and FOX.

[0019] Another aspect of the invention is a composition comprising the delivery vehicle as defined herein.

[0020] The composition may be a pharmaceutical composition, a non-pathogenic microorganism such as a commensal bacterium for example in a probiotic formulation, or a dietary supplement. The composition may be formulated for topical, enteral or parenteral administration.

[0021] A further aspect of the invention is a composition as defined herein for use as a medicament.

[0022] Also provided according to the invention is a composition as defined herein for use in the treatment or prevention of an infection caused by an antibiotic-resistant microorganism comprising one or more antibiotic resistance genes targeted by the RNA guide molecules of the recombinant polynucleotide.

[0023] Further provided according to the invention a method of inactivating antibiotic resistance in an antibiotic-resistant microorganism, the method comprising introducing into the microorganism the delivery vehicle as defined herein.

[0024] Another aspect of the invention provides a host cell comprising the recombinant polynucleotide as defined herein. The host cell may be a commensal bacterium.

[0025] The present application discloses a recombinant polynucleotide comprising a clustered regularly interspaced short palindromic repeat (CRISPR) array nucleic acid sequence having or transcribing an RNA guide molecule with a spacer sequence sufficiently complementary to a target sequence of an antibiotic resistance gene in a microorganism for the antibiotic resistance gene to be inactivated in the presence of a CRISPR associated (Cas) DNA-binding polypeptide or a functional equivalent or a modified version thereof, thereby sensitising the microorganism to the antibiotic.

[0026] Also disclosed is a delivery vehicle for introducing a polynucleotide into a microorganism, such as an antibiotic-resistant microorganism, in which the delivery vehicle comprises a recombinant polynucleotide for inactivation of DNA carrying a gene encoding an antibiotic resistance enzyme which confers antibiotic resistance to the microorganism, and in which the recombinant polynucleotide comprises a clustered regularly interspaced short palindromic repeat (CRISPR) array nucleic acid sequence having or transcribing an RNA guide molecule with a spacer sequence sufficiently complementary to a target DNA sequence of the antibiotic resistance gene for the antibiotic resistance gene to be targeted and inactivated in the presence of a CRISPR associated (Cas) DNA-binding polypeptide or a functional equivalent or a modified version thereof, thereby sensitising the microorganism to the antibiotic, wherein the delivery vehicle is a non-virulent or a lysogenic bacteriophage.

[0027] One general aim of the present invention is inactivation of DNA carrying a gene encoding an antibiotic resistance enzyme using a CRISPR/Cas system. An advantage of the invention is that one or more existing antibiotics can be used to treat infectious disease, as microorganisms become re-sensitised to the antibiotics or are prevented from acquiring antibiotic resistance.

[0028] The target sequence of an antibiotic resistance gene may be a sequence flanking the gene itself which, if disrupted, inactivates the antibiotic resistance gene. For example, if the antibiotic resistance gene is located on a plasmid, the invention may encompass a target sequence in the plasmid.

[0029] In contrast to prior art approaches of inactivating antibiotic resistance enzymes, the present invention will not require new drug development and the concomitant regulatory approval required for each new drug. Rather, the

invention provides a tool which can be applied to target and inactivate relevant antibiotic resistance genes directly rather than the gene products. For example, a gene encoding an antibiotic resistance enzyme, or a gene encoding a protein regulating the uptake and export of an antibiotic by altering the membrane permeability and efflux pump expression, respectively, can be targeted.

[0030] The CRISPR/Cas system is an RNA-mediated genome defense pathway that is part of a natural bacterial and archaeal immune system against nucleic acid invaders, analogous to the eukaryotic RNAi pathway (see for example Grissa et al., 2007, BMC Informatics 8: 172; Horvath & Barrangou, 2010, Science, 327: 167-170; Gasiunas et al., 2012, Proc. Natl Acad. Sci. USA 109: E2579; Marraffini & Sontheimer, 2008, Science, 322: 1843-1845; Garneau et al., 2010, Nature 468: 67). Natural CRISPR systems contain a combination of Cas genes as well as non-coding RNA elements capable of programming the specificity of the CRISPR-mediated nucleic acid cleavage. Three types (I-III) of CRISPR systems have been identified thus far in a wide range of bacterial and archaeal hosts. Each CRISPR locus is composed of a series of short DNA direct repeats separated by non-repetitive spacer sequences. The spacer sequences, in nature, typically originate from foreign genetic elements such as bacteriophage and plasmids. As used herein, the series of repeats plus non-repetitive spacer sequences is known as a CRISPR array. The CRISPR array is transcribed and hybridised with repeat complementary tracrRNA followed by cleavage within the direct repeats and processed into short mature dual tracrRNA:crRNAs containing individual spacer sequences, which direct Cas nucleases to a target site (also known as a "protospacer"). For example, the Type II CRISPR/Cas9 system, a well-studied example, carries out a targeted DNA double-strand break ("DSB") in four steps. Firstly, two RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Secondly, tracrRNA hybridises to the repeat regions of the pre-crRNA and mediates the processing of pre-crRNA into mature crRNAs (also referred to herein as "RNA guide molecules gRNA" containing individual or monomer spacer sequences. Thirdly, the mature crRNA:tracrRNA complex directs Cas9 protein in the form of a ribonucleoprotein to the target DNA via base-pairing between the spacer on the crRNA and the target site on the target DNA. Finally, Cas9 mediates cleavage of target DNA and creates a DSB.

[0031] In the present invention, as elaborated herein, modified CRISPR constructs are used to target antibiotic resistance genes. The recombinant polynucleotide of the invention using such a construct is also referred to herein as an "assassin construct" which is used to effect inactivation of such genes.

[0032] The main focus of using CRISPR technology to date has been for use as a DNA editing tool for reverse genetics, primarily in eukaryotes. However, WO2007/025097 describes the use of CRISPR technology for modulating resistance in a cell against an invading target nucleic acid or a transcription product thereof, especially against invading bacteriophages. Methods for downregulating prokaryotic gene expression using CRISPR technology to target mRNA transcribed by the genes have been suggested for example in WO2010/075424. WO2012/164565 describes a CRISPR system from *Lactococcus* and use of the system for modulating resistance of a cell against an invading target nucleic acid or a transcription product thereof. The present invention, by contrast, concerns *inter alia* inactivation in an antibiotic-resistant microorganism of genes involved in conferring the antibiotic resistance.

[0033] According to the invention, the RNA guide molecule mediates binding of the Cas DNA-binding polypeptide or its functional equivalent or its modified version to the antibiotic resistance gene. This mirrors the natural system described above.

[0034] The Cas DNA-binding polypeptide or its functional equivalent or its modified version may also be capable of binding to RNA or other nucleic acid molecules. In other words, the requirement for the Cas DNA-binding polypeptide or its functional equivalent or its modified version to be capable of binding DNA does not exclude the polypeptide or its functional equivalent or its modified version being capable of binding RNA or other nucleic acid molecules. The Cas DNA-binding polypeptide or its functional equivalent or its modified version may be referred to as a Cas nucleic acid-binding polypeptide or its functional equivalent or its modified version.

[0035] For certain applications, the microorganism may have a natural endogenous, or introduced engineered, Cas DNA-binding polypeptide or functional equivalent or modified version. This means that the recombinant polynucleotide of the invention is not required to encode the Cas DNA-binding polypeptide or functional equivalent or modified version. Alternatively, the recombinant polynucleotide of the invention may further comprise a nucleic acid sequence which encodes the Cas DNA-binding polypeptide or its functional equivalent or modified version. In another aspect, the recombinant polynucleotide of the invention does not encode the Cas DNA-binding polypeptide or its functional equivalent or modified version but may be used in conjunction with a separate polynucleotide which does. Other means

for introducing the Cas DNA-binding polypeptide or its functional equivalent or its modified version into the microorganism may be used.

[0036] An exemplar Cas DNA-binding polypeptide according to the invention is Cas9 or a functional equivalent thereof or a modified version thereof.

[0037] In the recombinant polynucleotide according to various aspects of the invention, the CRISPR array nucleic acid sequence has or transcribes multiple RNA guide molecules each comprising a spacer sequence sufficiently complementary to a target sequence of the antibiotic resistance gene or one or more additional antibiotic resistance genes. The or each RNA guide molecule is transcribed from its own promoter sequence.

[0038] Having multiple RNA guide molecules allows different antibiotic resistance (or other types of) genes in a microorganism to be targeted and inactivated simultaneously.

[0039] The recombinant polynucleotide according to various aspects of the invention may additionally be designed to include an RNA guide molecule (such as a further RNA guide molecule) targeting a gene involved in pathogenicity or other aspects of microbial metabolism. For example, certain pathogens form biofilms that make it difficult for antibiotics to gain access to them. One or more genes involved in bacterial metabolism for biofilm production may be targeted.

[0040] Spacer sequence distal from a promoter are typically less efficiently transcribed. Ideally, multiple RNA guide molecules to different targets should be more or less equally represented. Thus, one promoter transcribing each RNA guide molecule is used (instead of relying on a long polycistronic RNA guide molecule [or precursor crRNA] transcription).

[0041] For example, there are many resistance genes encoding beta-lactamases (*bla* genes) giving resistance to a large range of different beta-lactam antibiotics. DNA constructs expressing multiple RNA guide molecules, which are each individually transcribed from their own such promoters, may be used to target a number of different *bla* genes.

[0042] Thus in aspects of the invention, the CRISPR array nucleic acid sequence may have or transcribe one or more RNA guide molecules each comprising a spacer sequence sufficiently complementary to a target sequence of one or more beta-lactamase genes.

[0043] For example, the one or more RNA guide molecules may target one or more or all of the genes selected from the group consisting of: NDM, VIM, IMP, KPC, OXA, TEM, SHV, CTX, OKP, LEN, GES, MIR, ACT, ACC, CMY, LAT, and FOX.

[0044] In particular, the one or more RNA guide molecules may comprise a spacer sequence sufficiently complementary to target sequences of the beta lactam family of antibiotic resistance genes, including one or more or all of the following: a first spacer sequence sufficiently complementary to target sequences for NDM-1, -2, -10; a second spacer sufficiently complementary to target sequences for VIM-1, -2, -4, -12, -19, -26, -27- 33, 34; a third spacer sufficiently complementary to target sequences for IMP-32, -38, -48; a fourth spacer sufficiently complementary to target sequences for KPC- 1, -2, -3, -4, -6, -7, -8,-11 , -12 , -14 , -15 , -16, -17; a fifth spacer sufficiently complementary to target sequences for OXA-48; a sixth spacer sufficiently complementary to target sequences for TEM-1,-1B, -3,-139, -162, -183, -192, -197, -198, -209, a seventh spacer sufficiently complementary to target sequences for SHV and its variants; and an eighth spacer sufficiently complementary to target sequences for CTX and its variants.

[0045] The antibiotic resistance gene to be inactivated may be located on a chromosome, or on an extrachromosomal replicating DNA molecule known as a replicon and including plasmids and bacteriophage.

[0046] The CRISPR/Cas system used according to an aspect of the invention generates a DSB in the target sequence. Where the target sequence is located on a chromosome or a replicon such as a bacterial chromosome or plasmid, then a DSB can lead to degradation and hence loss of the chromosome or replicon suffering such a DSB. If the target sequence is located on a bacterial chromosome then the cell may die directly as a consequence of the DSB. Additionally, some plasmids (including natural plasmids) carry killing functions that only become toxic if the cell loses the plasmid, which is a natural mechanism to ensure faithful inheritance of plasmids in dividing cells. If a plasmid carrying the target sequence of the antibiotic resistance gene also carries such a killing function, and the plasmid is lost as a result of the DSB generated, the cell may die (see Sengupta & Austin, 2011, Infect. Immun. 79: 2502-2509).

[0047] In the event that cell death caused by such DSB increases selection pressure for resistance against the recombinant polynucleotide according to various aspects of the present invention, this may be mitigated by, for example, employing a modified Cas DNA-binding polypeptide which seals the target site after generating a deletion to inactivate the target sequence of the antibiotic resistance gene, rather than generate a DSB.

[0048] Thus the Cas DNA-binding polypeptide according to various aspects of the invention may in certain aspects be substituted by a modified Cas DNA-binding polypeptide comprising a recombinase catalytic domain, wherein the modified Cas DNA-binding polypeptide does not generate DSBs but creates a deletion and reseals a site in the target sequence.

[0049] The modified Cas DNA-binding polypeptide may for example be a modified Cas9 protein comprising a recombinase catalytic domain.

[0050] The recombinant polynucleotide according to various aspects of the invention may further comprise a nucleotide sequence which encodes a gene conferring a selective advantage to the microorganism, for example thereby increasing the efficiency of delivery of the CRISPR/Cas system to the target microorganism. For example, the gene may confer a growth advantage over non-infected siblings, or genes encoding a bacteriocin - these are protein toxins produced by bacteria to kill or inhibit growth of other bacteria - and corresponding immunity polypeptide may be used.

[0051] The selective advantage to the microorganism may include or be one which prevents or diminishes the effect of loss of a replicon due to a DSB caused by Cas DNA-binding polypeptide. For example, the nucleotide sequence which encodes a gene conferring a selective advantage to the microorganism may encode an antitoxin that neutralises the effect of a toxin or killer function carried by a replicon on which the target sequence is located. Also, the nucleotide sequence which encodes a gene conferring a selective advantage to the microorganism may encode one or more proteins that are encoded by a replicon subject to degradation due to a DSB caused by Cas DNA-binding polypeptide.

[0052] In an aspect of the invention, there is provided a delivery vehicle for introducing a polynucleotide into a microorganism, in which the delivery vehicle comprises the recombinant polynucleotide as defined herein.

[0053] The delivery vehicle according to various some aspects of the invention may be a a non-virulent or a lysogenic bacteriophage. Alternatively, the delivery vehicle may be a plasmid such as a conjugative plasmid or other plasmid replicon, a nucleotide vector, or linear double-stranded DNA (dsDNA).

[0054] The delivery vehicle may be a non-virulent bacteriophage, such as bacteriophage M13, a filamentous phage that infects *Escherichia coli* cells, replicates and is secreted from the bacterial host cell without killing the bacterial host, which continues to grow and divide more slowly. Another suitable filamentous phage is NgoPhi6 isolated from *Neisseria gonorrhoeae* that is capable of infecting a variety of Gram negative bacteria without killing the host.

[0055] Alternatively, lysogenic phage may be used that do not always kills host cells following infection, but instead infect and become dormant prophage.

[0056] This invention may thus use a novel system to inactivate antibiotic resistance genes in bacteria primarily using bacteriophage that do not kill bacteria, and/or conjugative plasmids and/or direct DNA transformation, as the delivery mechanisms for the recombinant polynucleotide of the invention.

[0057] In a further aspect of the invention, there is provided a composition comprising the delivery vehicle as defined herein.

[0058] The composition may be a pharmaceutical composition, a non-pathogenic microorganism such as a commensal bacterium for example in a probiotic formulation, or a dietary supplement.

[0059] As used herein, a "pharmaceutical composition" refers to a preparation of one or more of the active agents (such the recombinant polynucleotide or the delivery vehicle as described herein) with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of the active agent to an organism.

[0060] The composition may be formulated for topical, enteral or parenteral administration.

[0061] Compositions of the present invention may, if desired, be presented in a pack, dispenser device or kit, each of which may contain one or more unit dosage forms containing the active agent(s). The pack, dispenser device or kit may be accompanied by instructions for administration.

[0062] Also provided according to the invention is the composition as defined herein for use as a medicament.

[0063] In another aspect there is provided according to the invention a composition as defined herein for use in the treatment or prevention of an infection caused by an antibiotic-resistant microorganism comprising an antibiotic resistance gene targeted by the RNA guide molecule of the recombinant polynucleotide.

[0064] Also disclosed is a method of treating or preventing an infection in a subject caused by an antibiotic-resistant microorganism comprising an antibiotic resistance gene, in which the method comprises the step of introducing into the microorganism a therapeutically effective amount of the composition as defined herein where the RNA guide molecule targets the antibiotic resistance gene, thereby inactivating the antibiotic resistance gene and sensitising the microorganism to the antibiotic.

[0065] The composition may be administered topically or orally. Alternatively the composition may be administered by intravenous, parenteral, ophthalmic or pulmonary administration.

[0066] Compositions of the present invention for administration topically can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion or dusting powder.

[0067] Compositions provided herein may be formulated for administration by inhalation. For example, the compositions may be in a form as an aerosol, a mist or a powder. Thus compositions described herein may be delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant such as for example dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. Where using a pressurised aerosol, a dosage unit may be determined by providing a valve to deliver a metered amount.

[0068] In the disclosed method, the subject may be a plant, a fish, a bird, a reptile or a mammal (such as a human).

[0069] According to the disclosed method, the delivery vehicle may be transferred from the microorganism directly into another microorganism (such as antibiotic-resistant microorganism) by plasmid conjugation or bacteriophage infection.

[0070] The disclosed method may further comprise a step of simultaneously or subsequently administering to the subject an antibiotic to which a microorganism has become sensitised.

[0071] A further aspect of the invention provides a method of inactivating antibiotic resistance in a microorganism, the method comprising introducing into the microorganism of the delivery vehicle as defined herein.

[0072] Also provided according to the invention is a host cell comprising the recombinant polynucleotide defined here. The host cell may, for example, be a commensal bacterium.

[0073] Microorganisms targeted by various aspects of the invention may be on a body surface, localised (for example, contained within an organ, at a site of a surgical wound or other wound, within an abscess), or may be systemic. Included is the treatment of bacterial infections that are amenable to therapy by topical application for example using bacteriophage of the invention.

[0074] The present disclosure also encompasses coating of surfaces other than body surfaces with the recombinant polynucleotide, delivery vehicle or composition of the present invention, for example wound dressings or medical device surfaces.

[0075] Further aspects, features and non-limiting embodiments of the present invention will now be described below with

reference to the following drawings:

Figure 1. CRISPR/Cas9-mediated bacterial immunisation against antibiotic resistant genes on a plasmid: I, CRISPR/Cas locus, where boxes denote different spacer sequences targeting different antibiotic resistance genes; II, gRNA-Cas9 where boxes denote different gRNAs targeting each antibiotic resistance gene; III, plasmid harbouring antibiotic resistance gene; IV, target recognition and positioning of Cas9; V, cleaved plasmid, VI: bacteriophage. **Ap^R** = ampicillin resistant, **Cm^R** = chloramphenicol resistant, **Km^R** = kanamycin resistant. **Ap^S** = ampicillin sensitive, **Cm^S** = chloramphenicol sensitive, **Km^S** = kanamycin sensitive. **Bla**= beta-lactamase, **CAT** = chloramphenicol acetyl transferase, **APH** = aminoglycoside phosphotransferase. **1. Injection** - CRISPR/Cas9 is injected into the bacterial cell along with phage DNA by bacteria-specific phage infection. **2. Lysogenisation** - Phage DNA is lysogenised and integrates into the bacterial host chromosome (**B. chr.**). **3. crRNA biogenesis and assembly of Cas9** - Pre-crRNA is transcribed and hybridised with tracrRNA and processed to make mature crRNA:tracrRNA (an RNA guide molecule, or "gRNA"), which is assembled with Cas9. **4. Recognition** - These gRNA-Cas9 complexes recognise target DNA on the plasmid. **5. Cleavage** - The gRNA-Cas9 complexes cleave DNA at the sites recognised by crRNAs. **6. Inactivation** - This leads to inactivation of the production of antibiotic resistant enzymes; **7. Sensitive** - Thus, the bacterial cell becomes sensitive to various antibiotics.

Figure 2. Preventing non-pathogenic bacteria and asymptomatic pathogens from a future encounter with antibiotic resistance genes: I, CRISPR/Cas locus, exemplified here as present in the bacterial chromosome (**B. Chr.**) and where boxes denote different spacer sequences targeting different antibiotic resistance genes; II, gRNA-Cas9, where boxes denote different gRNAs targeting each antibiotic resistance gene; III, relaxase -an enzyme that makes a strand-specific, sequence-specific nick in double-stranded DNA to initiate conjugal transfer of plasmid DNA; IV, bacteriophage, V, plasmid; VI, double-stranded DNA; VII, single-stranded DNA. Three entry pathways to encounter future antibiotic resistance genes are shown. **1. Transformation**- Entry of naked DNA carrying antibiotic resistance gene into the bacterial cell, **2. Bacteriophage-mediated transduction**- Phage carrying antibiotic resistance gene infects a bacterial cell. **3 Conjugation**- Plasmid carrying antibiotic resistance gene is conjugally transferred from a donor bacterial cell to a recipient bacterial cell. When these antibiotic resistance genes are introduced into the "immunised" cell; it is pre-armed with a CRISPR/Cas locus encoding a gRNA-Cas9 that finds the specific target sequence on the antibiotic resistance gene and cleaves it to disrupt the gene.

Figure 3. Re-sensitising symptomatic pathogens to antibiotics: I, CRISPR/Cas locus in the bacterial chromosome (**B. Chr.**), where boxes denote different spacer sequences targeting each antibiotic resistance gene; II, gRNA-Cas9, where boxes denote different gRNAs targeting each antibiotic resistance gene; III, antibiotics; IV, protein synthesis is disrupted by cleaving corresponding gene; V, plasmid. This figure shows an asymptomatic pathogen becoming symptomatic because of an opportunistic infection. The pathogen contains plasmid DNA that provides various antibiotic resistance agents such as **1. Efflux pumps**- capable of pumping antibiotics out of the bacterial cell, **2 Antibiotic degradation enzymes**-and **3. Antibiotic modification enzymes**. Each antibiotic resistant agent is disrupted (X) by gRNA-Cas9-mediated site-specific cleavage of corresponding genes.

Figure 4. Three possible CRISPR/Cas delivery routes: I, CRISPR/Cas locus where boxes denote different spacer sequences targeting each antibiotic resistance gene; II, relaxase -an enzyme that makes a strand-specific, sequence-specific nick in double-stranded DNA to initiate conjugal transfer of plasmid DNA; III, bacteriophage; IV, plasmid; V, double-stranded DNA; VI, single-stranded DNA. This figure shows three possible delivery routes of CRISPR/Cas9 expression construct. **1. Transformation**- Entry of naked DNA carrying CRISPR/Cas9 into the bacterial cell via a DNA receptor on the cell surface, followed by integration (4) into the bacterial chromosome (**B. Chr.**), **2. Bacteriophage-mediated transduction**- Phage carrying CRISPR/Cas9 infects a bacterial cell, followed by circularisation (5) and then phage-mediated integration (4) into the bacterial chromosome (**B. Chr.**). **3 Conjugation**- Plasmid carrying CRISPR/Cas9 is conjugally transferred from a donor bacterial cell to a recipient bacterial cell, followed by circularisation (5) and plasmid replication. In all cases, boxes in the CRISPR/Cas9 locus denote different spacer sequences targeting each antibiotic resistance gene.

Figure 5. Structure of bidirectional antibiotic resistant transmission model (see also Am J Epidemiol. 2013;178(4):508-520) and the effect of antibiotic resistance gene inactivation therapy: A, Antibiotic Resistance is Dominant; B, Antibiotic Sensitivity is Dominant; S, Susceptible, AS, Antibiotic Sensitive; AR, Antibiotic Resistant; T, Transmission; R, Recovery, C, Conversion, CCD, CRISPR/Cas9 delivery. Antibiotic resistance genes in an antibiotic resistant state and the encounter of antibiotic resistance genes in a sensitive state are disrupted for example by gRNA-mediated Cas9 cleavage. Antibiotic resistance gene inactivation therapy converts the bidirectional model (A) to an

almost unidirectional conversion model (B) by increasing the conversion rate from antibiotic resistant to sensitive and decreasing the conversion rate from antibiotic sensitive to resistant. The area of each square represents the population density of each state. The width of the arrows is proportional to the magnitude of each parameter (transmission, recovery and conversion), i.e. transmission of antibiotic resistant bacteria is assumed to be higher than antibiotic sensitive bacteria in this figure. Recovery from the infection of pathogens sensitive to antibiotics is higher than for antibiotic resistant pathogens. In the presence of antibiotics, antibiotic-sensitive pathogens are converted to antibiotic resistant pathogens much more than the reverse conversion from resistant to sensitive pathogens because of the selection pressure. The treatment aim is to reverse these conversion parameters to drive the antibiotic resistant pathogen population to a sensitive state by introducing CRISPR/Cas9 into the bacteria.

Figure 6. Structure of superinfection antibiotic resistant transmission model and the effect of antibiotic resistance gene inactivation therapy: The bidirectional antibiotic resistance transmission model depicted in Figure 5 can additionally or alternatively be described by the following superinfection antibiotic resistance transmission model (see also Am J Epidemiol. 2013;178(4):508-520, as for Figure 5). When the antibiotic resistance genes are disrupted for example by gRNA-mediated Cas9 cleavage, this allows the population shift from the antibiotic resistant state to the antibiotic sensitive state via the superinfection state. Disruption of antibiotic resistance genes increases the conversion rate from the antibiotic resistant to the sensitive state. This figure gives a comparison of the relative population density before (Figure 6A) and after (Figure 6B) applying the CRISPR-Cas system. The population is composed of **S**, Susceptible; **lw**, sensitive; **lz**, resistant; and **lwz**, superinfection state. The area of each circle is proportional to the relative population density in each state. In this simulation, initial density in each state is assumed to be identical (0.25 each, represented by a thin-lined circle). Thick lined circles represent the population density at the equilibrium state. CRISPR-Cas system is clearly contributing to an increase of the population in the susceptible state, thus the recovery rate in the equilibrium state (i.e. **S** is expanding in **B**) and to reduce the population in the resistant state (i.e. **lz** is shrinking in **B**). The width of the arrows is proportional to the magnitude of each parameter (infection, recovery and state conversion), i.e. the infection of antibiotic resistant bacteria is assumed to be lower than that of antibiotic sensitive bacteria in this figure. Recovery from the infection of the antibiotic sensitive pathogens is higher than that from the infection of the antibiotic resistant pathogens, because antibiotics are effective on the sensitive strains. In the presence of antibiotics, the antibiotic sensitive pathogens are converted to the antibiotic resistant pathogens much more than the reverse conversion because of the antibiotic selection pressure. The aim of the treatment is to reverse these conversion parameters and to drive the antibiotic resistant pathogen population to the sensitive state.

Figure 7. Structure of CRISPR locus: This figure shows CRISPR locus containing six spacers targeting six different regions. Each crRNA is transcribed monocistronically from the same promoters denoted **P** to control the transcription level identical for each target. Each crRNA transcript starts with a leader sequence **L** and terminates with a terminator sequence **T**. Transcripts of each pre-crRNA are shown as arrows and boxes containing different spacer sequences are indicated by unique shading.

Figure 8. Mapping short bacterial off-target sequence on the *bla* gene sequence. The figure shows the local alignment of bacterial short sequences (SEQ ID NOs: 3-5, 8-14, 17-23 and 26-33) mapped to the beta lactamase gene. Beta lactamase sequence (SEQ ID NOs: 1-2, 6-7, 15-16 and 24-25) is shown in grey in the top of each panel, PAM (protospacer adjacent motif) sequence is shown in black. Base pairing region with crRNA is underlined, off-target seed sequence on the bacterial genome is italicised. Off-target seed sequence, including PAM sequence, is indicated by two vertical lines. Two numbers on the sequence of beta lactamase gene are the expected two base positions where the phosphodiester bond is cleaved by Cas9 (see Example 1 below).

Figure 9. Predicted crRNA secondary structure. With reference to Figure 8 and Example 1, predicted secondary structures of the crRNA sequences using mFold are shown. The sequences of CR05, CR30, CR70 and CR90 shown in Figure 9 correspond to SEQ ID NOs: 34-37, respectively.

Figure 10. Expected cleavage positions on beta-lactamase gene from pBR322 (SEQ ID NO: 38). Two protospacer sequences, which are base-pairing with crRNA spacer sequences, are underlined (protospacer strand). Two anti-protospacer sequences, which are displaced when protospacer sequences are base pairing with crRNA spacer sequences, are bold italicised (anti-protospacer strand). Associated PAM sequences are indicated either boxed small letters (on protospacer strand) or boxed capital letters (on anti-protospacer strand). Expected cleavage positions are indicated by asterisks. Leader sequence is underlined from 1st to 69th base and highlighted in grey.

Figure 11. Photograph of electrophoretically separated DNA products on a 0.8% agarose gel showing PCR amplicons generated in Example 2 from each of the three regions plus the EcoRV digested vector pACYC184.

The marked lanes are as follows: 1*-NEB (N3232S) 1 Kb molecular markers, 2 µg/lane; 2 - Fragment 1, tracrRNA-Cas9 region : 4758 bp; 3* - NEB (N3232S) 1 Kb molecular markers, 0.75 µg/lane; 4 - pACYC184 uncut; 5 - pACYC184 EcoRV cut: 4245 bp; 6 - pACYC184 EcoRV cut: 4245 bp; 7* - NEB (N3232S) 1 Kb molecular markers, 0.12 µg/lane; 8 - Fragment 2, leader and first direct repeat region : 276 bp; 9* - NEB (N3232S) 1 Kb molecular markers, 0.2 µg/lane; and 10 - Fragment 3, Second direct repeat region : 452 bp. Note: * The mass of the each PCR amplicon is estimated by comparing the intensity of the appropriate marker band using NIH ImageJ 1.48v software(<http://imagej.nih.gov/ij/>).

Figure 12. Plasmid map of pNB100 constructed in Example 2. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). Two direct repeats (DR) are shown as narrow white rectangular boxes adjacent to the 3' end of leader sequence.

Figure 13. Photographs show results of "Nemesis symbiotic activity" (NSA) according to an embodiment of the invention by bacterial cell mating (see Example 2). The left plate shows JA200 pNT3 x DH5α pNB100 in Ap100Cm35, while the right plate shows JA200 pNT3 x DH5α pNB102 in Ap100Cm35, both plated at 5×10^7 cells /ml.

Figure 14. Photographs show results of NSA according to another embodiment of the invention by plasmid transformation (see Example 2). Left: LB Cm35 plate. Colonies 1-40 are DH5α pBR322 transformed with pNB102; Colonies 45-60 are DH5α pBR322 transformed with pNB100. All colonies show resistance to Cm carried on plasmids pNB100 and pNB102; Right: LB Ap100 plate. Note that colonies 1-40 have lost ApR following transformation with pNB102 carrying the spacer region targeted against the beta-lactamase gene carried on the plasmid pBR322 in strain NBEc001, thereby demonstrating Nemesis symbiotic activity. pNB100 lacking this spacer region but carrying the Cas9 gene is unable to inactivate the beta-lactamase gene.

Figure 15. Shows a phagemid of Ngophi6. ORF11 and ORF7 of Ngophi6 are deleted from Ngophi6 genome. Coding sequences are represented by the arrows indicating the translation polarity of each ORF. The corresponding gene nomenclature of each Ngophi6 phage ORF to M13 are ORF1(gII), ORF2 (gV), ORF4 (gVIII), ORFV (gVIII), ORF8 (gVI), ORF9 (gI). M13 gene nomenclatures are in the parenthesis. The second T of the putative left integration site L = CTTATAT is changed to A to give L' = CATATAT to avoid integration. MCS = Multiple cloning site. The location of Ngophi6 and M13mp18 are indicated by the large two open arrows.

Figure 16. Shows a set of spacer sequences (SEQ ID NOs: 39-60) that encode 20 guide RNA molecules targeted against 117 different *bla* genes identified in the NCBI ARDB database for *Klebsiella pneumoniae* (see Example 5). Candidate spacer sequences were identified to disrupt all the *Klebsiella pneumoniae* beta lactamase genes found in the ARDB database. Beta lactamase gene sequences are collected from the ARDB database with the keyword *Klebsiella pneumoniae*. Redundant sequences were removed and unique sequences used for multiple sequence alignment using web program Clustal Omega. One canonical sequence was chosen from each cluster and the 20 nt spacer sequences predicted by the web program Jack Lin's CRISPR/Cas9 gRNA finder were collected. The spacer sequence is chosen to maximise the ratio of the proto-spacer sequence found in the sequences belonging to the same branch. Thus each of the example spacer sequences shown in the 4th column has the capability to disrupt the genes in the third column. Beta lactamase genes used in this analysis are: SHV-a = 1, 2, 2a, 5, 5a, 11, 12, 14, 26, 27, 28, 31, 33, 38, 43, 44, 48, 55, 56, 60, 61, 62, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,85, 89, 92, 98, 99, 101, 103, 106, 107, 108, 109, CTXM-b = 1, 3, 10, 12, 15, 22, 32, 54, 60, 62, 68, CTXM-c = 13, 14, 16, 18, 19, 24, 26, CTXM-d = 2, 35, 59, CTXM-e = 26, 63, TEM-f = 1, 1b, 3, ESBL, 139, KPC-g = 1, 2, 3, 4, OKP-h =A11, A12, A16, A17, B13, B-SB613, 6, LEN-i = 2, 17, 18, 19, 20, 21, 22, 24, GES-j = 1, 3, 4, 5, VIM-a = 1, 2, 4, 12, 19, IMP-b = 4, 8, CMY-a= 2, 4, 25, 31, 36, LAT-b = 1, 2, CMY-c = 1, 8b, 10, 19, FOX-d = 1, 5, 7, OXA-a = 1, 30, 47, OXA-2, OXA-9, OXA-b = 10, 17. Beta lactam antibiotics are classified into four classes, penams, cepheems, carbapenems and monobactams. One antibiotic name is listed as an example under each class. The beta lactamase, which can open the beta lactam ring is indicated by R. For example, carbapenem is inactivated by KPC. If it is desired to re-sensitise bacteria to carbapenem, the spacer sequence 5'-TTGTTGCTGAAGGAGTTGGG should be employed into spacer array to inactivate KPC genes. Note that the spacer sequence for CMY-a can also be employed for LAT-b cleavage. The example of spacer sequences are shown from 5' to 3' direction.

Figure 17. Shows a set of spacer sequences (SEQ ID NOs: 61-77) that encode 17 guide RNA molecules targeted against 154 different *bla* genes identified in the CARD database for *Klebsiella pneumoniae* (see Example 5). Candidate spacer sequences were identified to disrupt all the *Klebsiella pneumoniae* beta lactamase genes found in the CARD database. This table was created with the same method explained in the figure legend in Figure 16. The example of spacer sequences are shown from 5' to 3' direction.

Figure 18. Map of a modified Cas DNA-binding polypeptide, Cas9R. A genetic fusion between Cas9 and Tn3 resolvase. Resolvase and Cas9 are indicated by arrows. The direction of the arrowhead represents the transcription polarity. Functional domain names of Cas9 are shown in the boxes below Cas9 open arrow. This Cas9 is the endonuclease activity deficient mutant dCas9, with amino acid substitutions D10A in RuvCI domain, H840A in HNH domain (as described by Tsai et al. [2014, Nature Biotechnology 32: 569-576]). A mutant Tn3 resolvase (as described by Proudfoot et al. [2011 PLoS ONE 6(4): e19537]) is fused to the N-terminus of this dCas9 via a 12 mer polypeptide linker. Positions of some of these substituted amino acid residues reducing the specificity of the recombination site are indicated by short vertical bars in the N terminal domain, residues 1-148, of the resolvase. The full list of these substitutions is: R2A, E56K, G101S, D102Y, M103I, Q105L, V107F, E132A, L135R. In the Cas9 regions of the fusion: RuvCI, II, III, HNH and PI (PAM interaction) domains are nuclease domains, REC1a and REC1b are recognition domains of repeat and anti-repeat RNA, respectively. REC2 domain does not have any contact to the protospacer-gRNA heteroduplex. Four CRISPR spacer sequences S1, S2, S3 and S4 are arrayed under the expression of one CRISPR leader sequence and are required to bring about the Cas9R-mediated recombination event by the mutant Tn3 resolvase leading to the deletion and re-ligation of the target sequence. Tn3R = Tn3 Resolvase, R = Direct repeat, L = Leader sequence.

Figure 19. Schematic showing site-specific positioning of resolvase by gRNA directed Cas9. The open arrow in step I is the target antibiotic resistance gene on the plasmid for inactivation. Each recombination site A (A1, A2) and B (B1, B2) are recognised by gRNA independently and correctly positioned resolvases are dimerised in close proximity (step II). Dimers in each recombination site A1+A2 and B1+B2 are tetramerised to form a synapse (step III). The synaptic complex (III) is enlarged, gRNAs are presented as dotted arrows designated S1, S2, S3 and S4. Large ovals represent dCas9, longitudinal ovals are resolvases connected via linker peptides. White and grey longitudinal ovals are resolvase catalytic domains dimerising on the recombination site B and A, respectively. The vertical arrows indicate the cleavage position on the recombination sites by resolvase. The thin horizontal parallel arrows represent DNA containing the recombination site A1+A2 and the thick horizontal parallel arrows represent DNA containing the recombination sites B1+B2. The arrowhead shows the 3' end of the DNA sequence. Short black block arrows are locations of each of the PAM sequences.

Figure 20. Schematic showing exchanging half site of the recombination site A1+A2 and B1+B2 followed by strand resolution and sealing break point. Half-site of recombination A1 and B1 are exchanged and ligated and resolved. The region of the target antibiotic gene is resolved as a circular DNA, while the rest of the chromosomal or plasmid replicon is re-circularised (step IV). Short black block arrows are locations of each PAM sequences after resolution.

Figure 21. Shows a set of spacer sequences (SEQ ID NOs: 78-85) that encode 8 guide RNA molecules targeted against the class A genes, SHV-a, CTX-M-b, TEM-c, KPC-d; the class B genes VIM-e, IMP-f, NDM-g and the class D gene, OXA-48 where SHV-a = 1, 1a, 2, 2a, 5, 5a, 11, 12, 14, 18, 20, 21, 22, 23, 26, 27, 28, 31, 32, 33, 38, 43, 44, 48, 52, 55, 56, 60, 61, 62, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 89, 92, 98, 99, 100, 101, 103, 106, 107, 108, 109, 110, 111, 121, 136, 134, 137, 140, 143, 144, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 158, 159, 160, 161, 162, 163, 164, 165, 168, 172, 173, 178, 179; CTXM-b = 1, 3, 10, 12, 15, 19, 22, 32, 52, 54, 59, 60, 62, 68, 71, 80, 81, 99, 141, 147; TEM-c = 1, 1B, 3, 139, 162, 183, 192, 197, 198, 209; KPC-d = 1, 2, 3, 4, 6, 7, 8, 11, 12, 14, 15, 16, 17; VIM-e = 1, 2, 4, 19, 26, 27, 33, 34; IMP-f = 4, 8, 32, 38; and NDM-g = 1, 9, 10 (see Example 7).

Figure 22. Shows a table giving the sequences (SEQ ID NOs: 86-98) of the oligonucleotides used in the construction of plasmids pNB200, 202, 203, 104A, 104B and 108 (see Example 7).

Figure 23. Plasmid map of pNB104A constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The tetramer spacer concatemer (Figure 29A) was digested with *BsaI*, whose restriction site is located in A1 and A2, and ligated to *BsaI* spacer cloning sites on pNB202 to give pNB203. The single promoter and spacer region (6221-7001) on pNB104A is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The concatenated spacers (targeted against NDM, IMP, VIM and KPC) are located downstream of the single promoter.

Figure 24. Plasmid map of pNB104B constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The single promoter regions (6221-6987) on pNB104B is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The concatenated spacers (targeted against OXA-48, SHV, TEM and CTX-M) are located under expression from the single promoter.

Figure 25. Plasmid map of pNB108 constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The octamer spacer concatemer (Figure 29B) was digested with *Bsal*, whose restriction site is located in A1 and A2, and ligated to *Bsal* spacer cloning sites on pNB100 to give pNB108. The single promoter and spacer region (6221-7225) on pNB108 is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The concatenated spacers (targeted against NDM, IMP, VIM, KPC, OXA-48, SHV, TEM and CTX-M) are located under the single promoter.

Figure 26. Plasmid map of pNB200 constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The dual promoter cassette was synthesised by PCR from the template pNB100 with primer pair NB018 and NB019, the amplicon was digested with *BbvI* and ligated to the *Bsal* site of pNB100 to give pNB200, the small *Bsal* fragment of pNB100, from position 5776-5741 (see Figure 12) is replaced in the process. The dual promoter and two spacer cloning region (6221-7382) on pNB200 is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The restriction enzymes *Bsal* and *SapI* are utilised to clone upstream and downstream spacer sequences, respectively.

Figure 27. Plasmid map of pNB202 constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The tetramer spacer concatemer (Figure 29A) was digested with *SapI*, whose restriction site is located in B1 and B2, and ligated to *SapI* spacer cloning sites on pNB200 to give pNB202. The dual promoter and spacer regions (6221-7329) on pNB202 is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The concatenated spacers (targeted against OXA-48, SHV, TEM and CTX-M) are located downstream of the second promoter.

Figure 28. Plasmid map of pNB203 constructed in Example 7. The plasmid map was drawn by SnapGene viewer ver. 2.4.3 free version (<http://www.snapgene.com>). The tetra spacer concatemer a+b+c+d shown in Figure 29A was digested with *Bsal*, whose restriction site is located in A1 and A2, and ligated to *Bsal* spacer cloning sites on pNB202 to give pNB203. The dual promoter and spacer regions (6221-7501) on pNB203 is shown. P = Promoter, L = Leader, R = Direct repeat, S = Spacer, T = Tail. The concatenated spacers (targeted against NDM, IMP, VIM and KPC) are located downstream of the first promoter. The concatenated spacers (targeted against OXA-48, SHV, TEM and CTX-M) are located downstream of the second promoter.

Figure 29A. Tetramer spacer concatenation in Example 7. The numbers associating oligos are corresponding to the primer numbers listed in Figure 22. Oligos are pairwise annealed between 26 and 27, 28 and 34, 35 and 31, 32 and 36 via a, c, e and g unique spacer region (I), respectively and extended in individual tubes (II). Dimer concatemer from 26 and 27 concatenate spacer a and b. Dimer concatemer from 28 and 34 concatenate spacer b, c and d. Dimer concatemer from 35 and 31 concatenate spacer e and f. Dimer concatemer from 32 and 36 concatenate spacer f, g and h (II). Concatenated dimmers a+b and b+c+d, e+f and f+g+h are further hybridised via b and f spacer region, respectively and extended to concatenate four spacers a, b, c and d or e, f, g and h (III).

The tetramer spacer concatemer e+f+g+h was digested with *SapI*, whose restriction site is located in B1 and B2, and ligated to *SapI* spacer cloning sites on pNB200 to give pNB202. Tetra spacer concatemer a+b+c+d was digested with *Bsal*, whose restriction site is located in A1 and A2, and ligated to *Bsal* spacer cloning sites on pNB202 to give pNB203. a = 20 mer spacer for NDM, b = 20 mer spacer for IMP, c = 20 mer spacer for VIM, d = 20 mer spacer for KPC, e = 20 mer spacer for OXA-48, f = 20 mer spacer for SHV, g = 20 mer spacer for TEM, h = 20 mer spacer for CTX-M.

Figure 29B. Octamer spacer concatenation in Example 7. The tetramer spacer concatemer a+b+c+d and e+f+g+h were amplified with primer pair NB026 and NB029, NB030 and NB033, respectively (V), and hybridise tetra concatemer via spacer d region followed by extension to yield octamer spacer a+b+c+d+e+f+g+h. This octamer was digested with *Bsal* and ligated to *Bsal*, whose restriction site is located in A1 and A2, and ligated to *Bsal* spacer cloning sites on pNB100 to give pNB108. a = 20 mer spacer for NDM, b = 20 mer spacer for IMP, c = 20 mer spacer for VIM, d = 20 mer spacer for KPC, e = 20 mer spacer for OXA-48, f = 20 mer spacer for SHV, g = 20 mer spacer for TEM, h = 20 mer spacer for CTX-M.

Figure 30. Photographs showing results of "Nemesis symbiotic activity" (NSA) according to an embodiment of the invention by bacterial cell mating (see Example 7). Fig 30A, top left plate shows JA200 pNT3 x DH5α pNB100 in Ap100Cm35, while top right plate shows JA200 pNT3 x DH5α pNB102 in Ap100Cm35. Fig 30B shows NCTC13440 x DH5α pNB100, the top left plate and NCTC13353 x DH5α pNB100, the top right plate; and NCTC13440 x DH5α pNB104A the bottom left plate and NCTC13353 x DH5α pNB104B, the bottom right plate all in Ap100Cm35. Fig 30C shows JA200 pNT3 x DH5α pNB100 (5-), NCTC13440 x DH5α pNB100 (2-) and NCTC13353 x DH5α pNB100 (4-), top left plate; and JA200 pNT3 x DH5α pNB108 (5/8), NCTC13440 x DH5α pNB108 (2/8) and NCTC13353 x DH5α pNB108

(4/8), top right plate and JA200 pNT3 x DH5 α pNB100 (5+), bottom plate, all in Ap1 00Cm35.

[0076] As used herein, the term "antibiotic" refers to a classical antibiotic that is produced by a microorganism that is antagonistic to the growth of other microorganisms and also encompasses more generally an antimicrobial agent that is capable of killing or inhibiting the growth of a microorganism, including chemically synthesised versions and variants of naturally occurring antibiotics.

[0077] The term "sufficiently complementary" means that the sequence identity of the spacer sequence and the target sequence is such that the RNA guide molecule comprising the spacer sequence is able to hybridise, preferably specifically and selectively, with the target sequence, thereby allowing for inactivation of the antibiotic resistance gene comprising the target sequence via the CRISPR/Cas system described herein. For example, the spacer sequence may have at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity over its entire length with the target sequence.

[0078] The term "functional equivalent" as used herein refers to a polypeptide which is capable of the same activity as a Cas DNA-binding polypeptide (or, as used herein, a Cas nucleic acid-binding polypeptide). The "functional equivalent" may have the same qualitative biological property as the Cas DNA-binding polypeptide. "Functional equivalents" include, but are not limited to, fragments or derivatives of a native Cas DNA-binding polypeptide and its fragments, provided that the equivalents have a biological activity in common with a corresponding native sequence polypeptide. Although structural identity is not necessarily required for common biological activity, in one aspect the functional equivalent may have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity over its entire length with a Cas DNA-binding polypeptide, for example Cas9 (Ferretti et al, 2001, PNAS, 98 No. 8: 4658-4663, Gene ID: 901176, Cas9 GI: 15675041; SEQ ID NO: 99).

[0079] The term "Cas DNA-binding polypeptide" encompasses a full-length Cas polypeptide, an enzymatically active fragment of a Cas polypeptide, and enzymatically active derivatives of a Cas polypeptide or fragment thereof. Suitable derivatives of a Cas polypeptide or a fragment thereof include but are not limited to mutants, fusions, covalent modifications of a Cas protein or a fragment thereof.

[0080] The term "modified" Cas DNA-binding polypeptide encompasses Cas DNA-binding polypeptides as defined above except that the DSB catalytic function of the polypeptide is replaced by a DNA sealing function due for example to the presence of a recombinase catalytic domain. Further features of such modified Cas DNA-binding polypeptides are described herein.

[0081] Sequence identity between nucleotide or amino acid sequences can be determined by comparing an alignment of the sequences. When an equivalent position in the compared sequences is occupied by the same base or amino acid, then the molecules are identical at that position. Scoring an alignment as a percentage of identity is a function of the number of identical amino acids or bases at positions shared by the compared sequences. When comparing sequences, optimal alignments may require gaps to be introduced into one or more of the sequences to take into consideration possible insertions and deletions in the sequences. Sequence comparison methods may employ gap penalties so that, for the same number of identical molecules in sequences being compared, a sequence alignment with as few gaps as possible, reflecting higher relatedness between the two compared sequences, will achieve a higher score than one with many gaps. Calculation of maximum percent identity involves the production of an optimal alignment, taking into consideration gap penalties.

[0082] Suitable computer programs for carrying out sequence comparisons are widely available in the commercial and public sector. Examples include MatGat (Campanella et al., 2003, BMC Bioinformatics 4: 29; program available from <http://bitincka.com/ledion/matgat>), Gap (Needleman & Wunsch, 1970, J. Mol. Biol. 48: 443-453), FASTA (Altschul et al., 1990, J. Mol. Biol. 215: 403-410; program available from <http://www.ebi.ac.uk/fasta>), Clustal W 2.0 and X 2.0 (Larkin et al., 2007, Bioinformatics 23: 2947-2948; program available from <http://www.ebi.ac.uk/tools/clustalw2>) and EMBOSS Pairwise Alignment Algorithms (Needleman & Wunsch, 1970, supra; Kruskal, 1983, In: Time warps, string edits and macromolecules: the theory and practice of sequence comparison, Sankoff & Kruskal (eds), pp 1-44, Addison Wesley; programs available from <http://www.ebi.ac.uk/tools/emboss/align>). All programs may be run using default parameters.

[0083] For example, sequence comparisons may be undertaken using the "needle" method of the EMBOSS Pairwise Alignment Algorithms, which determines an optimum alignment (including gaps) of two sequences when considered over their entire length and provides a percentage identity score. Default parameters for amino acid sequence comparisons ("Protein Molecule" option) may be Gap Extend penalty: 0.5, Gap Open penalty: 10.0, Matrix: Blosom 62. Default parameters for nucleotide sequence comparisons ("DNA Molecule" option) may be Gap Extend penalty: 0.5, Gap Open penalty: 10.0, Matrix: DNAsfull.

[0084] In one aspect of the invention, a sequence comparison may be performed over the full length of the reference sequence.

[0085] As used herein, the term "gene" refers to a DNA sequence from which a polypeptide is encoded or a non-coding, functional RNA is transcribed.

[0086] The term "antibiotic resistance gene" encompasses a gene, or the encoding portion thereof, which encodes a product or transcribes a functional RNA that confers antibiotic resistance. For example, the antibiotic resistance gene may be a gene or the encoding portion thereof which contributes to any of the four resistance mechanisms described above. The antibiotic resistance gene may for example encode (1) an enzyme which degrades an antibiotic, (2) an enzyme which modifies an antibiotic, (3) a pump such as an efflux pump, or (4) a mutated target which suppresses the effect of the antibiotic.

[0087] The term "polynucleotide" refers to a polymeric form of nucleotide of any length, for example RNA (such as mRNA) or DNA. The term also includes, particularly for oligonucleotide markers, the known types of modifications, for example, labels which are known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications, such as, for example, those with unchanged linkages, e.g., methyl phosphates, phosphotriesters, phosphoramidates, carbamates, etc. and with charged linkages.

[0088] The term "polypeptide" as used herein refers to a polymer of amino acids. The term does not refer to a specific length of the polymer, so peptides, oligopeptides and proteins are included within the definition of polypeptide. The term "polypeptide" may include post-expression modifications, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition of "polypeptide" are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids), polypeptides with substituted linkages, as well as other modifications known in the art both naturally occurring and non-naturally occurring.

[0089] The term "microorganism" encompasses prokaryotes such as bacteria and archaea (for example, those belonging to the the Euryarchaeota and Crenarchaeota). Bacteria include both Gram positive and Gram negative bacteria. Some species of clinically significant, pathogenic fungi are included in the definition of microorganisms, for example members of the genus *Candida*, *Aspergillus*, *Cryptococcus*, *Histoplasma*, *Pneumocystis* and *Stachybotrys*.

[0090] Various aspects of the invention are shown in the figures and described below.

[0091] In the present invention, an advantage of using a bacteriophage or conjugative plasmid that comprises the recombinant polynucleotide of the invention is that each serves as a "Trojan horse" that, following infection of the bacteriophage, or following plasmid conjugation, results in the insertion of the "assassin construct" into the target bacteria or other microorganism.

[0092] The assassin construct once inserted into the target microorganism also provides an immunisation of the cells against the future arrival of a plasmid harbouring antibiotic resistance genes (see Figure 2), in addition, of course to disrupting such genes already present (see Figures 1 and 3).

[0093] The assassin constructs then begin the process of degradation of the antibiotic resistance genes. If a DSB created by the Cas DNA-binding protein of the invention destroys a replicon carrying such an antibiotic resistant gene then a microorganism harbouring the antibiotic resistance gene may be killed directly by an assassin construct. If the microorganism survives the DSB, the resistance gene will be inactivated, and a patient may then be treated with the antibiotic(s) to which the microorganism has now become sensitised.

[0094] Importantly, there should be no or reduced direct selection pressure acting against this event if and until patients

are subsequently treated with antibiotics. Thus there should be little or no direct selection for bacteriophage (or plasmid) resistance in the pathogenic bacteria or other microorganisms and therefore no or less establishment of an "evolutionary arms race" - sometimes a significant limiting feature of the known use of bacteriophage directly as bactericidal agents.

[0095] In the event that DSB-induced killing of a microorganism increases selection pressure for resistance to a bacteriophage or conjugative plasmid delivery agent, the problem could be mitigated by, for example, using a modified Cas DNA polypeptide as defined herein.

[0096] This present invention provides potential agents for oral, topical and probiotic, dietary supplement delivery as well as an epidemiological tool to silently inactivate antibiotic resistance genes in pathogenic bacteria or other microorganisms (see Figure 3). Patients scheduled for surgery, or other treatment in hospital, may well be treated with recombinant bacteriophage carrying CRISPR/Cas9 (or other) assassin constructs targeted against antibiotic resistance genes prophylactically in advance of hospital admission. In this way, pathogens present in their microbiome can be directly killed or purged of antibiotic resistance genes in anticipation of any post-operative infection that might occur requiring treatment with antibiotics.

[0097] Thus this present invention provides an epidemiological tool to silently inactivate antibiotic resistance genes in pathogenic bacteria.

[0098] To effect exemplification of the invention, a set of CRISPR/Cas9 assassins targeted against selected antibiotics may be constructed. Variables are the bacteriophage (also referred to herein synonymously simply as "phage"), or conjugative plasmid, or DNA, delivery agent: a range of bacteriophage and plasmid agents may be developed that are specific to a range of important bacterial pathogens.

[0099] The extent to which a single generalised bacteriophage or plasmid delivery agent needs to be modified to target different bacterial pathogens depends on the details of the specificity of the interactions of either the phage proteins involved in the phage life-cycle, or the plasmid biology and the pathogenic bacterial target.

[0100] Both lysogenic phage that infect hosts and become dormant as prophage, as well as non-virulent phage that replicate but do not kill the host, may be developed. With regards to lysogenic phage specificity, only the lysogenic life cycle of the phage and hence the specificity involved in (i) entry of the phage into the bacterial cell and (ii) its subsequent integration into an attachment site in the target chromosome is required. Integration may not be needed and may be replaced by using the phage to deliver a plasmid that can then excise, for example by cre-lox recombination, and replicate independently in the cell. Non-virulent M13 phage and derivatives thereof may be used.

[0101] A functional lytic cycle in lysogenic phage may be retained such that low levels of entry into the lytic cycle in lysogenised bacteria will generate new phage that can go on to subsequently infect other bacteria (either pathogenic bacteria or non-pathogenic bacteria, to provide immunity). From the point of view of the epidemiological spread of the phage in the pathogenic population this may not be necessary and a single initial infection may suffice. This can be tested experimentally. Optimal conditions for efficient infection and the appropriate multiplicity of infection are identified.

[0102] Experiments may be performed in a model system (see Figure 1). For example, *E. coli* carrying multiple drug resistance, for example, to ampicillin, chloramphenicol, and kanamycin or targeted against commonly used antibiotics against which resistance is widespread.

[0103] Experiments may also be performed with a target pathogen, for example, *Klebsiella pneumoniae* carbapenemase ("KPC"). KPC is responsible for infection and death in hospitals in the UK.

[0104] Delivery by bacteriophage: The phage delivery system (see for example Figure 2, route 2) may be suitable for the treatment of wounds and burns infected by antibiotic-resistant bacteria.

[0105] Delivery of the assassin construct targeted against these antibiotics by two different *E.coli* lysogenic bacteriophage: bacteriophage lambda and bacteriophage Mu may be used. Bacteriophage lambda has a specific integration site in the host chromosome known as the lambda attachment site. Bacteriophage Mu is able to integrate randomly into the host genome and has the advantage that no specific attachment sites in bacteria are required.

[0106] Phage may also be used to deliver a plasmid replicon containing the recombinant polynucleotide of the invention that excises by cre-lox recombination following infection as discussed above or by use of phage P1 that replicates as an episome. The specificity involved in successful infection is recognition of a membrane protein on the bacterial cell surface. In the case of lambda this is the maltose permease protein that transports the sugar maltose into the bacterial cell. In the case of bacteriophage Mu the receptor is LPS.

[0107] Male-specific phage M13 that infect *E.coli* cells carrying the F-factor plasmid may also be used to deliver CRISPR/Cas9 constructs (or other assassin constructs of the invention) targeted against one or more antibiotic resistance genes. M13 is a well studied phage, which replicates, but does not kill the bacterial host.

[0108] Successful elimination of resistance to target antibiotics following the lyogenisation by recombinant bacteriophage, or infection by M13 recombinants carrying the assassin construct directed against these antibiotic resistance genes is evaluated.

[0109] Studies on other closely related Enterobacteriaceae carrying resistance to the same antibiotics may be performed. These may include *Salmonella typhimurium*, and *Shigella flexneri* in addition to *Klebsiella pneumoniae* discussed above.

[0110] In order to do this, modified phage are constructed with different genes encoding the tail fibre protein of the bacteriophage in order to allow it to interact with a different receptor present on the bacterial surface. Lysogenic phage, or male-specific phage, like M13, that are natural hosts of these bacteria may be used.

[0111] The phenomenon of phase variation whereby bacteriophage are able to switch their host specificity by the inversion, at a low frequency, of a DNA segment to control gene expression and express alternative tail fibre proteins may also be exploited. And in that way develop phage delivery systems that are versatile. For example phage Mu carries an invertible G segment (regulated by a Mu-encoded site-specific recombinase, Gin) giving rise to two phage types G(+) able to infect *E.coli* K12 and G(-) able to infect *Enterobacter cloacae*, *Citrobacter freundii*, *Serratia marcescens* and *Erwinia carotovora*.

[0112] Another example is the *Neisseria gonorrhoeae* filamentous phage NgoPhi6, or modified forms thereof. The natural (wild type) phage has a wide host range for Gram negative bacteria (alpha, beta and gamma proteobacteria) - see Piekarowicz et al. (2014 J. Virol. 88: 1002 - 1010). The natural phage is not lytic but lysogenic and has an integration site on the host genome. In one aspect of the invention, the ability of the phage to integrate into the host chromosome is removed and the phage is engineered to replicate independently. The substitution of the left integration site L, CTTATAT with L', CATATAT will eliminate the integration event. In order to replicate the phage genome extra-chromosomally, the M13 ori and M13 gene II can be used to mimic the M13 phage replication. The modification may be kept to a minimum to maintain the ability of the progeny production from the infected bacteria. Although the maximum packaging size is unknown, a phage DNA of around 12 Kb is experimentally demonstrated as packageable and phage progeny produced from the bacteria infected with this phage are infectable. The length of the phage is around 4 microns, which is 4.4 times longer than M13 phage particle, and indicates the higher packaging capacity of DNA longer than M13 - i.e. assuming that the packaging size of DNA is proportional to the size of the phage particle length, DNA packaging capacity of the NgoPhi6 phage will 4 microns/0.9 microns x 6407 nt = 28475 nt, large enough for packaging phage genome along with a recombinant polynucleotide of the invention, including for example a CRISPR-Cas9 construct if required. The exemplified structure of the phage vector (phagemid) meets the requirements - see Figure 15.

[0113] Delivery by conjugative plasmids: Delivery of the assassin constructs targeted against these antibiotics by selected broad-host range conjugative plasmids may be evaluated (see Figure 4, route 3). Here, the plasmids may be delivered by a benign non-pathogenic host. The application here may be for the GI tract as a probiotic and may be used prophylactically. In this aspect, the possible lethal effects of DSBs caused by Cas DNA-binding protein are not a concern since the plasmid will not be transferred to the recipient.

[0114] Similarly demonstration of the successful elimination of resistance to the three target antibiotics following conjugal transfer of plasmids carrying the assassin cargo may be evaluated.

[0115] Delivery by transformation of linear DNA: Delivery of the assassin construct targeted against these antibiotics by linear double-stranded DNA transformation (see Figure 4, route 1) may also be performed. Here, the DNA is

delivered via DNA receptor on the surface of the bacteria from the bacterial surrounding environment.

Examples

[0116] The present invention is illustrated by the following non-limiting examples.

Example 1

[0117] The aim of Example 1 is to demonstrate a proof-of-concept for resurrection of antibiotic efficacy by introduction of a CRISPR/Cas9 construct in non-pathogenic bacterial strains of *Escherichia coli*.

[0118] A CRISPR/Cas9 construct is made directly from genomic DNA isolated from the *Streptococcus pyogenes* strain SF370, which is obtained from: http://www.straininfo.net/strains/1178GG/browser;jsessionid=A07A638D6D2472EA2FEDBD3_A1928F347.straininfo2. Here the Cas9 coding region plus adjacent regulatory regions and DNA encoding the tracrRNA is extracted by PCR, using sequence-specific DNA primers and cloned into a suitable plasmid cloning vector. A unit repeat of CRISPR array comprising the direct repeats flanking a spacer sequence is similarly extracted by PCR and modified to replace the spacer sequence by a cloning site to allow the subsequent introduction of spacer sequences designed to target DNA regions of choice such as antibiotic resistance genes. It is useful to have a positive selection for bacterial transformants carrying the desired recombinants in which such a spacer sequence has been successfully cloned into the cloning site. Appendix 3 gives an example of such a positive selection.

[0119] Alternatively an equivalent CRISPR/Cas9 gene targeting construct, though lacking a positive selection for recombinants, is obtained from a pCas9 plasmid such as for example available from Addgene: <http://www.addgene.org/42876/>. This plasmid carries the Cas9 gene plus a DNA sequences encoding tracrRNA and CRISPR array with a unique cloning site in order to introduce the spacer sequence desired to target a given DNA sequence for cleavage by the Cas9 endonuclease. For exemplification purposes, use of this existing pCas9 plasmid is described below.

[0120] Example 1 shows that bacteria carrying a beta-lactamase (bla) gene conferring resistance to the beta-lactam antibiotic, ampicillin become sensitive to ampicillin following introduction of a modified CRISPR/Cas9 construct targeted against the *bla* gene: the CRISPR/Cas9/anti-*bla* construct.

Materials and Methods

A. Bacterial strains, plasmids and phage

1. Bacterial strains:

[0121] DH5 α is (F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ 80d/lacZ Δ M15 Δ (lacZYA-argF)U169, hsdR17(r κ ⁻ m κ ⁺), λ -).

JM109 is (endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB⁺ Δ (lac-proAB) e14- [F' traD36 proAB⁺ lacI^q lacZ Δ M15]hsdR17(r κ ⁻m κ ⁺)).

2. Plasmids:

[0122] pUC18 (*Ori* pMB1); pCas9 (pACYC184-based vector with *Ori* p15A, CRISPR locus plus Cas9 gene, CM^R);

pCRISPR (*Ori* pMB1, CRISPR, Kn^R).

3. Phage: M13mp18

[0123] In Example 1A, in one strain *E.coli* DH5 α and carrying pBR322 a medium copy plasmid or alternatively a low copy plasmid, the CRISPR/Cas9/anti-*bla* construct is delivered, by naked DNA transformation in plasmid pCas9, designated pCas9::anti-*bla*. The already present plasmid pBR322, or the low copy plasmid expresses the beta-lactamase derived from bacterial transposon Tn3; pBR322 also carries resistance to tetracycline. As pCas9::anti-*bla* carries resistance to chloramphenicol, selection for cells maintaining pCas9::anti-*bla* is achieved by addition of chloramphenicol to the growth medium. In a separate negative control experiment DH5 α cells with pBR322, or a low copy plasmid are transformed with pCas9 (that is a plasmid in all respects like pCas9::anti-*bla* but lacking anti-*bla* which is the spacer sequence targeted against the *bla* gene: it is predicted that pCas9, in lacking the anti-*bla* would not be able to attack and inactivate the *bla* gene. Again pCas9 is maintained by the presence of chloramphenicol.

[0124] Beta-lactamase activity can be detected by nitrocefin, which is a chromogenic derivative of cephalosporin, when the beta-lactam ring is hydrolysed, ultraviolet absorption of intact nitrocefin is shifted to around 500 nm, which allows visual detection of the presence of beta lactamase.

[0125] Let the total number of bacteria resistant to chloramphenicol be N_0 and the number of beta-lactamase resistant bacteria be N_r . Growth of N_r manifest as red colonies in the presence of nitrocefin. Let the number of beta lactamase sensitive bacteria be N_w . Growth of N_w colonies manifest as white colonies in the presence of nitrocefin. Thus the efficacy of CRISPR/Cas9/anti-*bla*-mediated inactivation of the *bla* gene efficiency is calculated by measuring the fraction of white colonies, i.e. $N_w/N_0 = (N_0 - N_r)/N_0$.

[0126] Alternatively beta lactamase activity is seen directly challenging the bacteria on the LB plate containing ampicillin. Total bacteria resistant to chloramphenicol is N_0 , ampicillin resistant bacteria is N_a , then CRISPR/Cas9/anti-*bla*-mediated inactivation of the *bla* gene efficiency can be defined by measuring the fraction of the ampicillin sensitive colony, $1 - N_a/N_0$.

[0127] In Example 1B, an M13 phage delivery system is used to introduce CRISPR/Cas9/anti-*bla* construct into the *E. coli* strain, JM109, expressing beta lactamase gene from a resident plasmid.

[0128] M13::CRISPR/Cas9/anti-*bla* phage recombinant is prepared as follows: the CRISPR/Cas9/anti-*bla* construct is isolated from pCas9::anti-*bla* by digesting this construct with *Sa*II and *Xba*I. The digested fragment size is 5796 bp. The fragment is cloned at *Sa*II (GTCGAC) and *Xba*I (TCTAGA) site of M13mp18 RF I. The entire size of the M13mp18 containing CRISPR/Cas9/ anti-*bla* construct is 13035 bp. This M13 recombinant phage DNA is transformed to *E.coli* JM109, a bacterial strain carrying the F' plasmid and recombinant M13 phage extruded from the bacteria is purified and used to introduce the CRISPR/Cas9 construct to *E.coli* JM109 harbouring pBR322. As a negative control, an equivalent M13::CRISPR/Cas9 phage recombinant lacking anti-*bla* region is prepared from pCas9 by restriction enzyme *Sa*II and *Xba*I and the amplicon is cloned at *Sa*II and *Xba*I site of M13mp18 RF I.

[0129] When M13 infects the bacterial cells, it does not kill them, but the phage DNA replicates inside the cell and expresses phage genes. Thus M13 phage infection with an M13::CRISPR/Cas9/anti-*bla* phage recombinant should result in inactivation of the *bla* gene, in contrast, in a negative control, to infection by an M13::CRISPR/Cas9 phage recombinant lacking anti-*bla* region. Because M13 phage infection slows down the rate of cell growth, when infected cells grown on a lawn of cells yield turbid plaques of slow growing infected cells. If nitrocefin is added to the growth medium, the efficacy of CRISPR/Cas9/anti-*bla*-mediated inactivation of the *bla* gene efficiency is calculated by measuring the fraction of white colonies to red colonies, when plaques are picked and grown as colonies to remove the background lawn. Plaques may also be picked and plated onto LB plate with/without ampicillin to score the ratio of ampicillin sensitive to ampicillin resistant colonies that will result.

B. Selection of spacer sequence from the target sequence

[0130] We can use Guide RNA Target Design Tool (see; <https://www.blueheronbio.com/external/tools/gRNASrc.jsp>)

from BlueHeron to select spacer sequence from the target. This program simply returns the 20 nt spacer sequence with the appropriate PAM (protospacer adjacent motif) sequence in the 3' end and GC content. It does not consider secondary structure stability and sequence specificity. Secondary structure prediction and specificity search is performed manually.

[0131] We choose the actual spacer sequence from the candidate sequences obtained in the above program, which should meet the following two criteria: 1) low tendency to form stable secondary structure of crRNA, 2) no target DNA on the host genomic DNA. It may be very difficult to find a unique sequence to satisfy criterion No.2. Considering mismatched target data from Figure 3 E in Jinek et al Science 337, 816 (2012), criterion No.2 is relaxed to allow a matched sequence up to the 12th nucleotide position in the target sequence (the first nucleotide position is counted from just next to the PAM sequence). In other words, when the first 12 mer protospacer sequence of the target sequence is completely matched to the 12 mer sequence of crRNA spacer sequence in the 3' end, but the rest of the sequence is not matched, it is assumed that target dsDNA is not cleaved. The specificity check of the protospacer sequence along the *E.coli* K12 genome sequence is performed by BLAST. The *bla* sequence is searched against the subject sequence *Escherichia coli* str. substr. MG1655 ([http://www.ncbi.nlm.nih.gov/nucleotide/556503834?report=genbank&log\\$=nuclalign&blast_rank=1&RID=JUYB76FX014](http://www.ncbi.nlm.nih.gov/nucleotide/556503834?report=genbank&log$=nuclalign&blast_rank=1&RID=JUYB76FX014)), and each of any matched chromosomal sequence is mapped against the *bla* sequence for counting the seed sequence from the canonical PAM (NGG) sequence. Secondary structures can be predicted by mFold. (<http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form>) to choose the sequence whose G is large as possible, preferably to be positive for crRNA spacer secondary structure. The following is the way to select the appropriate spacer sequences from the *bla* sequence.

Table 1. Candidate anti-protospacer sequence.

Seq	Location	anti-protospacer seq	SEQ ID NO	MG1655	pCas9	pBR322	PAM	GC	ΔG
				Off targ	Off targ	Off targ			
05	83-102(F)	TAGATAACTACGATACGGGA	100	CGGGA	None	None	GGG	0.48	-0.40
05	83-102(F)	TAGATAACTACGATACGGGA	100	5			GGG	0.48	+0.50
22	442-461(F)	GATCGTTGTCAGAAGTAAGT	101	AGTAAGT	AGTAAGT	None	TGG	0.43	-0.80
22	442-461(F)	GATCGTTGTCAGAAGTAAGT	101	7	7		TGG	0.43	-0.50
30	647-666(F)	ACTTTAAAAGTGCTCATCAT	102	TCAT	ATCAT	None	TGG	0.35	-1.30
30	647-666(F)	ACTTTAAAAGTGCTCATCAT	102	4	5		TGG	0.35	-1.30
35	767-786 (F)	TTTACTTTCACCAGCGTTTC	103	GCGTTTC	TTTC	None	TGG	0.43	+1.30
35	767-786 (F)	TTTACTTTCACCAGCGTTTC	103	7	4		TGG	0.43	+2.20
65	231-250 (RC)	ATTAATAGACTGGATGGAGG	104	GATGGAGG	GAGG	GAGG	CGG	0.48	+0.00
65	231-250 (RC)	ATTAATAGACTGGATGGAGG	104	8	4	4	CGG	0.48	+0.90
66	234-253 (RC)	ACAATTAATAGACTGGATGG	105	GATGG	None	None	AGG	0.39	-0.30
66	234-253 (RC)	ACAATTAATAGACTGGATGG	105	5			AGG	0.39	+0.20
67	237-256 (RC)	GCAACAATTAATAGACTGGA	106	GACTGGA	CTGGA	CTGGA	TGG	0.39	-0.20
67	237-256 (RC)	GCAACAATTAATAGACTGGA	106	7	5	5	TGG	0.39	-0.20
	241-260		107						

Seq	Location	anti-protospacer seq	SEQ ID NO	MG1655	pCas9	pBR322	PAM	GC	ΔG
68	(RC)	CCCGGCAACAATTAATAGAC		AATAGAC	AGAC	None	TGG	0.48	+1.80
68	241-260 (RC)	CCCGGCAACAATTAATAGAC	107	7	4		TGG	0.48	+2.60
69	259-278 (RC)	AACTACTTACTCTAGCTTCC	108	AGCTTCC	GCTTCC	None	CGG	0.48	+0.60
69	259-278 (RC)	AACTACTTACTCTAGCTTCC	108	7	6		CGG	0.48	+1.60
70	284-303 (RC)	ACGTTGCGCAAACATTAAC	109	TATTAAC	None	TAAC	TGG	0.43	-1.90
70	284-303 (RC)	ACGTTGCGCAAACATTAAC	109	7		4	TGG	0.43	-1.90
73	375-394 (RC)	TGTAACTCGCCTTGATCGTT	110	TCGTT	CGTT	CGTT	GGG	0.52	-0.50
73	375-394 (RC)	TGTAACTCGCCTTGATCGTT	110	5	4	4	GGG	0.52	+0.10
74	376-395 (RC)	ATGTAACTCGCCTTGATCGT	111	TTGATCGT	TCGT	None	TGG	0.48	-0.50
74	376-395 (RC)	ATGTAACTCGCCTTGATCGT	111	8	4		TGG	0.48	+0.10
81	443-462(RC)	AACTTACTTCTGACAACGAT	112	CAACGAT	None	None	CGG	0.43	+0.40
81	443-462(RC)	AACTTACTTCTGACAACGAT	112	7			CGG	0.43	+0.40
84	528-547(RC)	AGTCACAGAAAAGCATCTTA	113	GCATCTTA	None	None	CGG	0.43	-0.50
84	528-547(RC)	AGTCACAGAAAAGCATCTTA	113	8			CGG	0.43	+0.50
90	638-657(RC)	ACTTTTAAAGTTCTGCTATG	114	GCTATG	None	None	TGG	0.35	-0.70
90	638-657(RC)	ACTTTTAAAGTTCTGCTATG	114	6			TGG	0.35	+0.10

[0132] All the target sequence from the *bla* gene was obtained using Guide RNA Target Design Tool (<https://www.blueheronbio.com/external/tools/gRNASrc.jsp>) from BlueHeron. There are 98 target candidate sequences returned. Bacterial off-target chromosomal short similar sequences are mapped against the *bla* gene followed by counting the seed sequence from the canonical PAM sequence. Choose the sequences whose seed sequence number is less than eight and whose Gibbs free energy is relatively large. The summary of the property of the selected target sequences is shown in Table 1. This table also shows nucleotide length of the seed sequence of the off-target sequences on pCas9 and pBR322.

Oligo cassette sequence for spacer sequence

[0133] The following four spacer sequences are crRNA generating cassettes targeting beta-lactamase on pBR322 in *E. coli* as a host strain, which meet the above two criteria. crRNA CR05 cleaves phosphodiester bond between 762nd base C and 763rd base C, CR30 cleaves phosphodiester bond between 198th base G and 199th base A, CR70 cleaves phosphodiester bonds between 575th base T and 576th base A and CR90 cleaves phosphodiester bonds between 221st base T and 222nd base A on the beta-lactamase gene.

[0134] Adaptors for single targets on the beta-lactamase gene.

CR05
5'-AAACTAGATAACTACGATACGGGAg SEQ ID NO: 115 atctattgatgctatgccctcAAAA-5' SEQ ID NO: 116

CR30
5'-AAACACTTTTAAAGTGCTCATCATg SEQ ID NO: 117 tgaaattttcacgagtagtacAAAA-5' SEQ ID NO: 118 *DraI*

CR70
5'-AAACACGTTGCGCAAAC TATTAACg SEQ ID NO: 119 tgcaacgcgtttgataattgcAAAA-5' SEQ ID NO: 120 *AcI*

CR90
5'-AAACACTTTTAAAGTTCTGCTATGg SEQ ID NO: 121 tgaaaatttcaagacgataccAAAA-5' SEQ ID NO: 122 *DraI*

[0135] Adaptor for dual targets on the beta-lactamase gene.
Internal direct repeat sequence is italicised and underlined.

CR30+CR90 SEQ ID NO: 123
5' -AAACACTTTAAAGTGCTCATCATGTTT TAGAGCTATGCTGTTTTGAATGGTCCCAAACACTTTTAAAGTTCTGCTATGg
tgaaattttcacgagtagtacaaaatctcgatacgcacaaaacttaccagggttttgtgaaaatttcaagacgataccAAAA
DraI CR30 DraI CR90

SEQ ID NO: 124

[0136] The 5' end of each oligo is phosphorylated and ready for cloning at *BsaI* sites.
Sites of six base cutter restriction endonucleases are underlined, which are useful to screen the recombinants. We can also employ one of the cassette oligos as a primer to screen the recombinants by PCR together with another unique primer for the plasmid vector.

Appendix 1

pCas9 plasmid sequence (SEQ ID NO: 125)

[0137] Cas 9 gene, CRISPR expression locus and tracrRNA (all from *S. pyogenes*)

GAATTCCGGATGAGCATTTCATCAGGCGGGCAAGAATGTGAATAAAGGCGGGATAAAACTTGTGCTTATTTTTCTTTACGG
TCTTTAAAAAGGCCGTAAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCYCAAAATGT
TCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGA
AAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCAATATGGTGAAAGTTGGAACCTCTTACGTGCCGAT
CAACGCTCTCATTTTCGCCAAAGTTGGCCCGAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTTCTGCGAAG
TGATCTTCCGTCACAGGTATTTTATTCGGCGCAAGTGCGTCGGGTGATGCTGCCAACTTACTGATTTAGTGATGATGGT
GTTTTTGAGGTTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCCYGTTCAGCTACTGACGGGGTGGTGGGTAAOGGC
AAAAGCACCGCCGGACATCAGCGCTAGCGGAGTGTATACTGGCTTACTATGTTGGCACTGATGAGGGTGTCACTGAAGTG
CTTCATGTGGCAGGAGAAAAAGGCTGCACCGGTGCGTCAGCAGAAATATGTGATACAGGATATATTTCCGCTTCCFCGCTC
ACTGACTCGCTACGCTCGGTCTGTTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCTCTGGAAGATGC
CAGGAAGATACTTAACAGGGAGTGAAGGGCCCGCGCAAAAGCCGTTTTTCCATAGGCTCCGCCCCCTGACAAAGCATCA
CGAAATCTGACGCTCAAACTCAGTGGTGGCGAAACCCGACAGGACTATATAAGATACCAGGCGTTTCGCCCCGGGGCTCCCC
TCGTTGCCCTCTCCTGTTCTCTGCTTTCCGTTTTACCGGTCTCATCCGCTGTTATGGCCGCTTTGCTCATTTCCACGCCCT
GACACTCAGTTCCGGGTAGGCAGTTCTGCTCCAAGCTGGACTGTATGCACGAACCCCGGTTTCAGTCCGACCGCTGCGCCT
TATCCGGTAACTATCGTCTTGAGTCCAAACCCGAAAGACAAGCAAAAGGACCACTGGCAGCAGCCACTGGTAATTGATTT
AGAGGAGTTAGTCTTGAAGTCAATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTTGGTGACTGCGCTCCATCAAGCC
AGTTACCTCGGTTCAAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTTCAGAG
CAAGAGATTACCGCCAGACCAAAACGATCTCAAGAAGATCATCTTATTAAATCAGATAAAATATTTCTAGATTTTCAGTGCA
ATTTATCTCTTCAAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTAATTCTCATGTTTGACAGCTTATCATC
GATAAGCTTTAAATGCGGTAGTTTATCAGAGTTAAATTGCTAACGCAGTCAGGCACCGGTGATGAAATCTAACAATGCGCT
CATCGTCATCCTCGGCACCGTCAACCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGCTACTGCCGGGCCCTCTTGCGGG
ATTACGAAATCATCCTCGGAGCTTAGTAGGTTTAGCAAGATGGCAGCGCCAAATGTAGAATGATAAAAGGATTAAGAG
ATCAATTTCCCTAAAAATGATAAAACAAGCGTCTTGAAAGCGCTTGTTTTTTTGGTTTCGAGTCAGAGTAGAATAGAAGT
ATCAaaaaaaagcaccgactcggtgccactttttcaagttgataacggactagccttatttttaacttgctatgctggttttg
aatggtttccAACAGATTAATTTATAACTTTTATAACAAATAATCAAGGAGARATTCAAAGAAATTTATCAGCCATAAAA
CAATACCTAATACATAGAAATGAAACAAAATAAACACTTCTTAAAGAAATTTTGTGTAAATCAATTAATTAATTAAG
TACTGGGTAAATATTTCTGAAGAGATATTTGAAAAAGAAAAATTAAAGCATATTAAACTAATTTCCGGAGGTCACTAAAA
CTATTAATTGAATCATCAACCTCATTATGGATTTAATTAACCTTTTATTTTAGGAGGCCAAA

ATGGAJAAGAAAAATCTCAAAGGCTTAGATAACGGCACAAATAGCGTCGGATGGGCGGTGAACACAGAGAAATAAAGG
TCCGTCTAAAAAGTTCAAGGTTCTGGGAAATACAGACCGCCACAGATCAAAAAAAATCTTATAGGGGCTCTTTATTTG
ACAGTGGAGACACAGCGGAAGCGACTCTCTCAAACGGACAGCTCTGTAAGGATATACAGCTCGGAAGAACTGTATTTGT
TATCTACAGGAGATTTCTCAAATGAGATGGCGAAAGTAGATGATAGTTTCTTCATCGACTTGAAGAGTCTTTCTGGT
GGAAGAAGACAAGAAGCATGAACGTCACTCCTATTTTGGAAATATAGTAGATGAAGTTGCTTATCATGAGAAATATCCAA
CTATCTATCATCTCGGAAAAAAATGGCAGATCTCTACTGATAAAGCGGATTTGCGCTTAATCTATTTGGCCTTAGCGCAT
ATGATTAAGTTTCGTGGTCAATTTCTGATTGAGGGAGATTTAAATCCTGATAACAGTGAATGGGACAAACCTATTTATCCA
GTTTGGTACAAACCTACAAATCAATTAATTAAGAAAAACCCATTAACGCAAGTGGAGTAGATGCTAAAGCGATTTCTCTG
CACGAATGAGTAAATCAAGACGATAGAAAACTTCATTCGCTCAGCTCCCCGGTGAAGAAAAATGGCTTAATTTGGGAAAT
CTCATCTGCTTTGTCATTTGGTTTTGACCCCTAATTTTAAACCAATTTTGAATTTGGCAGAAGATGCTAAATACAGCTTTT
AAAAGATACCTACGATGATTTAGATAATTTATTTGGCGCAAAATGGAGATCAATATGCTGATTCGCTTTTGGCAGCTA

AGAATTTATCAGATGCTATTTTACTTTTCAGAAATCCTAAGAGTAAATACITGAAAIAACTTAAGGCCTCCCTATCAGCTTCA
ATGATTAACCGCTACGATGAACATCATCAAGACTTGACTCTTTTAAAGCTTTAGTTCGACAACTTCCAGAAAAGTAA
TAAAGAAATCTTTTGTCAATCAAAAACGGATATGCAGGTTATATTGATGGGGGAGCTAGCCAGAAGAAATTTATA
AATTTATCAAACCAATTTTAGAAAAAATGGATGGTACTGAGGAATCATTTGGTGAACCTAAATCGTGAAGATTTGCTGCGC
AAGCAACGGACCTTTGACAACGGCTCTATTTCCCAATCAATTCACCTGGGTGAGCTGCACTGCTATTTTGAGAAGACAAGA
AGACTTTTATCCATTTTCAAAGACAATCGTGAGAAGATGAAAAAATCTTGACTTTTCGAATTCCTTATATGTTGGTCTC

CATTGGCGCGCTGGCAATAGTCGTTTTTGCACTGGATGACTCGGAAGTCTGAAGAAACAATTACCCCATGGAATTTGAAGAA
GTTGTTCGATAAAGGTGCTTCAGCTCAATCATTTATTTGAACGCATGACAAACTTTGATAAAAACTTCCAAATGAAAAAGT
ACTACCAAAACATAGTTTGCTTTATGAGTATTTTACGGTTTATAACGAATTGACAAAGGTCAAATATGTTACTGAAGGAA
TGCGAAAACCAAGCATTTCTTTTCAGGTGAACAGAAGAAAGCCATTGTTTGACTTACTCTTCAAACAAAATCGAAAAGTAACC
GTTAAGCAATTTAAAAGAAGATTACTTCAAACAAAATAGAATGTTTTGATAGTGTGAAATTTCCAGGAGTTGAAGATAGATT
TAAATGCTTCACTAGGTACCTACCATGATTTGCTAAAAATTTATTAAGATAAAGATTTTTTGGATAAAGAAGAAAAAGA
ATAATCTAGAGGATATTTGTTTAAACATTCACCTTATTTGAAGATAGGGAGATGATTTAGGAAAGACTTAAACATATGCT
CACCTCTTTGATGATAGGTGATGAAACAGCTTAAACGCTCGCGTTTACTGCTGGGGACGTTTGTCTCGAAAAATTGAT
TAAATGGTATTAAGGATTAAGCAATCTGGCAAAACAATATAGATTTTGTGAATCAGATGGTTTGGCCAAATCGCAATTTTA
TTGCAGCTGATCCATGATGATGATTTGACATTTAAAGAAGACATTCAAAAAGCACAACTGTCTGGAACAAGGCGATAGTTTA
CATGAACATACTGCAAAATTTAGCTGGTAGCCCTGCTATTAATAAGGTAATTTACAGACTGTAAGATGTTGTTGATGAATTT
GGTCAAAGTAAATGGGGCGGCATAAGCCAGAAAAATATCGTTATTGAAATGGGCAGTGAATAACAGACAACCTAAAGGGCC
AGAAAAATTCGCGAGAGCGGTATGAACGAATCGAAGAAGGTATCAAAGAAATTAGGAAGTCAAGATTTTAAAGAGCATCCT
GTTGAAAAATACCTCAATTCGCAAAAAGAAAGCTCTATCTCTATTTATCTCCAAAAAGGAAGAGACATGATGTTGGACCAAGA
ATTAGATATCAATCGTTTAAAGTATATGATGTCGATTCACATTGTTCCACAAAGTTTCTCTAAAGACGATTCACATAGACA
ATAAGGTCTCAACGCGTTCTGATAAAAAATCGTGGTAAATCGGATAACGTTCCAAAGTGAAGAAGTAGTCAAAGAGATGAAA
AACTATTGGAGACAACCTCTAAACGCCAAGTTAAATCCTCAACGTAAGTTTGATTAATTAACGAAAGCTGAACGTTGGAGG
TTTGAGTGAACCTTGATAAAGCTGGTTTTATCAAACGCCAATTTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAA
TTTTGGATAGTCCGATGAATACTAAATACGATGAAATGATAAACTTATTCGAGAGGTAAAGTGAATACCTTAAATCT
AAATTAGTTCTCTGACTCCGAAAAGATTTCCCAATCTATAAAGTAGCTGAGATTAACAATTACCATCATGCCCATGATGC
GTATCTAAATGGCGCTCGTTGGAACTGCTTTGATTAAGAAATATCCAAAATCTGAATCGGAGTTTGTCTAATGGTGAATATA
AAGTTTAAAGATGTTCTGAAAAATGATTTGCTAAGTCTGAGCAAGAAATAGGCAAGCAACCGCAAAAATATTTCTTTACTCT
AATATCATGAACCTCTCTCAAACAGAAATTTACACTGCAAAATGGAGAGATTCGCAACGCCCTCTAATCGAAACTAATGG
GGAAACTGGAGAAATTTGCTGGGATAAAGGGCGAGATTTTGCACAGTGGCGAAAGTATTTGTCATGCCCAAGCTCAATA
TTGTCAAGAAACAGAAATACAGACAGGCGGATTTCTCAAGGAGTCAATTTTACCAAAAAGAAATTCGAGCAAGCTTATT
GCTCGTAAAAAAGACTGGGATCCAAAAAATATGTTGGTTTGATAGTCCAAACGGTAGCTTACTCAGTCTAGTGGTTGCT
TAAGGTGGAAAAAGGGAAATCGAAGAAATTAATAACCGCTTAAAGAGTTTACTAGGGATCACAAATTAAGGAAAGAAATGCT
TTGAAAAAAATCCGATCGACTTTTAGAAGCTAAAGGATATAAGGAAGTCAAAAAAGACTTAATCATTAACCTACCTAAA
TATAGTCTTTTGTAGTGAAGAAACGGTCTGAACGGATGCTGGCTAGTGGCGGAGAAATTAACAAAGGAAATGAGCTGGC
TCTGCCAAGCAAAATATGTGAATTTTATATTTAGCTAGTCAATTAAGAAAGTGAAGGGTAGTCCAGAAATTAACGAAC
AAAAACAATTTGTTTGGAGGAGCATTAAGCATTAATTAAGATGAGATTAATGAGCAAAATCAGTGAATTTTCTAAGCGTGT
ATTTTAGCAGATGCCAATTTAGAATAAGTTTCTTAGTGCATATAACAAACATAGAGACAAACCAATACGTGAACAAGCAGA
AAATAATATTCATTTAATTTACGTGAGCAATTTTGGAGCTCCCGCTGCTTTAAATATTTTATACAACAAATGAATCGTA
AAGCATATACGTCTACAAAAGAAATTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTATGAACACAGCAT
GATTTGAGTCAGCTAGGAGGTGACTGA

-10 promoter (SEQ ID NO: 127)

AGTAATTTTAGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAATACTCTTAATAAATCAGT

Leader sequence (SEQ ID NO: 128)
AATACAGGGCTTTGACACCTCAGATCTAGCTGAGACAAATAGTGGGATTACGAAATTTTATAGACAAAATAGTCTA

Direct repeat	Spacer	Direct repeat
GGGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACT	GAGACCAGTCTCGGAAGCTCAAGGCTCTCGTTTTAGAGCT	
	BsaI	BsaI
repeat	Spacer	Direct repeat
ATGCTGTTTTGAATGGTCCCAAAACTTCAGCACACTGAGACTCGTTGAGTTCCATGTTTTAGAGCTATGCTGTTTTGAAT		
GGACTCCATCAACATTCGCGATGATAACTTGAGAAAGAGGCTTAATACCAGCAGTCGGAATCCTTCTATTTCTGT		
JAAAGCGTTTTCATGTTATAATAGGCAAAAGAGAGTAGTGTGATCGTCCATTCGACAGCATCGCCAGTCACTATGGCG		
TGCTGCTAGCGCTATATGCGTTGATGCAATTTCTATGCGCACCGGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCGCG		
CCAGTCCYGTGCTTCGCTACTTGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTTCTTGIGGATCCTCTA		
CGCCGGAGCGATCGTGGCGCGCATCACCGCGCCACAGGTGGGTTGCTGGCGCTTATATCGCCGACATCACCGATGGGG		
AAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTCGGCGTGGGTATGGTGGCAGGCCCCGTGGCGGGGGACTG		
TTGGGCGCCATCTCTTGCATGCACCATTCCTTGGCGCGCGGTGCTCAACGSCCTCAACCTACTACTGGGCTGCTTCCT		
AATGCAGSAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAAGCTCTTCCGGTGGCGC		
GGGGCATGACTATCGTTCGCGCACTTATGACTGTCTTCTTATCATGCAACTCGTAGGACAGGTGCGCGCAGCGCTCTGG		
GTCAATTTTCGGCGAGGACCGCTTTCGCTGGAGCGCGACGATGATCGGCTGTCTGCTTGGGTATTTCGAAATCTTGCACGC		
CCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAACGTTTCGGCGAGAAGCAGGCCATTATCGCCGGCATGGCGGCCG		
ACGGCGTGGGCTACGCTCTTGTGGCGTTCGCGACGCGAGGCTGGATGGGCTTCCCAATATGATTTCTCTCGCTTCGGCG		
GGCATCGGGATGCCCGGCTGTCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCT		
CGCGGCTCTTACCAGCTTAACCTTCGATCATTTGGACCGCTGATCGTCACGGGCATTTATGCGCGCTTGGCGAGCACATGGA		

ACGGGTGGCATGGATTGTAGGCGCGCGCTTATACCTTGTCTGCTTCCCGCGTTGCGTTCGCGGTGCATGGAGCCGGGCGC
ACCTCGACCTGAATGGAAGCGCGCGCACCTCGCTAACGGATTCACCACCTCCAAGAATGGAGCCAATCAATTTCTGCGG
AGAACTGTGAATGCGCAAAACCAACCTTGGCAGAACATATCCATCGCGTCCGCCATCTCCAGCAGCCGCACGGCGGCAT
CTCGGGCAGCGTTGGGCTCTGGCCACGGGTGCGCATGATCGTGTCTCTGTCTGAGGACCGGCTAGGCTGGCGGGGTT
GCCCTTACTGGTTAGCAGAAATGAATCACCGATAGGCGAGCGAAGTGAAGCGACTGCTGCTGCAAAACGCTTCTGCGACTGA
GCAACAACATGAATGGTCTTCGGTTTCCGHTTTCGTAAGATCTGAAACCGCGGAAGTCCCTACGTGCTGCTGAAGTTG
CCCGCAACAGAGAGTGGAAACACCGGTGATACCAGATACTATGACTGAGAGTCAACGCGATGAGCGGCCYCATTTCTTT
ATTTGAGTTACAACAGTCCGCACCGCTGTCCGGTAGCTCCTTCCGGTGGCGCGGGGCATGACTATGCTCGCCGCACTT
ATGACTGTCTTCTTTATCATGCAACTCTGAGGACAGGTGCGCGCAGCGCCCAACAGTCCCCCGGCCACGGGGCTGCCAC
CATACCACGCGCAACAGCGCCTGCAACATTATGTTCCGGATCTGCTCGCAGGATGCTGCTGGCTACCTGTGGAA
CACCTACATCTGTATTAACGAAGCGCTAACCGTTTTTATCAGGCTCTGGGAGGCGAGAAATGAATGATCATATCGTCAATTA
TTTACCTCCACGGGGAGAGCCCTGAGCAAACTGGCCCTCAGGCATTTGAGAAGCACACGGTCAACACTGCTTCCGGTAGTCAAT
AAACCGGTAAACAGCAATAGACATAAGCGGCTATTTAAACGACCTTGCCTGAACCGACGACCGGGTGAATTTGCTTT
GAATTTCTGCCATTCTATCGCTTATTAATCACTTATTCAGGCGTAGCACCGGCGTTAAGGGCACCAATAACTGCCTTAA
AAAAATTAACGCGCGCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTCGCGGACATGGAAGCCATCACA
GACGGCATGATGAACCTGAATCGCCAGCGGCATAGCACCTTGTGCGCTTGGCTATAATATTTGCCCATGGTGAAACGG
GGGCGAAGAGTTGTCCATATTTGGCCACGTTTTAAATCAAAACTGGTGAAACTCACCCAGGAGTTGGCTGAGACGAAAC
ATATTTCTCAATAAACCCCTTTAGGGAAATAGGCCAGGTTTTTACCCTGAACACGCCACATCTTCCGAATATATGTGTAGAAA
CTGCGGAAATCGCTGGTATTTCACTCCAGAGCGATGAAACGTTTCAGTTTTGCTCATGGAACCGGTGTAAACAGGGT
GAACATATCCATATACAGGCTCACCGTCTTCAATGCCATACG

[0138] The reverse complement of tracrRNA is in lowercase, Cas9 coding sequence (SEQ ID NO: 126) is boxed and

direct repeat sequence in CRISPR is in bold. Promoter sequences were predicted by neural network algorithm (http://www.fruitfly.org/seq_tools/promoter.html). The two unique sites, *Sa*/I (GTCGAC) and *Xba* I (TCTAGA) highlighted in bold italicised black are utilised to isolate the CRISPR/Cas9 construct for cloning into M13mp18. The pACYC184 backbone sequence is italicised.

[0139] The information of Appendix 1 above is alternatively presented as follows.

pCas9 plasmid sequence (SEQ ID NO: 125)

[0140] Cas 9 gene, CRISPR expression locus and tracrRNA (all from *S. pyogenes*)

*GAATTCCGGATGAGCATTTTCATCAGGCGGGCAAGAATGTGAATAAAGCCCGGATAAAACCTTGTCCTATTTTTCTTTACGG
TCITTTAAAAAGGCCGTAAATATCCAGCTGAACGCTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAATGT
TCITTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGA
AAATCTCGATAAATCAAAAATACGCCCGGTAGTGAATCTTATTTCATTATGTTGAAAGTTGGAAACCTCTTACGTGCCGAT
CAACGCTCTCATTTTCGCCAAAAGTTGGCCGAGGGCTTCCCGGTATCAACAGGACACCCAGCAITTTATTTATCTPGCGAAG
TGAATCTTCCGTCACAGGTATTTATTTCCGGCCAAAAGTGGCTCGGGTGATGCTGCCAACTTACTGATTTAGTGTATGATGGT
GTTTTTGAAGTGTCTCAGTGGCTTCTGTTTCTATACAGCTGTCCCTCCTGTTCAAGTACTGACGGGTGGTGGCTTAACGGC
AAAAGCACCGCCGACATCAGCGCTAGCGGAGTGTATATCGGCTTACTATGTTGGGACTGATGAGGGTGTCACTGAAGTG
CTTCATGTGGCAGAGAAAAGAGGCTGACCGGTGGCTCAGCAGATATGTGATACAGGATATATTCGGCTTCCTCGCTC
ACTGACTCGCTACGCTCGGTCCTTCSACTGCGSCSAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCCTGGAAGATGC
CAGGAAGATACCTTAAACAGGAAGTGAGAGGGCCGCCGCAAGCGGTTTTTCCATAGGCTCCGCCCCCGTGACAAAGCAACA
CGAAATCTGACGCTCAAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACAGGGCGTTTCCCGCTGGCGGGTCCCT
TCGTGGGCTCTCCCTGTTTCCTGCCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCGCGCTTTGTCTCATTCCACGCGCT
GACACTCGATTCCCGGGTAGGCACTTCGCTCCAGCTGGACTGTATGCCAGAAACCCCGGTTCCAGTCCGACCGCTGGCGCT
TATCCGGTAACCTATCGCTTTGAGTCCAAACCCGAAAGACATGCAAAAACCACTGGCAGCAGCCACTGGTAATTGATTT
AGAGGAGTTAGTCTTTGAAGTCATGCGCCCGTTAAAGCTAAACTGAAAGGACAAAGTTTGTGTGACTCGGCTCCTCCAGGCC
AGTTACCTCGGTTCAAGAGTTTGTAGCTCAGAGAACCCTCGAAAACCCGCCCTGCAGGGCGGTTTTTTTCGTTTTCAGAG
CAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTCAAGATTTCAGTGCA
ATTTATCTCTCAAAATGTAGCACTTGAAGTCAAGCCCATACGATATAAGTTGTAATTTCTATGTTTGAACAGCTTATCTATC
GATAAGCTTTAATGGGTTAGTTTATCAGCTTAAATGCTAACGCAGTCAGGCACCGGTGATGAAATCTAACAAATCGGCT
CATCGTCATCCTCGGCACCGTCACCGTGCAATGCTGTAGGCATAGGCTTGGTTATGCCGTACTGCCGGGCGCTCTTGGCGG
ATTCAGGAATCTTCCTGTGGAGCTTGTAGGTTAGCAAGATGGCAGCGCTAAATGTAGAATGATTAAGAGATTAAGAG
ATTAATTTCCCTAAAACATATAAAACAGCGTTTTGAAAGCGCTTGTTTTTTGGTTTTGCACTCAGAGTAGAATAGAGAT
ATCAAAAAGACACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCCTATTTTAACTTGCTATGCTGTTTTG
AATGGTTCCACACAGATTATctttataactctttataacaaataatcaagtgagaaattcagaagaaattccatGAGCCATAAAA
CAACTACTTAATCTATAGAAATGATTAACAAAATAAACTACTCTTCAAAAGAAATTTGTGCTATATAATCTATTATTATTAG
TA"gggtaaatattctttcaagagataattctgaaagaaagaaataaagagcaataTTAAACTAAATTTCCGAGGGTCA"AAAA
CTACTATTGAAATCATCAAACTCATACGGATTAACTTTAACTTTAGAGAGCAAAAATGGATAAGAAATACT*

*CATAGGGCTTAGATATCGGCACAAATAGCGTCTGGAATGGCGGTATCACTGANTGAATATGAAGTTCGGCTCAAAAAGTTC
AAGGTTCTGGGAAATACAGACCGCACAGTATCAAAAATAATCTTACAGGGGCTCTTTTATTGTACAGCTGGAGAGACAGC
GGAGGCGACTCGCTCCAAACGGACAGCTCCGAGAGGTATACAGCTCGGAAGAACCGTATTTGCTATCTACAGGAGACTTT
TTC"CAATGAGATGGCGAAAGTAGATGATGTTCTTTCATCGACTTGAGAGTCTTTTCTGGTGGAGAGAGACAGAG
CATGAACGTCACTCCTATTTTTGGAAATATAGTAGTAAAGTGTCTTATCATGAGAAATATCCAACATCTATCATCTCGG
AAAAAAAT"TGTTAGATTCT"ACTGATTAAGCGGATCTGGCGTTTATCT"ATTTGGGCTTAGCGCATATGATTAAGTTCTGTE
GTGATTTCTTGATTGAGGGAGATCTTAATCCTGATTAATAGTGACTGGGCAAAACTATTEATCCAGTTTGATCAAACTATC
AATCAATTAATTTGAAGAAACCCCTATTAACGCAAGTGAGTGAATGCTAAAGCGGATTCCTTCTGCACGATTGAGTAATAC
AAGACGATTAAGAAATCTCATTTGCTCAGCTCCCGGGTGAGAGAGAAATAGGCTTAATTTGGGAATCTCATTTGCTTTGTCTAT
TGGTTTTGACCCCTAATCTTAAGTCAAAATTTGATTTGGCAGAGAGTCTAAATACAGGCTTTCAAAAAGTACTGACGAT
GATGATTTAGATAAATTTATTTGGCGCAATTTGGAGATCAATATGCTGATTTGTTTTTGGCAGCTAAGAAATTTATCAGATGC
TACTTTACTTTCAGATATCCTAAGAGTAAACTACTGAAATAACTAAGGCTCCCGCTACAGGCTCAAGCTTAAGCTTAAGCGCTAGC
ATGAGACATCATCAAGACTCGACTCTTTAAAAGCTTAGTTCGACAAACAACTTCGAGAAAGATATAAGAAATCTCTTTT
GATCAATCAAAAACGGATATGAGGTTTATATTGATGGGAGCTAGCGAAGAGAAATTTTATTAATTTATCAAAACCAAT
TTTAGAAAAAATGGATGGTACTGAGGAATTATTGGTGAACATAAATCTGAAGATTTGCTGCGCAAGCAACGGACTTTTG
ACAAAGGGCTCTATCTCCCGATCAAACTCAGCTGGGTGAGGCTGCAGGCTATCTTGAGAGACAGAGAGACTTTATCCACTT
TTTAAAGACAAATCGTGAGAAATTTGAAAATCTTGACTTTTCGAATTTCTTATTTATGTTGGTCCATTTGGGCGGTGGCAA
TAGTGGTTTTGCACTGGACTCGGAAGTCTGAAGAAACAAATTACCGGATGGAACTTTGAAGAGTTGTGATATAAGGGTG
CTCGAGCTCAATTCATTTATAGCGCATGACAAACTTGATAAAACCTTCCAAATGAATAAGTACTACCAAAACACAGT
TTGCTTTATAGTACTTTTACGGCTTATAACGAATTGACAAAGGTCAAACTATGTTACTGAAAGGAATGGCAAAACCGAGCTT
TCTTTCAGGTTGACAGAGAAAGGCCATTTGTGATTTACTCTTCAAAACAAATCGAAAGATAACGCTTTAAGCAATTAAGAG
AAGATTATTTCAAAAATTAAGATCTTTTGATAGTGTGAATTTTCAGAGTTTGAAGTGAATTAAGTGTCTCATTAAGT
ACCTACCATGATTTCTTAAAAATTAATAAGATAAGATCTTTTGGATAATGAAGAAATGAAGATATCTTAGAGGATAT
TGTTTTTAACATTTGACCTTTATTTGAAGATAGGGAGATGATTAAGAAAGCTTAAGACATATGCTCACCTCTTTGATGATA
AGGCTATGAACAGGCTTAAACGTGCGCGTTATAC"GGTTGGGGAGCTTTGTCTCGAAAATTGATTAATSGTATTAGGGAT
AAGCAATCTGGCAAAACAAATATTAGATTTTGTGAACAGATGCTTTGCCAATCGCAATTTTATGCACTGATCCAGTGA
TGATGTTTTGACATTAAGAGAGACATTTCAAAAGCACAACTGTCTGGACAAAGCGATAGTTTACATTAACATTAAGTGA
ATTTAGCTGCTAGGCCCTGCTATTAAAAAGAGTATTTTACAGACTGTAAAAGTTGT"GAAGAAATTTGTCAAAATTTGAGG
CGGCATTAAGCGAGAAATCTGCTATTGAATGGCACCTGAAAATCAGACAACTCAAAAGGGCCGAAAAAATTCGCGAGAG
GCCATGAAGACGAATCGAGAGAGGTATCAAGAGATTAAGAAATCAGATCTTAAGAGGCACTCTGTTGAAGATTAAGTCAAT
TGCAAAATGAAGAGCTCTATCTCTATTATCTCCAAATGGAGAGACATGTATGTGGACCAAGATTAAGATATTATCTGT
TTAAGTGATTTATGATGTGATCAGATTTCTCCAGAGAGTTTCCCTAAGAGAGGATTAATAGACATTAAGGCTTATAGCGG
TTCTGATTAATACTGTGTTAATCGGATTAAGTTTCAAGTGAAGAGTATCAAAAGATGAAGAACTATTGGAGCAAC
TTCTAAAACGGCAAGTAACTCACTCAACCTAAGTTTGATAACTTAACGAAAGGCTGAACGTGGAGGCTTGAGTGAACCTGAT
AAAGCTGGTTTTATCAAAACGCCAATTTGTTGAAGCTGCCAAATCACTAAAGCATTTGGCCAAATTTTGGATAGTCCGAT
GAACACTAAATACGATGAATATGATTAATCTTATCGAGAGTTTAAAGTGATTACCTTAAATCTAAATTAAGTTTCTGACT
TCCGAAAGAGATTTCCAACTCTATATAAGTACGTGAGACTAACCACTACCACTCATGCCCATGATGGCTATCAATAGCGGCTC
GTGGAGCTGCTTTGATTAAGAAATTTCAAAACTTGAATCGGAGTTTGTCTATTTGGTATTAAGATTTATGATGTTCCG
TAAATGATTTGCTAAGTCTGAGCAAGAAATAGGCCAAACCAACCTAATTTCTTTTACTCTAATATCATGAACCTCT
TCAAAACAGAAATTCACCTTGCAAATGGAGAGATTCGCAACCGCCCTCAATCGAACTAATGGGGAAGCTGGAGAAATCT
GTCTGGGATTAAGGGCGAGATTTTCCCACTGTGCGCAAGCTATGTCTCATGCCCAAGCTCAATTTGTGAAGAAACAGAG
AGTACAGAGAGGGCGGATTTCTCCAGGGAGTCAATTTTACCAAAAAGAAATTCGGACAGGCTTATTTGCTCGTAAAAAGACT
GGGATCCAAAAAATATGGTGGTTTGTATGTTCCAAAGGTAAGCTTATTCAGTCCCTAGTGGTTGCTAAGGTGGAAAAAGG
AAATCGAGAGAGTTAAAACTCGTTAAAGAGTTACTAGGGGATCAAACTTATGGAAGAGAGTTCTTTGAAAAAATCCGAT
TGACTTTT"TAGAGCTTAAGGATTAAGGAATTAAGGAAGTTAAAAAGACTTAATCATTAACCTACCTAAATATAGCTTTTGAAGT
TAGAAAAACGGTCTCAACAGGATGGTGGCTAGTGGCGAGAAATTACAAAAGGAAGATGAGCTGAGCTCTGCCAAGCAAGCTAT
GTGAATTTT"TTATATTTTAGCTAGTCAATTTGAAGAGTTGAAGGGTAGTCAGAGAGATTAAGCAAAACAACTATTTGT
GGAGCAGCATAGGATTAATTTAGATGAGATTAATGAGCAAACTAGTGAATTTTCTAAGCGTGTATTCTTAGCAGATGCCA
ATCTAGATTAAGCTCTTATGTGCAATATAACAAACATAGAGACAAACCACTAGCTGAACAGCAGAGAAATATTATCTACTTA
TTTACGTTTGAAGAGCTTTGGAGCTCCGCTGCTTTTAAATTTT"GTATACAACTATGATCGTAAGAGATTAAGCTCTAC
AAAAAGATTTTAGATGCCACTCTTATCCATCAATCCATCACTGGTCTTTATGAACACCGCATTTGATTGAGTCAAGCTAG
GAGGTGACTGAAGTATATctttagatgaagactattctttaaataactaaaaatatggtataataactctAAATAAATCCAGT
AATACAGCGGCTTTTCAAGACTGAAGCTTAGCTGAGACAAATAGTCCGATTACGAAATTTTTTAGACAAAAATAGTCTAC
GAGTTTTTAGAGCTATGCTGTTTTGAAGGTGCCAAACTGAGACCGACTCCGAAGCTCAAAAGGCTCTGTTTTAGAGTT
ATGCTGTTTTTGAAGGTGCCAAAAGCTCAGCACACTGAGACTTGTTCAGTTCCATGT"TTTAGAGCTATGCTGTTTTGAAT
GGACTCCATTCAGATTTGCCATGATTAATTTGAGAAAGAGGTTAATACAGAGTTCGGATACCTTCTATTTCTTTCTGT
TAAAGCGTTTTACCTTAATAGGCAAAAGAGAGTAGTGTGATCTGCTTCCGACAGCATTCGCGAGTCACTATGGCT
TGTGCTAGGCTATATGGCTTTGATGCAATTTCTATGCGCACCGGTTCTCGAGGACATGTCCGAGCGCTTTGGCGCGCG
CCAGTCTGTGCTGGCTTGGTACTTTGAGCCACTATCGACTACGGATATAGGGCACCAACCGGCTCTGTGGAATGCTCTPA
CGCCGAGCGCATCGTGGCGGCATCACCGCGCCACAGGTGCGGTTGCTGGCGCCTATATCGCGGACATCACCGATGGGG
AAGATCGGGCTCGCCACTTCGGGCTCATAGGCGCTTGTTTCGGGCTGSGTATGGTGGCAGGGCCGCTGGCGSGGGGACTG
TTGGGCGCATCTCTTTGCACTGCACTCATTTCTTGGCGCGCGTGTGTAAAGGCTCAACCTACTACTGGGCTGCTTCT
AATGCAAGAGTTCGATTAAGGGAGAGCGTCCAGCGATGCCCTTGAGAGGCTTCAACCCAGTCAAGCTCCTTCGGGTGGGCG
GGGCAATGATCTGTGGCGGCACTTATGACTGTGTTTTTATCATGCAACTCTGTAAGACAGGTGCGCGCACGCTCTG
GTCATTTTTGGCGAGGACCGCTTTCTGTGGAGCGCGACGATGATCGGCTGTCTGCTTGGGATTCGGAATCTTGCAAGC
CCTCGCTCAAGGCTTCTGTCACTGGTCCGCCACCAAGGTTTTCGGGAGAGAGCAGGCCATTAACCGCGCATGGCGCGG
ACGCGCTGGGCTACGTTCTGTGGGCTTCGCGACCGAGGGCTGGATGGCGCTTCCCATTTATGATTTCTTCTGCTTCGCG
GCACTGGGATCGGCCCGTTCGAGGCGCATGCTGTCCAGGCAAGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCT
CGCGGCTCTTACCGGCTTAATTCGATCATTTGAGCCGCTGAATGCTCAGGGCGATTATGCGGCTCGGGGAGCACAAGGA
ACGGGTTGGCATGAGATTGTAGGGCGCGCGCTTATACCTGTCTGCGCTCCCGCGTTGGGTGGCGGTGCATGGAGCGCGGG
ACCTCGACCTGATGGAAGCGCGCGGCACTCTCACTAAGGATTCAACACTCCAAAGATTAAGACCAATCAATTTCTGGCG
AGAATCTGTAATTCGCAAAACCAACCTTTGGCAAGACATATCCATCGGCTCCGCCATCTCCAGCAGCGCGCACGCGCGCAT
CTCGGCGAGGCTTGGGTCTGGGCAAGGCTGCAATGATCGTGTCTCTGTGTTGAGGACCGCGCTAGGCTGGCGGGGTT
GGCTTACTGGTTAGCGAATGATATCAACGATACGCGAGCGAACHGTGAAGCGAATGCTGCTGCAAAACGTTGCGAGCTGA*

GCACCAACATGAATGGTCTTCGGTTTCGGTAAAGTCTGGAAACGCGGAAGTCCCTACGTGCTGCTGAAGTTG
CCGGCAACAGAGAGTGGAAACCAACGGGTGATACGATACATGACTGAGAGTGAACGCCATGAGCGGCTCATTTCTT
ATTCTGAGTTACAAACACTCCGCACCGGTGTCCGGTAGCTTCTTCCGGTGGGCGCGGGGCATGACTATCTCCCGCATCTT
ATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTSCCGGAGCGSCCAACAGTCCCGCGGCCACGGGGCTGCCAC
CATACCGCGCGGAAACAAGCGGCTGGACCACTAATGTTCCGGATCTGGATCGCAGGATGCTGCTGGCTACCGCTGTGGAA
CAGCTACATCTGTATTAAAGGAGCGCTAACCGTTTATCGGGCTCTGGAGGCGAGAAATAATGATCATCTCAATTA
TTACCTCCACGGGGAGAGCTGAGCAAACTGGGCTCAGGCATTGAGAAAGCACCGGTACACTGCTTCCGGTAGTCAAT
AAACCGGTAAACCAAGCAATAGACATAAGCGGCTATTACGACCGCTGCCCTGAACCGGACCGGGGTGGAATTGCTTTC
GAATTTCTGCCATTTCATCGGCTTATTATCACTTATTCAGGCGTAGCACCAGGCGTTTAAGGGCACCAATAACTGCCTTAA

AAAAATTAGCCCCGGCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAAGCATTCGCGGACATGGAAGCCATCACA
GACGGCATGATGAACCTGAATCGCCAGCGCATCAGCAGCTTGTCCGCTTGCGCTATAATATTTGCCCATGCTGAAAACGG
GGGCGAAGAAAGTTGTCCATATTGGCCAGCTTAAATCAAAACTGGTGAAACTCACCAGGGATTGGCTGAGACGAAAAAC
ATATTTCTCAATAAACCTTTAGGGAAATAGGCCAGGTTTTACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAA
CTGCCGAAATCGTGTGTATTCACTCCAGGCGATGAAACGTTTCAGTTTGTCTGATGGAACCGGTCTAACAAAGGT
GAACACTATCCCATATCACCAGCTCACCCTCTTTGATTGCCATACG

[0141] Backbone vector pACYC184 sequence is italicised, sequence positions are numbered from G of EcoRI site underlined. The reverse complement of tracrRNA is in italicised bold located from 1844 to 1929, Cas9 initiation and termination codons are indicated by bold three letters, starting at nucleotide No. 2225 and ending at 6331 followed by leader sequence 6389-6483 indicated by italicised bold letters, first, second and third direct repeat sequences are underlined, between the first and second direct repeat in which spacer cloning region is located.

[0142] This spacer cloning region contains two inverted *BsaI* sites indicated by bold italicised letters 5'-GAGACC-3' and 5'-GGTCTC-3' for creating 5' four bases protruding spacer cloning sites 5'-GTTT-3' and 5'-TTTT-3', respectively. Promoter sequences were predicted as above, indicated by lower case for forward promoter for Cas9 and leader sequence and italicised lower case for reverse promoter for tracrRNA, the putative transcription start site is indicated by bold uppercase. The two unique sites, *SaI* I (GTCGAC) and *Xba* I (TCTAGA) highlighted in bold italicised black are utilised to isolate the CRISPR/Cas9 construct for cloning into M13mp18.

Appendix 2

Modification of spacer cloning site on pCas9

[0143] This system exploits the fact that expression of a minigene yields a certain oligopeptide that depletes the tRNA pool in the host cell, when induced for expression, which leads to the disruption of protein synthesis (Tenson T, Vega-Herrera J, Kloss P, Guarneros G, Mankin AS. J. Bacteriol. 1999; 181:1617-1622). Applying this concept to cloning the spacer sequence: when the spacer sequence is inserted this interrupts the minigene and the oligopeptide expression does not occur, thus tRNA is not depleted, thus only the bacteria harbouring a plasmid with insert can survive under conditions of induced expression; whilst bacteria harbouring the plasmid without insert cannot grow. The following (SEQ ID NO: 129) is the sequence structure. In order to construct this structure, bacteria should express the *lac* I repressor constitutively to switch off minigene transcription. Recombinant selection should be performed in the presence of IPTG to induce transcription.

5' AAACTGAGACC GGGCAGTGAAGCGCAACGCAATTAA CATTAAGGCACCCAGGCT TTGACCAATTAATCATCGGCTCGTATAATG
BsaI O3lac -35 Ptac -10

TGTGG AATTGTGAGCGGATAACAA TTTTCACAC GCAGG TCACATATGAGA TAATAATAACTAGCTGAATTC CTAGCGTCTGTAAT
O2lac S.D. M R Trp terminator

GAGCGGCTTTTCTTGGTCTCGTTT-3'
BsaI


[0144] *BsaI* recognition sites are underlined. lac operator 3 and 1 are bold italicised. Tac promoter is in bold letters, -35 and -10 region in the promoter sequence are underlined, Shine-Dalgarno sequence is boxed, first dipeptide is in bold M and R followed by three consecutive termination codons italicised TAA. Tryptophan terminator signal sequence is employed, indicated by italicised letters.

Appendix 3

Expected cleavage site on target sequence using CR90 spacer sequence


First processing event

[0145] tracrRNA hybridises to the direct repeat region of pre-crRNA indicated by upper case letters using the sequence underlined. Bacterial RNase III cleaves the double-stranded RNA region at indicated position "I", first processing event.




Structure after 1st processing event

[0146]



[0147] The first processing event may also be depicted as follows: tracrRNAs indicated by lower case letters hybridise to the direct repeat region of pre-crRNA indicated by upper case bold black letters. Bacterial RNase III cleaves the double-stranded RNA region at indicated position with arrows, which is first processing event. Phosphodiester bond between 22nd and 23rd base in the first and second direct repeat are cleaved. Italicised spacer sequence CR90 is boxed.



Second processing event

AGGCTTGGATTAAGCTGGTTTATCAAAACGCCAATTGGTTGAAACTCGCCAAATCACTAAGCATGTGGCACAAATTTGGGATAGTGGCA
TGAATACTAAATACGATGAAAATGATAAACTTATTCGAGAGGTTAAAGTGAATTACCTTAAAACTCTAAATTAGTTTCTGACTTCGGAAA
AGATTTCCAAATTCCTATAAAGTACGTGAGATTAAACAATTACCATCATGCCCATGATGGGTATCTTAAATGCCGTGGTTGGAAGTGCCTTG
ATTAAGAAATATCCAAAACCTTGAATCGGAGTTTGTCTATGGTGAATTATAAAGTTTATGATGTTGGTAAAAATGATTGCTAAGTCTGAGC
AAGAAATACCCAAAGCAACCCGCAAAATATTTCTTTTACTCTAATATCATCAACTTCTTCAAAACAGAAAATTACACTTCCAAATCGAGA
GATTCCGCAAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTTGTCTGGGATAAAGGGCGAGATTTGCCACAGTGGCGAAA
GTATTGTCCATGCCCAAGTCAATATTGTCAAGAAAACAGAAGTACAGACAGGGCGGATTCTCCAAGGAGTCAATTTTACCAGAAAAGAA
ATTCCGGACAAGCTTATTGCTCGTAAAAAAGACTGGGATCCAAAAAATATGGTGGTTTGTGATAGTCCAAACGGTACGCTTATTCAGTCC
AGTGGTTGCTAAGGTGGAAAAAGGGAAATCGAAGAAGTTAAAAATCCGTTAAAGAGTTACTAGGGATCACAATTATGGAAAGAAGTTCC
TTTGAAAAAATCCGATTGACTTTTGTAGAAGCTAAAGGATATAAGGAAGTTAAAAAAGACTTAATCATTAAACTACCTAAATATAGTC

TTTTTGAGTTAGAAAACGGTCGTAAACGGATGCTGGCTAGTSCCGGAGAATTACAAAAAGGAAATGAGCTGGCTCTGCCAAGCZAATA
TGTGAATTTTATATTTAGCTAGTCATTATGAAAAGTTGAAGGGTAGTCCAGAAGATTAACGAACAAAAACAATTGTTTGTGGAGCAG
CATAACCATTTTATACATGAGATTATTCACCAATCACTCAATTTTCTAAGCCTGTTATTTTAGCAGATCCCAATTTAGATAAACTTC
TTAGTGCATATAACAAACATAGAGACAAACCAATACGTGAACAAGGCAGAAAATATTATTCATTTATTTACGTGACGAAATCTTGGAGC
TCCCGCTGCTTTTAAATATTTTGATACAACCAATTGATCGTAAACGATATACGTCACAAAAGAAGTTTGTAGATGCCACTCTTATCCAT
CAATCCATCACTGCTCTTTATCAAAACCGCATTCGATTGACTCAGCTAGCAGCTCACTCATGCCCACGTGAAGTATATGATTTTCCGC
AGTATA

2. 2. Fragment 2 (SEQ ID NO: 141), Leader and first direct repeat: amplicon length = 276 bp Forward primer is from 860648 to 860671 and reverse primer is from 860862 to 860806 on *S. pyogenes* genomic DNA.

ATTGATTTGAGTCAGCTAGGAGGTGACTGATGGCCACGTGAACATAATGATTTTCCGCAGTATATTTAGATGAAGATTATTTCTTAA
TAAGTAAAAATATGGTATAAATCTCTTAATAAATGCAGTATAACAGGGGCTTTTCAAGACTGAAGTCTAGCTGAGACAAATAGTGGCA
TTACGAAATTTTATAGACAAAATAGTCTACGAGGTTTGTAGAGCTATGCTGTTTGAATGGTCCCAAACTCAGACCAGTCTCGGACG
TCCAAAGGTCTC

3. 3. Fragment 3 (SEQ ID NO: 144), Second direct repeat: amplicon length = 452 bp Forward primer is from 861221 to 861276 and reverse primer is from861613 to 861594 on *S. pyogenes* genomic DNA. Decamer sequence from 861246-861255 GGTCTCCATT (SEQ ID NO: 142), which contains *Bsa*I recognition sequence on the genomic DNA, was substituted with GGTCCCAAAA (SEQ ID NO: 143) to destroy *Bsa*I recognition sequence and convert the 7th truncated direct repeat in the CRISPR array on the genome to the canonical 2nd direct repeat sequence in this vector.

GAGACCAGTCTCGGACGTCCAAAGGTCTCTCTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAACAACATTTGCCGATGATAACTTLAGAG
AAAGAGGCTTAAATACCAGCAGTCGGATACCTTCTCTATTTCTGTCTTAAAGGCTTTTCAATGTTATAATAGGCCAAAAGAAGTATGCTT
GATGGAAACAAACATTTTATGATTAAAGCCATATGGGGTTAAGCAAGGGGAGGTAGTTGGAGAGGTTTACGGTGGATTGAACGCCTA
ACATTTACGTTTAACCCATTCCACCTAAGACAACCTACTTCCAAATACTTGCCTAAGCCAGCAGCGCCCTTGCCTCATAAACCTTTTGA
TCCTAAACTTAAAGCTTACATGACAAGTGGTCTCTTTTAATTGGCATAATTCTTCCGGACTAAGGTGCTATCGTCCATTCCGACAGC
ATCGCCAGTCAAC

[0157] PCR conditions to generate the three fragments were:

	Fragment 1	Fragment 2	Fragment 3
5X Q5 Reaction Buffer	1 x	1 x	1 x
10 mM dNTPs	200 µM	200 µM	200 µM
10 µM Forward Primer	0.5 µM	0.5 µM	0.5 µM
10 µM Reverse Primer	0.5 µM	0.5 µM	0.5 µM
<i>S. pyogenes</i> DNA 50 - 100 ng/ul	1 ng/µl	1 ng/µl	1 ng/µl
Q5 High-Fidelity DNA Polymerase 2 U/µL(NEB)	0.04 U/µl	0.02 U/µl	0.02 U/µl
Thermocycling condition			
Initial Denaturation	98°C_60 sec	98°C_60 sec	98°C_60 sec
35 Cycles	98°C_10 sec	98°C_10 sec	98°C_10 sec
	64°C_30 sec	62°C_30 sec	62°C_30 sec
	72°C_240 sec	72°C_30 sec	72°C_30 sec
Final Extension	72°C_120sec	72°C_120 sec	72°C_120 sec
Hold	4 °C	4 °C	4 °C

[0158] Results showing the PCR amplicons are provided in Figure 11.

Assembly of pNB100 from three PCR amplicons, tracrRNA-cas9, leader and first direct repeat, second direct repeat; plus pACYC184 digested with EcoRV

[0159] We employed a Gibson assembly kit from NEB (E5510) and followed the protocol provided by the manufacturer

to assemble the above three PCR amplicons along with pACYC184. The component of each fragment in the assembling reaction is shown in the following table.

0.1 pmol/μL Fragment 1	0.2 pmol
0.2 pmol/μL Fragment 2	0.2 pmol
0.2 pmol/μL Fragment 3	0.2 pmol
0.01 pmol/μL pACYC184	0.04 pmol
Fragments 1 :: Fragment 2 : Fragment 3 : vector	5: 5 : 5 : 1
Gibson Assembly Master Mix (2X)	1x
Incubation	50°C for 1 hr

[0160] 2 μL of the assembly reaction was transformed to DH5α competent cells (purchased from New England Biolabs) followed by selection on chloramphenicol (35μg/mL) LB plates. The recombinants were screened by PCR using the three primer sets used for obtaining the initial three fragments. The plasmid templates giving three desired amplicons were isolated from the candidate clones and were subjected to sequence analysis.

The sequence of the final construct of pNB100 (SEQ ID NO: 145)

[0161]
GAATTCCGGATGAGCATTTCATCAGGCGGGCAAGATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTCTTTACGG
TCTTTAAAAAGCCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCICAAAATGT

TCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTFTTCTCCATTTTAGCTTCCTTAGCTCCTGA
AAATCTCGATAAATCAAAAAATACGCCCCGGTAGTGATCTTATTTTCATTATGGTGAAAGTTGGAACCTCTTACGTGCCGAT
CAACGTCTCATTTCGCCAAAAGTTGGCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTTCTGCCAAG
TGATCTTCCGTCACAGGTATTTTATTCGGCGCAAAGTGCCTCGGGTGATGCTGCCAACTTACTGATTTAGTGATGATGGT
GTTTTTGAGGTGCTCCAGTGGCTTCTGTTTCTATCAGCTGTCCCTCCTGTTCAGCTACTGACGGGGTGGTGCGTTAACGGC
AAAAGCACCGCCGGACATCAGCGCTAGCGGAGTGATACTGGCTTACTATGTTGGCACTGATGAGGGTGTGAGTGAAGTG
CTTCATGTGGCAGGAGAAAAAGGCTGCACCGGTGCGTCAGCAGAATATGTGATACAGGATATATTCGGCTTCCTCGCTC
ACTGACTCGCTACGGCTCGGTCTGACTGCGGCGAGCGGAAATGGCTTACGAAACGGGGCGGAGATTTCCCTGGAAGATGC
CAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGGGCCAAAGCCGTTTTTTCATAGGGCTCCGCCCCCTGACAAGCATCA
CGAAATCTGACGGCTCAAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCCAGCGTTTCCCCCTGGCGGGTCCC
TCGTGCGCTCTCCTGTTTCTGCTTTTCGGTTTACCGGTGTCTATCCGCTGTATGGCCGCGTTTGCTCATTTCCACGCT
GACACTCAGTTCCGGGTAGGCAGTTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCGTTTCACTCCGACCGCTGCCGCT
TATCCGGTAACATATCGTCTTGAGTCCAACCCGGAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTT
AGAGGAGTTAGTCTTGAAGTCATGCCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGGCTCCTCCAAAGCC
AGTTACCTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGGCGGTTTTTCGTTTTACAG
CAAGAGATTACGGCGAGACCAAAACGATCTCAAGAAGATCATCTTATTATCAGATAAAATATTTCTAGATTTGAGTGCA
ATTTATCTCTTCAAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTAATTTCTCATGTTTGACAGCTTATCATC
GATAAGCTTTAATGCGGTAGTTTATCAGATTAATTTGCTAACGCCAGTCAGGCACCGTGTATGAAATCTAACAAATGCGCT
CATCGTCATCCTCGGCACCGTCACCTTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCTCTTGGGGG
ATCCAGAAGTCTTTTCTTGCACTGTTTCTCTTTCTTTATGATAGTTTACGAAATCATCTCTGTGGAGCTTAGTAGGTTTA
GCAAGAUGGCAGCGCTAAATGTAGAAAGATAAAAAGGATTAAGAGATTAATTTCCCTAAAAATGATAAAACAAGCGTTT
GAAAGCGCTTGTTTTTTGGTTTGCAGTCAGAGTAGAATAGAAGTATCAAAAAAGCACCGACTCGGTGCCACTTTTTCA
AGTTGATAACGGACTAGCCTTATTTTAACTTGCTATGCTGTTTTGAAATGGTTCCAAACAAGATTATTTTATAAAGTTTATA
ACAAATAATCAAGGAGAAATTCAAAGAAATTTATCAGCCATAAAACAATACCTAATCTATAGAAGGATAACAAATAAA
CTACTTTTTTAAAGAAATTTTGGTTATAATCTATTTATTTAAGTATTTGGGTAACTTTTTTGAAGAGATATTTTGAAA
AAGAAAAATTAAGGCATATTAAGCAATTTTCGGAGGTCATTAAGCACTATTAAGAAATCATCAAACTCATTAAGGATTTA
ATTTAAACTTTTTATTTTACGGAGGCAAAAATGCTATGAGAACTACTCARTAGGCTTAGATATCGGCAAAATAGCGTCGGA
DGGCGGTGATCAGCTGATGAGTACAGGTTCCGCTCTAAGAGTTCAAGGTTCTGGGAATACAGACCGCCACAGCTATCAA
AAAAATCTTACAGGCGCTCTTTTACTTTGBCGGTGGAGATACAGCGGAGACGACTCGCCCGAAGCGACAGCTCTGTAGAA
GGGATACAGCTCGGAGAAATCGTATCTGTTATCTACAGGAGATTTTTTCAAATGAGATGGCGAAAGTAGATGATAGTTTC
TTTCATCGACTTGAAGAGTCTCTTTTGGTGGAAGAAGACAAAGACATGAACGTCATCCTACTTTTGGAAATATAGTAGA
TGAAGTTGCTTATCATGAGAAATATCCAACTATCTATCATCTGCGAAAAAAATGGTAGATCTTACTGATAAAGCGGAT
TGGCGCTCAATCTATTGGCGCTTAGCGCATATGATTAAGTTTCGTGGTCATTTTTTGATTTGAGGGAGATTTAAATCCTGAT
AATAGTGAATGGGACAAACTACTTATCCAGTTGGTACAAACCTACAATCAATATTTGAAGAAAACCTATTAACGCAAG
TGGAGTAGATGCTAAAGCGATCTCTCTGCAAGATTGAGTAAATCAAGACGATAGAAAAATCTATTGCTCAGCTCCCCG
GTGAGAAGAAAAATGGCTTATTTGGGAATCTCATTTGCTTTGTCATTGGGTTTGACCCCTAACTTTTAAATCAAAATTTGAT
TTGGCAGAGATGCTAAATACAGCTTTCAAAAGATACTTACGATGATGATTTAGATAATTTCAATGGCGCAAAATGGAGA
TCAATATGCTGATTTGTTTTGGCAGCTAAGAAATTAATCAGATGCTATTTTACTTTTTCAGATATCCAAAGAGTAAATACTG
AAATAACTAAGGCTCCCCATCAGCTTCAATGATTAAACGCTACGATGAACATCATCAAGACTTGACTCTTTTAAAGCT
TTAGTTTCGACAACTTTCCAGAAAAGTATAAGAAAATCTTTTGTGATCAATCAAAAAACGGAAATGAGGTTATATTA
TGGGGGAGCTAGCCAAAGAGAATTTTATAAAATTTATCAAACTAATTTAGAAAAATGATTTGGTACTTGGAGAAATTTTGG
TGAATCAAAATCGTGAAGAATTTGCTGGCGAAGCAACGGACTTTGACAAACGGCTCTATCCCATCAAAATTCATTTGGG
GAGCTGCAATGCTATTTTGAAGACAAAGAGACTTTTATCCAATTTTAAAAAGACAATCGTGAAGAAGATTGAAAAATCT
GACTTTCCGAATTCCTTATTTATGTTGGTCCATTGGCGCGTGGCAATAGTCTGTTTTCATGGATGGATGACTCGGAAGCTGAAG
AAACAAATACCCCATGGAAATTTGAAGAAGTTGTCGATAAAGGTGCTTTCAGCTCAATCAATTTATTTGAACGCATGACAAAC
TTTGATAAAAAATCTTCCAAATGAAAAAGTACTACCAAAACATAGTTTGTCTTATGAGTATTTACGGTTTATAACGAAT
GACAAAGGTCAAAATCTTACTGAAGGAATCGGAAAACAGCATTTCTTTTCAAGTGAACAGAAAGAACCATTTGTGAT
TACTCTTCAAAACAAATCGAAAAGTAACCGTTAAGCAATTAAGAAGAATTTATTTCAAAAAAALAGAAATGTTTGTATAG
GTGAAATTTTACGGAGTTGAAGATAGATTTAATGCTTCAATAGGTACCTACCAAGATTTGCTAAAAATTAATAAGATAAA
AGATTTTTTTGGATAATGAAGAAAATGAAGATATCTTAGAGGATATTGTTTTAAGCTTGACCTTATTTGAAGATAGGGAGA
TGATTTGAGGAAGACTTAAAAACATATGCTCACCTCTTTGATGATAAGGTGATGAACAGCTTAAACGTGCGCGTTATACT
GGTTGGGGAGCTTTGCTCTCGAAAATGATTAAATGGTATTAGGGATAAGCAATCTGGCAAAACAATATTAGATTTTTTGAA
ATCAGATGGTTTTTGCCAATCGCAATTTTATGCAGCTGATCCATGATGATAGTTTGACATTTAAAGAAGACATTCAAAAAG
CACAAGTGTCTGGACAAGGCGATAGTTTACATGAACATATTCGCAATTTAGCTGGTAGCCCTGCTATTAATAAAGGTAT
TTACAGACTGTAAAAATCTGTTGATGAATTTGGTCAAAGTAAATGGGGCGGCATAAGCCAGAAAAATATCGTTATTTGAAATGGC
ACGTGAAAAATCAGACAATCAAAAGGGCCAGAAAAATTCGCGAGAGCGTATGAACGAAATCGAAGAAGGTATCAAGAAAT
TAGGAAGTCAGATCTTAAAGAGCACCTGTGTGAAAATCACTCAATTCGAAATGAAAAGCTCTATCTCTATTTATCTCCAA

AAAGGAAGAGACAAGGATGGGACCAAGAAATAGATAATAACGTTTAAGTGAATTATGATGTCGATCACAATGTTCCACA
AAGTTTCCTTAAAGACGATTCAAATAGACAAATAAGGTCCTTAACGGCTTCTGATAAAAAACGTCGGTAAATCGGATAACGTTTC
CAAGTGAAGAAGTAGTCAAAAAAGATGAAAACTATTGGGAGACAACCTCTAAACGCCAAGTTAAATCACTCAACGTAAAGTTTC
GATTAATTTAACGAAAAGCTGAACGCTGGAGGTTTGGAGTGAACCTTGATAAAGCTGGCTTTATCAAACGCCAATTGGTTGAAAC
TCGCCAAATCACTAAGCATGTGGCACAAATTTTGGATAGTCGCATGAATACATAATACGATGAAAATGATAAACTTATTC
GAGAGGTTAAAGTGATTACCTTAAATCTAAATTAGTTTCTGACTTCCGAAAAGATTCCAAATCTATAAAGTACGTGAG

ATTAACAAATTACCATCATGCCCATGGATGCGTATCTAAATGCCGTGCTGGAACTGCTTTGATTAAGAAATATCCAAAACCT
TGAAATCGGAGTTTGTCTATGGTGATTCATAAAGTTTATGACGTTGCGTAAAAATGATTGCTAAGCTTGAGCAAGAAATAGGCA
AAGCAACCGCAAAATATTTCTTTACTCTAATATCATGAACTTCTTCAAAACAGAAATTACACTTGCAAAATGGAGAGATT
CGCAAAACGCCCTCTAATCGAAACTAATGGGGAAACTGGAGAAATTGTCTGGGATAAAGGGCGAGATTTTGCCACAGTGGC
CAAAATATGTGTCATGCCCCCAAGCTCAATATTGTCAAGCAAAACAGACATAGAGACAGCGCGAATTCTCCAAAGGACTCAATTT
TACCAAAAGAGAAATTCGGACAGCTCATTCGCCCTAABAAAGACTGGGATCCAAABAAACATCGGTGGTTTGGADAGTCTA
ACGCTAGCTTCTTCAAGTCCAGTGGCTAGTGGTTGCTAAGGTTGGAAAAAGGCAATTCGAAGAAGTTAAAAATCGCTTAAAGAGTTACCT
AGGGATGCAAAATTTTGAAGAAGATTCCTTTTGAABAAATCCGATTCGACTTTTCAAAAGCTAAAGSATATAAGGAAGTTA
AAAAAGGCTTAATCTTAATACCTAATTAATTAAGTCTTTTGGAGTTAGAAACGGTCTGTAACGGATGCTGGCTAGTGGC
GGAGAACTTACAAAAGCAATGAGCTGCTCTGCAAGCAATATGTGAATTTTAAATTAAGCTAGTCAATTAAGAAAG
GTTCAAGGCTAGTTCAGTACAGCAACGCAACCAAAACCACTCTTTGTTGGGCGAGGCTTACGCTACATTCAGATGAAATATTTG
AGCAAAATCAGTTAAATTTTCGAAGCTCTTAAATTTAGCAGATGCCAATTTAGATAAAGTTCTTAAATTCATATAACCAACCT
AGAGACAAACCAATACCGGCAACAGCAGAAATTTATTTCAATTTATTTACGTTGACGAAATCTTGGAGCTCCCGCTGCTTT
TAAATATTTTGATACAACAATTTGATCGTAAACGATATACGCTTACAAAAGAGTTTTAGATGCCACTCTTATCCATCAAT
CCATCACTGGTCTTTATGAACACCGCATTTGATTTGAGTCAGCTAGGAGGTTGACTGATGGCCACGTTGAACATATATGATTTT
CCGCAGTATATTTAGATGAAGATTATTTCTTAATAACTAAAAATATGGTATAATACCTTTAATAAATGCGAGTAATACAG
GGGCTTTTCAAGACTGAAGTCTAGCTGAGACAATAAGTGGGATTACGAAATTTTTTAGACAATAAATAGTCTACGAGGTTT
TAGAGCTATGCTAATTTGAATGGTCCCAAAACTGAGACCAGTCTCGGACGTCCAAAGGTCTGCTTTAGAGCTATGCTGT
TTTGAATGGTCCCAAAACCACTTTGCCGATGATAACTTTGAGAAAGAGGGTTAATACCAGCAGTCCGATACCTTCCTATTTC
TTCTCTTAAAGCTTTTCATGTTACAAATAGGCAAAAGAGAGTAGTGTGATGGAACATACATTTCTTATGATTAAGCCA
TATGGGGTTAAGCAAGGGGAGGTAGTTGGAGAGGTTTACGGTGGATTGAACGCCATAAGATTTACGTTTAAAGCGATTCTGA
GCTAAGACAAAGCTAGTTTCAAAATACCTTGGCTAAGCACGACGAGGCCCTTGGTGAATAAACCTTTTGAATCCATAAACCTTAAAGC
TTACATGACAAGTTGGTCTCTTTTAAATTTGGGATAATTTCTTGGGGACTAAGGTTGGTATCGTCCATTCCGACAGCATCGCCA
GTCACTATGGCGTGTCTTAGCGCTATATGGCTTGAATGCAATTTCTATGCGCACCCGTTCTCGGAGCATTGTCCGACCGCT
TTTGGCCGCGCCCACTCTGCTGCTTGGCTACTTGGAGCCATATCGACTACGCGCATCATGGCGACCACACCCGCTCT
GTGGATCTCTTACGCGGAGCATCTGTGGCCGGCATCACCGGCGCCACAGGTGGGTTGCTGGCGCTTATATCGCGGACA
TCACCGATGGGGAAGATCGGGCTCGCTACTTGGGGCTCATGAGCGCTTGTCTTGGCGTGGGTATGGTGGCAGGCCCGCTG
GCCGGGGGACTGTGTGGCGGCCATCTCTTGCATGCAACCATTTCTTGGCGCGCGGTGCTCAACGGGCTCAACCTACTACT
GGGCTGCTTCTTAAATGCGAGGATCGCATAAGGGAGAGCGTGCAGCCGATGCGCTTGAGAGGCTTCAACCCAGTCAGCTCTCT
TCCGGTGGGCGCGGGCATGACTATCTGCGCGCATTTATGACTGCTCTTTTATCATGCAACTCTAGGACAGGTGCCG
GCAGCGCTCTGGGTCAATTTTGGCGAGGACCGCTTCTGGCTGGAGCGCGACGATGATCGGCTGTGCTGTGGGTATTTCGG
AATCTTGACAGCCCTTCGCTCAAGCCCTTCTGCTACTGGTCCCGCCACCAAACTTTTGGCGGAGAAGCAGGCCATTATCGCG
GCATGGCGGGCGACGCGCTGGGTACGCTTTGCTGGCGTTGCGGACGCGAGGCTGGATGGCTTCCCCATATGATTTCTT
CTGCTTCCGGCGGCATCGGATGCTTGGGTGCGAGGCTATGCTTCCAGGCAGGTAGATGACGACCATCAGGACAGCT
TCAAGGATCTCTTGGCGGCTTCTTACCAGCTTAACTTGCATCATTTGGAGCGCTGATGCTCAGGCGAATTATGCGCGCTTGG
CGAGCACAATGGAACGGGTGGCATGGATTGTAGGCGCGCCCTATACCTTGTCTGCTTCCCGCGTTGGCTGCGGTGCA
TGGAGCGGGGCCACTTCGACCTGAATGGAAGCGCGCGGACCTTCGCTAACGGATTCAACCATCCAAGAATTGGAGCCAAT
CAATTTCTTGGCGAGAACTGTGAATGCGCAAAACCAACCTTGGCAGAACATATCCATCGGCTCCGCCATCTCCAGCAGCGG
CACGCGGGCGCATCTCGGGCAGGTTGGGTCTTGGCCACGGGTGCGCATGATCGTGTCTCTTGTGCTTGGAGACCCGGCTAG
GCTGGCGGGGTTCCTTACTGGTTAGCAGAATGAATCACCGATACCGGAGCGAAGCTGAAGCGACTGCTGCTGCAAAACG
TCTGCGACCTGAGCAACAACATGAATGGTCTTGGGTTTCCGTGTTTCTGTAAGTCTGGAAACGCGGAAGTCCCTACGTG
CTGCTGAAGTTGGCCGCAACAGAGAGTGGAAACCAACCGGTGATACCAGATACTATGACTGAGAGTCAACGCCATGAGCG
GCCTCATTTCTTATTTCTGAGTTACAACAGTCCGCACCGCTGTCCGGTAGCTCTTTCGGTGGGCGCGGGGCATGACTATC
GTGCGCGCACTTATGACTGTCTTCTTTATCATGCAACTCTGTAGGACAGGTGCGCGCAGCGGCCAACAGTCCCCCGGCCAC
GGGCGCTGCCACCATACCCACGCCGAAACAAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGC
TACCTGTGGAACACCTACATCTGTATTAAACGAAGCGCTAACCGTTTTTATCAGGCTCTGGGAGGCAGAAATAAATGATCA
TATCGTCAATTATTACCTCCACGGGGAGAGCGCTGAGCAAACTGGCGCTCAGGCATTTGAGAAGCACACGGTCCACTGCTT
CCGCTAGTCAATAAACCGGTAAACAGCAATAGACATAAGCGGCTATTAAACGACCCCTGCCCTGAACCGACGACCGGGTC
GAATTTGCTTTCGAATTTCTGCCATTCAATCCGCTTATTATCACTTATTCAGGCGTAGCACCGAGGCTTTAAGGGCACCAA
TAACCTGCTTAAAAAAATTAACGCCCCGCGCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTTGCGGCACATG
GAAGCCATCACAGACGGCATGATGAACCTGAATCGCCAGCGGCATCAGCACCTTGTGCGCTTGGCTATAATATTGCGCA
TGGTGAAAACGGGGCGGAAGAAGTTGTCCATATTGGCCACGTTTAAATCAAAACTGGTGAAACTCAACCCAGGGATTGGCT
GAGACGAAAACATATTCTCAATAAACCTTTAGGGAAATAGGCCAGGTTTTCACCGTAACACGCCACATCTTGGCAATA
TATGTGTAGAAACTGCCGGAAATCGTGGTATTGCACTCCAGAGCGATGAAAACGTTTCAGTTTGTCTCATGGAAACGG
TGTAACAAGGGTGAACACTATCCATATCAACAGCTCACCGCTTTTCATTGCCATACG

[0162] The total number of nucleotides is 9578 bp. The backbone vector pACYC184 sequence is italicised, sequence positions are numbered from G of *EcoRI* site (GAATTC) underlined. tracrRNA is located at nucleotide No. from 1889 to 1974 indicated bold letters, Cas9 initiation and termination codons are indicated by bold three letters, starting at nucleotide No. 2270 and ending at 6376 followed by leader sequence 6462-6556 indicated by italicised bold letters, first and second direct repeat sequences are underlined, between which spacer cloning region (30 mer) is located. This spacer cloning region contains two inverted *BsaI* sites indicated by bold italicised letters 5'-GAGACC-3' and 5'-GGTCTC-3' for creating 5' four bases protruding spacer cloning sites 5'-GTTT-3' and 5'-TTTT-3', respectively and one unique *AaII* (5'-GACGTC-3') site also indicated by bold italicised to reduce self-ligation in the event of incomplete *BsaI* digestion. Note the transition and transversion base changes G6573A, A6779T that were detected by Sanger sequencing and are shown in bold letters, respectively. However, these point mutations do not affect the CRISPR-Cas9 activity, which will be shown in the later section. The two unique sites, *SaI* (GTCGAC) and *XbaI* (TCTAGA) highlighted in bold italicised letters are utilised to isolate the CRISPR/Cas9 construct for cloning into M13mp18.

[0163] A plasmid map of pNB100 is shown in Figure 12.

[0164] The desired spacer sequence can be cloned in the clockwise direction between *BsaI* sites. This vector contains the p15A origin at 1393-848 and *cat* (chloramphenicol resistant) gene at 219-9137. Cutting positions of each restriction enzyme, indicated in the parentheses, refer to the position of the 5' cutting sites on the top strand within the recognition

sequence.

Construction of pNB102

[0165] pNB100 was digested with *Bsa*I and *Aat*II followed by purification using Agencourt ampure beads. The spacer sequence CR30 was employed from the discussion in B. Selection of spacer sequence from the target sequence in the Materials and Methods section above. The CR30 sequence is as follows :

5'-AAACACTTTAAAAGTGCTCATCATg (SEQ ID NO: 117)

tgaaattttcacgagtagtacAAAA-5' (SEQ ID NO: 118)

[0166] This double-stranded DNA cassette is generated by denaturation at 95 C for 1 min and re-annealing at -1 degree every min to 30 C in the 1 x T4 ligase buffer (50 mM Tris-HCl(pH 7.5 at 25 C), 10 mM MgCl₂, 1 mM ATP 10 mM DTT) plus 50 mM NaCl following the kinase reaction to add a phosphate moiety in the 5' terminus of each oligo. The annealed cassette contains 5' protruding four base compatible bases on both ends for the sites created on pNB102 by *Bsa*I digestion. This CR30 cassette was ligated to pNB100 by T4 DNA ligase and transformed to DH5α competent cells (purchased from New England Biolabs). The transformants were selected on chloramphenicol LB plate and were screened by PCR with the bottom sequence of the CR30 cassette as a reverse primer and a forward primer CF1: 5'-acgttgacgaatcttgagc, which anneals at 6209-6228 region on the recombinant plasmid to generate 409 bp PCR amplicon. PCR positive clones were sequenced to confirm the CR30 spacer sequence and this recombinant clone is designated as pNB102 and used for *in vitro beta lactamase*-gene disruption experiments. CR30 spacer anneals to the sense strand of *beta lactamase*-gene and cleaves the phosphodiester bonds between 188th and 189th nucleotide on the sense and antisense strand.

Construction of M13mp18::NB102

[0167] pNB102 was digested with unique restriction sites *Sa*II and *Xba*I to generate two fragments 6044 bp and 3524 bp. The fragment length was calculated from the 5' end of the restricted sites in the top strand within the restriction recognition sites. The 6044 bp fragments containing CRISPR locus with CR30 spacer sequence in the CRISPR array was separated from the 3524 bp fragment and purified on the preparative 1 % agarose gel. M13 mp18 was digested with *Sa*II- *Xba*I, followed by Agencourt ampure purification to remove the six bases *Sa*II-*Xba*I fragment from the reaction. These two purified fragments were combined and ligated by T4 DNA ligase and transformed to DH5αF'Iq competent cells (purchased from New England Biolabs). Transformed cells were plated along with freshly grown DH5αF'Iq cells as a phage indicator and IPTG/X-gal solution as a blue-white colour indicator with molten top agar to LB plate. White plaques collected from the lawn were screened by PCR for the presence of the CR30 spacer sequence. The correct phage constructs obtained were purified by two times single plaque isolation. The entire sequence length of the final construct is 13288 bp. This spacer CR30 positive recombinant is designated as M13mp18::NB102 and was used for the bla-gene inactivation experiments mediated by M13 phage delivery.

Delivery of CRISPR-Cas9 constructs to bacteria

[0168] Having constructed the CRISPR-Cas9 plasmid pNB100 and the derivative plasmid pNB102 carrying a spacer insertion targeted against the beta-lactamase (*bla*) genes encoded by the bacterial transposable elements Tn1 and Tn3, we then sought to demonstrate, using three delivery methods, (i) plasmid conjugation, (ii) plasmid DNA transformation, (iii) bacteriophage infection, that bacterial cells carrying copies of the CRISPR-Cas9 construct with bla-spacer insertion would be unable to grow in the presence of the beta-lactam antibiotic ampicillin.

[0169] Constructs that are able to inactivate target genes, including antibiotic resistant genes, via the CRISPR-Cas system, and which are an aspect of the present invention are also referred to herein as "Nemesis symbiotics".

"Nemesis symbiotic activity" (NSA) assay by plasmid conjugation: a prophylaxis experiment

[0170] We demonstrate here that Nemesis symbiotics can prevent the spread of antibiotic resistance by inhibiting conjugal transfer of conjugative plasmids carrying antibiotic resistance genes from a donor cell to a recipient cell carrying the Nemesis symbiotics. To do this we mated a recipient cell carrying the Nemesis symbiotics with a donor cell carrying a conjugative plasmid, plus a multicopy mobilisable plasmid carrying the *bla* gene encoding ampicillin resistance. In a successful mating, the conjugative plasmid will transfer itself plus the mobilisable plasmid carrying ampicillin resistance to the recipient. Exconjugants may be selected for resistance to both chloramphenicol present on a non-mobilisable plasmid in the recipient and ampicillin received from the donor. Successful Nemesis symbiotic activity will reduce the efficiency of transfer of ampicillin resistance.

[0171] The recipient cell DH5 α (F⁻ endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ 80dlacZ Δ M15 Δ (lacZYA-argF)U169, hsdR17(rK⁻ mK⁺), λ -) was purchased from New England Biolabs and transformed with the plasmids pNB100 or pNB102 or pACYC184, where plasmids encode chloramphenicol resistance and both pNB100 and pNB102 carry CRISPR-Cas9 but only pNB102 carries the spacer sequence targeted against the beta-lactamase gene. The plasmid pACYC184 is the non-mobilisable parent plasmid used for the construction of pNB100 and pNB102 as described above.

[0172] The donor strain JA200 (F⁺ thr-1, leu-6, DE(trpE)5, recA, lacY, thi, gal, xyl, ara, mtl) also carrying plasmid pNT3 is described by Saka et al. DNA Research 12, 63-68 (2005). The plasmid pNT3 is a mobilisable plasmid carrying the *bla* gene of Tn1.

[0173] A single colony of the donor JA200 pNT3 was picked from a Luria broth (LB) plate containing 100 μ g/mL Ampicillin and grown shaking at 37°C overnight in 1mL LB medium with 100 μ g/mL Ampicillin. A single colony each of the recipients, DH5 α pNB100 and DH5 α pNB102 was picked from a LB plate containing 35 μ g/mL Chloramphenicol and grown shaking at 37°C overnight in 1mL LB with 35 μ g/mL Chloramphenicol. To wash cells to remove antibiotics, 50 μ L of cells were added to 1mL LB in Eppendorf tubes and centrifuged 60 sec at 12500 rpm. Cells were resuspended in 50 μ L LB. To set up the mating JA200 pNT3 was spotted onto an LB plate, then 2 μ L of each DH5 α carrying pNB100 and pNB102 were added to this spot. Separate 2 μ L spottings of donor and recipients were also performed (i.e. not mated). Plates were incubated at 37°C for 4 hours. Cells were removed resuspended in LB and 100 μ L plated on LB plates containing both 100 μ g/mL Ampicillin and 35 μ g/mL Chloramphenicol (LB ApCm). 100 μ L of 10,000 fold (10^{-4}) dilutions were also plated on LB plates and incubated at 37°C overnight. The resultant colonies were counted as shown in the Table below.

Cells	LB ApCm plates	LB plates 10^{-4} dilution	Nemesis symbiotic activity
JA200 pNT3 x DH5 α pNB100	Confluent	Approx. 500	Negative
JA200 pNT3 x DH5 α pNB102	37	Approx. 500	Positive
JA200 pNT3 x DH5 α pACYC184	Confluent	Approx. 500	Negative
JA200 pNT3	0	Not done	Not applicable
DH5 α pNB100	0	Not done	Not applicable
DH5 α pNB102	0	Not done	Not applicable
DH5 α pACYC184	0	Not done	Not applicable

[0174] Photographs in Figure 13 show platings of the matings between: (A) JA200 pNT3 x DH5 α pNB100 (as expected lacking Nemesis symbiotic activity); and (B) JA200 pNT3 x DH5 α pNB102 (showing Nemesis symbiotic activity).

[0175] The 10^{-4} dilution plated on LB plates, gave approximately 500 colonies a count of 5×10^7 cells per mL in the mated cell suspension and for the JA200 pNT3 x DH5 α pNB102 only 3.7×10^2 cells/mL were able to grown on the LB Ap1 00Cm35 plates. Thus assuming half the cells are recipients/ex-conjugants then: 3.7×10^2 cells /ml divided by 2.5×10^7 gives a mating efficiency for the recipient carrying pNB102 of $1.2 \times 5 \times 10^{-5}$

[0176] The experiment demonstrated a significant reduction in CmR^{ap}R exconjugants in matings with DH5 α carrying pNB102 versus pNB100 x JA200 pNT3.

[0177] In order to measure the relative mating efficiencies more accurately, after a liquid mating cells were plated on LB plates to titre all cells, LB Ap100 plates to titre donors plus exconjugants, LB Cm plates to titre recipients plus exconjugants and LB Ap100Cm35 to titre exconjugants only.

[0178] For the liquid mating overnight cultures of 10 μ L of JA200 pNT3 were mixed with 10 μ L of recipients DH5 α pNB100 or DH5 α pNB102 200 μ L of LB added and tubes incubated overnight at 37°C. Mating mixtures were diluted 10⁻¹, 10⁻³, 10⁻⁵ in LB and 50 μ L of dilutions plated on LB, LB Ap100Cm35, LB Ap100 and LB Cm35 plates and plates incubated overnight at 37°C. The table below summarises the cell titres obtained.

Mated with JA200 pNT3	LB All cells	LB Ap Cm Exconjugants	LB Cm recipients and exconjugants	LB Ap donors and exconjugants	mating effic/donor	mating effic/recipient
pNB100	4.14 x 10 ⁸	2.80 x 10 ⁷	1.40 x 10 ⁸	2.64 x 10 ⁸	1.06 x 10 ⁻¹	2.00 x 10 ⁻¹
pNB102	5.16 x 10 ⁸	7.20 x 10 ³	1.78 x 10 ⁸	3.82 x 10 ⁸	1.88 x 10 ⁻⁵	4.04 x 10 ⁻⁵

[0179] The number of cells on LB Cm plus LB Ap plates should equal the number of cells on LB plates. For pNB100 1.40 x 10⁸ (Cm plates) plus 2.64 x 10⁸ (Ap plates) = 4.04 x 10⁸ which agrees very well with 4.14 x 10⁸ on LB plates. For pNB102 1.78 x 10⁸ (Cm plates) plus 3.82 x 10⁸ (Ap plates) = 5.6 x 10⁸ which agrees very well with 5.16 x 10⁸ on LB plates.

[0180] In conclusion, the data show that after overnight mating in liquid culture, there is a 5,000 fold reduction in mating efficiency per recipient comparing pNB102 with the spacer to pNB100 lacking the spacer.

NSA Assay by plasmid transformation

[0181] In this experiment, we demonstrate that introduction of Nemesis symbiotics to recipient cells by DNA transformation inactivates antibiotic resistance in the transformants.

[0182] In order to obtain a tester strain, DH5 α competent cells purchased from New England Biolabs were transformed with pBR322 (carrying the *bla* gene derived from Tn3) and selected on LB Ap100 plates. Competent cells of the derived strain DH5 α pBR322 were then prepared using the CaCl₂ protocol 25 (1.116) as described by Sambrook and Russell in Molecular Cloning: A Laboratory Manual (3rd Edition, 2001) and subsequently transformed with plasmids pNB100, pNB102 and pACYC184 with selection for CmR. Transformant colonies were then picked onto LB Cm35 and LB Ap100 plates. Primary transformants were replica toothpicked onto both LB Cm35 and LB Ap100 plates and incubated overnight at 37°C.

[0183] The results, depicted in Figure 14, show that all colonies toothpicked from DH5 α pBR322 transformed by pNB100 (lacking the *bla* gene target spacer sequence) remain resistant to ampicillin. In contrast all colonies toothpicked from DH5 α pBR322 transformed by pNB102 have lost ampicillin resistance, so demonstrating Nemesis symbiotic activity.

[0184] The experiments above do not give a value for the fraction of primary transformants where NSA has inactivated the *bla* gene. To address this, single colonies from the primary transformants were picked into 1mL LB and diluted 10⁻³ in LB. Then 100 μ L plated onto plates as follows, and results scored. The results showed that following transformation of DH5 α pBR322 with pNB102 fewer than 10⁻⁶ cells retain ApR. Nemesis symbiotic activity is very efficient.

NSA Assay by bacteriophage M13 infection

[0185] In this experiment, we demonstrate that introduction of Nemesis symbiotics to recipient cells by bacteriophage

infection inactivate antibiotic resistance in the transformants. We chose the male-specific filamentous phage M13 as the delivery agent for the Nemesis symbiotic construct. An M13 derivative M13mp18::NB102 carrying and the Cas9 CRISPR plus *bla* gene target spacer region of pNB102 was used to deliver the Nemesis symbiotic by infection of an F+ strain, JA200, carrying ampicillin resistance on the plasmid pNT3. 0.2mL of a fresh culture of this strain was added to 3 mL of LB top agar (Luria broth with 0.7% agar) and poured onto an LB plate. Then 2µL of phage stocks of M13mp18::NB102 (10⁸ pfu/mL) and as a control M13mp18 were spotted onto the lawn and the plate was incubated 8 hours at 37°C. Plaques were picked into 1.5 mL LB and grown shaking o/n at 37°C. A control strain DH5α lacking ampicillin resistance was also cultured overnight from a single colony picked into 1.5 mL LB.

Nitrocefin assay for beta lactamase activity was performed:

[0186] 1mL of the culture of cells was centrifuged for 60 sec at 12,500 rpm in microfuge then 2µL of stock nitrocefin (10mg/mL in DMSO) was added to 1mL of cell supernatant and absorbance of the degradation product of nitrocefin was measured at 482 nm in a spectrophotometer several time points after addition of nitrocefin. The Table below summarises the results.

Strain	30 sec	60 sec	2 min	5 min
JA200 pNT3 infected by M13mp8	0.5	0.64	0.73	0.79
JA200 pNT3 infected by M13mp8::NB102	0.08	0.09	0.11	0.15
DH5α	0.09	0.07	0.06	0.05

[0187] The experiments reported above provide the proof-of-concept that, in the model organism, *Escherichia coli*, DNA constructs carrying the Cas9 CRISPR region plus a spacer region with sequences directed against a target region of the beta-lactamase gene can inactivate ampicillin resistance when delivered by naked DNA transformation and bacteriophage infection as well as prevent transfer of ampicillin resistance by plasmid conjugation. It is apparent that Nemesis symbiotics of the invention can be applied to pathogenic bacteria and for other antibiotic resistance genes.

Example 3

[0188] The aim of Example 3 is to extend the proof-of-concept for resurrection of antibiotic efficacy by introduction of a CRISPR/Cas9 construct in a pathogenic bacterial strain of *Klebsiella pneumoniae*. Resistance to a newer class of beta-lactam antibiotics, the Carbapenems has emerged in Enterobacteriaceae by the acquisition of new *bla* genes that encode beta-lactamases able to degrade even the Carbapenems. *Klebsiella pneumoniae* strains with resistance to Carbapenems, KPC are important causes of morbidity and mortality among hospital-acquired and long-term care-associated infections. Noteworthy is the very high mortality (around 30-70%) among patients with bacteraemia or pulmonary infections.

[0189] Example 3 shows that a *Klebsiella pneumoniae* carrying a beta-lactamase (*bla*) gene conferring resistance to the beta-lactam antibiotic, ampicillin become sensitive to ampicillin following introduction of a modified CRISPR/Cas9 construct targeted against the *bla* gene. The same CRISPR/Cas9/anti-*bla* construct used in Example 1 or Example 2 is used and is delivered to *Klebsiella pneumoniae* by conjugation with a donor strain carrying a conjugative plasmid with CRISPR/Cas9/anti-*bla*. Ex-conjugant recipient *Klebsiella pneumoniae* carrying the plasmid with CRISPR/Cas9/anti-*bla*. construct is selected for on appropriate media with counter-selection against the donor cell and *Klebsiella pneumoniae* cells that failed to receive the plasmid.

[0190] As for Example 1 and Example 2, efficacy of the CRISPR/Cas9/anti-*bla* contstruct is evaluated by comparison to a negative control of a *Klebsiella pneumoniae* ex-conjugant strain that received a plasmid with CRISPR/Cas9 (*i.e.* lacking the anti-*bla* region). As in Example 1 and Example 2, the beta-lactamase activity can be detected by nitrocefin to count white versus red colonies. Also as in Example 1 and Example 2, alternatively beta lactamase activity is seen directly challenging the bacteria on the LB plate with/without ampicillin and measuring the fraction of the ampicillin sensitive colonies versus ampicillin resistant ones.

[0191] The identical experiment to that described above is also evaluated using instead a CRISPR/Cas9/anti-*blaCb*, where the CRISPR/Cas9/anti-*blaCb* construct carries a region, *anti-blaCb*, targeted against a *bla* gene encoding a beta-lactamase able to break down carbapenems and present in that particular *Klebsiella pneumoniae* strain.

Example 4

[0192] Example 4 provides delivery routes for the therapeutic constructs. These routes all apply to veterinary as well as human applications to be delivered orally, topically, probiotically and for use in surgical irrigation fluids and wound dressings.

[0193] Orally: Phage containing assassin construct as the active ingredient may be administered orally as a stabilised therapeutic preparation: either - administered before antibiotic therapy or administered in the form of an adjuvant complexed to an antibiotic. Conjugative plasmids containing assassin construct as the active ingredient may be administered as a culture of commensal bacteria carrying these plasmids in order to transmit these plasmids to gut flora thereby generating prophylactic protection against future infection with antibiotic resistant bacterial pathogens.

[0194] Topically: Phage containing assassin construct as the active ingredient may be administered topically as a stabilised medication (ointment, spray, powder etc): either - administered before antibiotic topical medication; or administered in the form of a complex with an antibiotic medication. Topical application of conjugative plasmids containing assassin construct as the active ingredient may be via a stabilised culture of commensal bacteria carrying these plasmids in order to transmit the plasmids to gut flora thereby generating prophylactic protection against future infection with antibiotic resistant bacterial pathogens.

[0195] Probiotically: Phage containing assassin construct as the active ingredient may be administered probiotically as a stabilised culture of commensal bacteria (e.g. *Lactobacillus* spp) carrying these plasmids in order to transmit the plasmids to gut flora thereby generating prophylactic protection against future infection with antibiotic resistant bacterial pathogens. One example of this may be the probiotic, prophylactic administration of such a preparation to patients in settings with a high risk of infection with antibiotic resistant bacterial pathogens such as hospitals, care homes, schools, transplantation centres etc. Another example may be the administration of such a preparation to livestock via animal feeds, thereby limiting the rise and horizontal transmission of antibiotic resistant bacteria. The use of the present invention in livestock thus represents one means for (indirect) prophylactic treatment of antibiotic resistant bacteria in humans.

[0196] Surgical irrigation fluids: Phage containing assassin construct as the active ingredient may be added to surgical irrigation fluids and also sprays for disinfecting fomites. Stabilised commensal bacterial cultures containing conjugative plasmids incorporating assassin constructs may be added as coatings to surgical wipes and to wound dressings.

Example 5

[0197] In this example, a construct is designed to include multiple RNA guide molecules where each RNA guide molecule is transcribed by its own promoter.

[0198] Figure 16 exemplifies a set of spacer sequences that we have identified encoding 20 guide RNA molecules targeted against 117 different *bla* genes identified in the NCBI ARDB database for *Klebsiella pneumoniae*. The beta lactamase gene type, spacer sequence and antibiotic resistance profile in *Klebsiella pneumoniae* obtained from NCBI ARDB database are shown.

[0199] Beta lactamase gene sequences were collected from the ARDB database with the keyword *Klebsiella pneumoniae*. Redundant sequences were removed and unique sequences used for multiple sequence alignment using web program Clustal Omega. One canonical sequence was chosen from each cluster and the 20 nt spacer sequences predicted by the web program Jack Lin's CRISPR/Cas9 gRNA finder collected. The spacer sequence was chosen to maximise the ratio of the proto-spacer sequence found in the sequences belonging to the same branch. Each of the example spacer sequences shown in the 4th column has the capability to disrupt the genes in the third column.

[0200] Beta lactamase genes used in this analysis are: SHV-a = 1, 2, 2a, 5, 5a, 11, 12, 14, 26, 27, 28, 31, 33, 38, 43, 44, 48, 55, 56, 60, 61, 62, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 89, 92, 98, 99, 101, 103, 106, 107, 108, 109, CTXM-b = 1, 3, 10, 12, 15, 22, 32, 54, 60, 62, 68, CTXM-c = 13, 14, 16, 18, 19, 24, 26, CTXM-d = 2, 35, 59, CTXM-e = 26, 63, TEM-f = 1, 1b, 3, ESBL, 139, KPC-g = 1, 2, 3, 4, OKP-h = A11, A12, A16, A17, B13, B-SB613, 6, LEN-i = 2, 17, 18, 19, 20, 21, 22, 24, GES-j = 1, 3, 4, 5, VIM-a = 1, 2, 4, 12, 19, IMP-b = 4, 8, CMY-a = 2, 4, 25, 31, 36, LAT-b = 1, 2, CMY-c = 1, 8b, 10, 19, FOX-d = 1, 5, 7, OXA-a = 1, 30, 47, OXA-2, OXA-9, OXA-b = 10, 17.

[0201] Beta lactam antibiotics were classified into four classes, penams, cepheems, carbapenem and monobactam. One antibiotic name is listed in Figure 16 as an example under each class. The beta lactamase, which can open the beta lactam ring is indicated by R. For example, carbapenem is inactivated by KPC. To re-sensitise bacteria to carbapenem, the spacer sequence 5'-TTGTTGCTGAAGGAGTTGGG (SEQ ID NO: 45) should be employed into the spacer array and inactivate KPC genes. Note that the spacer sequence for CMY-a can be employed to LAT-b cleavage.

[0202] Similarly, Figure 17 exemplifies a set of spacer sequences encoding 17 guide RNA molecules targeted against 154 different *bla* genes identified in the CARD database for *Klebsiella pneumoniae*. Beta lactamase gene type, spacer sequence and antibiotic resistance profile in *Klebsiella pneumoniae* obtained from the IIDR CARD database are shown.

[0203] Beta lactamase gene sequences were collected by filtering all the collected beta lactamase genes with the keyword *Klebsiella pneumoniae* and subjected to multiple sequence alignment using web program Clustal Omega. One canonical sequence from each cluster was chosen and the 20 nt spacer sequences predicted by the web program Jack Lin's CRISPR/Cas9 gRNA finder collected. The spacer sequence was chosen to maximise the ratio of the proto-spacer sequence found in the sequences belonging to the same branch. The each of the example spacer sequences shown in the 4th row has the capability to disrupt the genes in the third column.

[0204] Beta lactamase genes used in this analysis are: SHV-a = 1a, 5, 2a, 11, 18, 20, 21, 22, 23, 28, 31, 32, 52, 55, 98, 99, 100, 106, 107, 110, 111, 121, 134, 136, 137, 140, 143, 144, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 158, 159, 160, 161, 162, 163, 164, 165, 168, 172, 173, 178, 179, CTXM-b = 10, 12, 15, 52, 54, 62, 71, 80, CTXM-c = 19, 81, 99, 147, TEM-f = 1, 162, 183, 192, 197, 198, 209, KPC-g = 3, 4, 6, 7, 8, 11, 12, 14, 15, 16, 17, OKP-h = 5, 6, A1, A2, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B17, B18, B19, B20, LEN-i = 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, 22, 23, 24, GES-j = 1, 3, 4, VIM-a = 4, 26, 27, 28, 33, 34, IMP-b = 32, 38, NDM-c = 1, 9, 10, ACT-3, CMY-a = 25, 31, 56, 87, FOX-d = 8, 9, OXA-a = 1, 30, 47, OXA-1, OXA-a = 181, 204, 247, OXA-9.

[0205] Beta lactam antibiotics are classified into four classes, penams, cepheems, carbapenem and monobactam. In Figure 17, one antibiotic name is listed as an example under each class. The beta lactamase, which can open the beta lactam ring is indicated by R. For example, carbapenem is inactivated by KPC. To re-sensitize bacteria to carbapenem, the spacer sequence 5'-TTGTTGCTGAAGGAGTTGGG (SEQ ID NO: 45) should be employed into the spacer array and inactivate KPC genes.

Example 6

[0206] In this example, a modified Cas DNA-binding polypeptide is created that deletes and reseals rather than leaving a DSB.

[0207] As described above, DSBs caused by Cas DNA-binding polypeptide such as CRISPR-Cas9 can be lethal to the replicon targeted and can result in cell death rather than, for example, re-sensitisation to antibiotics, if an antibiotic resistance gene in the replicon is targeted for inactivation. Immediate cell death rather than such re-sensitisation to antibiotics for subsequent killing by antibiotic may increase selection pressure against delivery of the targeting constructs. Instead of DSBs, we may modify the Cas9 gene to allow the resealing of the targeted sequence after gene inactivation by introducing a deletion or inversion.

[0208] Tsai et al. (2014) have constructed a fusion between a catalytically inactive Cas9 (dCas9) protein to the wild-type nuclease domain of the restriction endonuclease *FokI* to increase the specificity of cleavage in eukaryotic cells. Proudfoot et al. (2011) have similarly fused zinc-finger DNA recognition domains to the catalytic domains of

recombinases to programme site-specific recombination at designated DNA sequences.

[0209] We here add appropriate recombinase domains to dCas9 to catalyse a recombination reaction rather than a DSB at a CRISPR-mediated RNA-guided desired position on the target genes.

[0210] The Cas9 resolvase fusion, called Cas9R in Figure 18, is directed to the desired sites determined by the Cas9 domain:guide RNA spacer sequences; and the fused resolvase is positioned at the recombination site. To generate a deletion between two recombination sites: A and B, resolvases must dimerise at each recombination site. Thus two Cas9Rs need to be positioned in close proximity at each recombination site A1A2 and B1B2 as designated by the sequences encoded by the spacers S1-S4. The correct orientations of A1 relative to A2 and B1 relative to B2 will need to be determined experimentally.

[0211] The orientation of the gRNA as shown Fig. 19 is already proved in the case of dCas9 fused *FokI* (Tsai et al., 2014) - i.e. PAM sequences of each protospacer sequence in the recombination sites are directly positioned at the outer boundaries of the full-length recombination site. Thus, we employ the same configuration of the annealed gRNA polarity.

[0212] Figures 19 and 20 show a schematic process as to how this Cas9R fusion resolvase resolves the synapse and parental replicon DNA is recircularised.

Example 7

[0213] The following experiments describe some proof-of-concept experiments performed to demonstrate that the CRISPR-Cas9 system can be used in a single construct to inactivate a large number of different beta-lactamase genes that may be found amongst microbial pathogens as well as amongst the non-pathogenic members of the microbiome.

[0214] In these exemplifications, plasmids are constructed that carry the CRISPR-Cas9 system plus derivatives carrying spacer sequences, flanked by direct repeats, targeted against up to eight of the following beta-lactamase families of resistance genes: SHV, CTX-M, TEM, KPC, VIM, IMP, NDM and OXA.

[0215] For each of these eight families of beta-lactamase genes, a single spacer is designed that will target a number of gene members of that family. These are: SHV-a = 1, 1a, 2, 2a, 5, 5a, 11, 12, 14, 18, 20, 21, 22, 23, 26, 27, 28, 31, 32, 33, 38, 43, 44, 48, 52, 55, 56, 60, 61, 62, 71, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 85, 89, 92, 98, 99, 100, 101, 103, 106, 107, 108, 109, 110, 111, 121, 136, 134, 137, 140, 143, 144, 147, 148, 149, 150, 151, 152, 153, 154, 155, 157, 158, 159, 160, 161, 162, 163, 164, 165, 168, 172, 173, 178, 179; CTXM-b= 1, 3, 10, 12, 15, 19, 22, 32, 52, 54, 59, 60, 62, 68, 71, 80, 81, 99, 141, 147; TEM-c = 1, 1B, 3, 139, 162, 183, 192, 197, 198, 209; KPC-d = 1, 2, 3, 4, 6, 7, 8, 11, 12, 14, 15, 16, 17 ; VIM-e = 1, 2, 4, 19, 26, 27, 33, 34; IMP-f = 4, 8, 32, 38; and NDM-g = 1, 9, 10.

[0216] Figure 21 shows the eight spacer sequences that were designed to target the eight beta-lactamase families of resistance genes: SHV, CTX-M, TEM, KPC, VIM, IMP, NDM and OXA-48. The primer sequences used in the construction of the plasmids are listed in a table in Figure 22.

[0217] In one exemplification, a plasmid derivative of pNB100 (Figure 12), pNB104A (Figure 23), a generally applicable DNA cassette, is described in the Examples that carries the CRISPR-Cas9 system plus derivatives carrying spacer sequences, flanked by direct repeats, targeted against four beta-lactamase families of antibiotic resistance genes in bacteria and are expressed off one promotor: NDM, IMP, VIM and KPC.

[0218] In another exemplification, a plasmid derivative of pNB100, pNB104B (Figure 24), a generally applicable DNA cassette, is described in the Examples that carries the CRISPR-Cas9 system plus derivatives carrying spacer sequences, flanked by direct repeats, targeted against four beta-lactamase families of antibiotic resistance genes in bacteria and are expressed off one promotor: OXA-48, SHV, TEM and CTX-M.

[0219] In another exemplification, a plasmid derivative of pNB100, pNB108 (Figure 25), a generally applicable DNA cassette, is described in the Examples that carries the CRISPR-Cas9 system plus derivatives carrying spacer sequences, flanked by direct repeats, targeted against eight beta-lactamase families of antibiotic resistance genes in bacteria and are expressed off one promotor: SHV, CTX-M, TEM, KPC, VIM, IMP, NDM and OXA-48.

[0220] In another exemplification, a plasmid derivative of pNB100 is constructed where spacer sequences can be expressed from a choice of two different promoters. This plasmid, pNB200 (Figure 26), carries a different unique restriction site downstream of each promoter to clone any desired spacer sequences flanked by their own direct repeats between two direct repeats in the CRISPR locus. Derivatives of pNB200 are described that carry the CRISPR-Cas9 system plus derivatives carrying spacer sequences, flanked by direct repeats, targeted against eight beta-lactamase families of resistance genes: SHV, CTX-M, TEM, KPC, VIM, IMP, NDM and OXA-48. In pNB202 (Figure 27), the second promoter is used to express spacers flanked by direct repeats to target the four beta-lactamase families of resistance genes: OXA-48, SHV, TEM and CTX-M. And in pNB203 (Figure 28), which is derived from pNB202, both promoters are used: the first to express spacers flanked by direct repeats to target four beta-lactamase families of resistance genes: NDM, IMP, VIM and KPC and the second promoter to express spacers flanked by direct repeats to target four beta-lactamase families of resistance genes: OXA-48, SHV, TEM and CTX-M.

Construction of pNB104A

[0221] The tetramer spacer concatemer a+b+c+d shown in Figure 29A was digested with *Bsal*, whose restriction site is located in A1 and A2, and ligated to *Bsal* spacer cloning sites on pNB100. The structure of the single promoter and spacer region (6221-7001) on pNB104A is shown in Figure 23. The four-space concatemer contains spacer sequences targeting NDM, IMP, VIM and KPC from the proximal to the distal end of the single promoter.

Construction of pNB104B

[0222] The tetramer spacer sequence concatemer e+f+g+h shown in Figure 29A was digested with *SapI*, whose restriction site is located in B1 and B2, and ligated to *SapI* spacer cloning sites on pNB200. While screening pNB202 screening this construct was found and confirmed by sequencing. A deletion event between the direct repeats adjacent to leader sequences had occurred and restored the direct repeat sequence to give pNB104B. The single promoter regions (6221-6987) on pNB104B is shown in Figure 24. The concatenated spacers (targeted against OXA-48, SHV, TEM and CTX-M) are located under the single promoter.

Construction of pNB108

[0223] The concatenated spacer array sequences A and B were amplified from the subcloned vector pCR Blunt II-TOPO_SpacerA and pCR Blunt II-TOPO_SpacerB with the primer set NB026 and NB029, NB030 and NB033, respectively. At the 3' end of amplicon of spacer A and 5' end of amplicon of spacer B are 20 bases of overlapped sequence from KPC spacer sequence. These two amplicons were gel purified and used for PCR-based pairwise cycle extension reaction in the absence of the primer. The extended material was re-amplified with primer set NB037 (5'-GGGCTGGCAAGCCACGTTTGGTG-3'; SEQ ID NO. 150) and NB038 (5'-CCGGGAGCTGCATGTGTCTCAGAGG-3'; SEQ ID NO. 151) to generate the full 8 spacer array concatemer. This eight-spacer concatemer was cloned into pCR Blunt II-TOPO vector and sequence was confirmed.

[0224] *Bsal* digestion of this pCR Blunt II-TOPO subclone removes the full 8 spacer array concatemer as a subclone from the pCR Blunt II-TOPO vector, which contains 5' protruding four base compatible bases on both ends for the sites created on pNB100 by *Bsal* digestion. Then pNB100 was digested with *Bsal* followed by agarose gel purification. The eight-spacer concatemer cassette, released from the pCR Blunt II-TOPO was ligated into pNB100 by T4 DNA ligase and transformed to DH5 α competent cells (purchased from New England Biolabs). The transformants were selected on chloramphenicol LB plates and were screened by PCR with the reverse primer NB021: 5'-GGTGA CTGATGGCCACGT (SEQ ID NO: 149) and a forward primer NB020: 5'-CCAACTACCTCCCCTTGCTTAAC (SEQ ID NO: 148), which anneal at 6368-6385 region and 7203-7225 region, respectively on the recombinant plasmid to generate 858 bp PCR amplicon. PCR-positive clones were sequenced to confirm the eight-spacer concatemer sequence and this recombinant clone is designated as pNB108 and used to demonstrate CRISPR/Cas9-mediated inactivation of targeted beta lactamase genes following DNA delivery to bacterial strains carrying such genes. A plasmid map of pNB108 is shown in Figure 25.

Construction of pNB200

[0225] The plasmid pNB200 contains two identical promotors for gRNA expression and carries a different unique restriction site *Bsa*I and *Sap*I downstream of each promotor to clone any desired spacer sequences flanked by their own direct repeats between two direct repeats in the CRISPR locus. The desired structure of the CRISPR array locus in pNB200 consists two sets of cassettes harbouring promotor-leader-direct repeat-spacer cloning region-direct repeat-tail tandemly. The forward primer NB018 anneals at the 5' end of the leader sequence to the promotor in pNB100 and introduces the first spacer cloning region, second direct repeat and tail sequence. The reverse primer NB019 anneals at the 3' end of leader sequence in pNB100 and introduces a third direct repeat, second spacer cloning region. This amplicon is cloned between *Bsa*I sites on pNB100 to give pNB200.

The amplified sequence (SEQ ID NO: 146) with primer NB018 and NB019 from pNB100 as template

[0226]
5'CCAAAACt**gagacc**CGCTGCGGACGTCCTCCAAAGGTCTCGTTT**AGAGCTATGCTGTTTGAA**TGGTCCCAAACTTG
CCGATGATAACTTGAGAAAGAGGGTTAAACACGAGCAGTCGGATACCTTCCGATTCCTTCTGTTAAAGCGTTTTCAGT
TAAATAAGGCAA**ATTTTAGATGAAGATTATTCTTAATAAC**TAAAAATATCGTATAAACTCTTAAATAATCCAGTAA
TACACCGCCTTTTCAAGACATCAAGTCTAGCTGACACAAATAGTCCGATTACGAAATTTT**TAGACAAAAATAGTCTAC**
GAGGTTTAGAGCTATGCTCTTTTGAATGGTCCCAAAACt**GAGACCGTCTCGGACgcagcGCCTCTCGTTT**TAGA.

[0227] The forward primer NB018 and the reverse primer NB019 are underlined and the initial annealing sites, for the first PCR cycle, are indicated by bold letters and italicised bold letters, respectively. This amplicon was digested with *Bbv*I (5'-GCAGCN8/N12) to create four bases compatible protruding 5' ends to *Bsa*I digested pNB100. *Bbv*I recognition sites are depicted by lower bold cases.

[0228] The PCR conditions to generate the dual promotor-leader cassette were:

Component	
Nuclease-Free water	41.25 µL
10 X PCR Buffer	5 µL
10 mM dNTPs	1 µL
10 µM Forward Primer NB018	1 µL
10 µM Reverse Primer NB019	1 µL
pNB100	0.5 µL
QIAGEN Hot Start Taq	0.25 µL

Cycle conditions

STEP	TEMP	TIME
Initial Denat.	95CC	15 min
35 Cycles	94CC	30 sec
	55 °C	30 sec
	72 °C	30 sec
Final Extension	72°C	10 min

The sequence of the modified CRISPR array in pNB200 (SEQ ID NO: 147)

[0230] The total number of nucleotides of pNB200 is 9919 bp. The sequence in the modified region is shown below, which replaces the small *BsaI* fragment in pNB100. The first and the second promoter sequences are underlined. Leader sequences are in bold case. Direct repeats are italicised and the spacer cloning region between direct repeats are indicated by italicised and underlined.

[0231] The first spacer array cloning region contains two inverted *BsaI* sites indicated by bold italicised underlined letters 5'-GAGACC-3' and 5'-GGTCTC-3' for creating 5' four bases protruding spacer cloning sites 5'-GTTT-3' and 5'-TTTT-3' on the vector, respectively and one unique *AaflI* (5'-GACGTC-3') site also indicated by bold italicised underlined letters to reduce self-ligation in the event of incomplete *BsaI* digestion.

[0232] The second spacer cloning region contains two inverted *SapI* sites indicated by bold italicised underlined letters 5'-GAAGAGC-3' and 5'-GCTCTTC-3' for creating 5' three bases protruding spacer cloning sites 5'-GTT-3' and 5'-TTT-3' on the vector, respectively.

```
GGTGACTGATGGCCACGTGAACATATGATTTTCCGCGAGTATATTTAGATGAAGATTATTTCTTAATACTAAAAAT
ATGGTATAAATACTCTTAATAAATGCAGTAATACAGGGGCTTTTCAAGACTGAAGTCTAGCTGAGACAAATAGTGCGAT
TACGAAATTTTTTAGACAAAAATAGTCTACGAGGTTTTAGAGCTATGCTATTTTGAATGGTCCCAAAAGTGAGACCTG
CTGCGGACGTCCAAGGGTCTCGTTTTAGAGCTATGCTGTTTTGAATGGTCCCAAAAGTtgccgatgataaacttgagaa
agaggggttaataaccagcagtcggataccttcctattctctctgttaaagcgctttcatgttataataggcaaaAITTTA
GATGAAGATTATTTCTTAATAACATAAAATATGGTATAATACTCTTAATAAATGCAGTAATACAGGGGCTTTTCAAGA
CTGAAGTCTAGCTGAGACAAATAGTGCGATTACGAAATTTTTTAGACAAAAATAGTCTACGAGTTTTAGAGCTATGC
TGTTTTGAATGGTCCCAAAAGTGAAGAGCGTCTCGGACGCAGCGCTCTTCGTTTTAGAGCTATGCTGTTTTGAATGGT
CCCAAAACaacattgcgatgataaacttgagaaagaggggttaataaccagcagtcggataccttcctattctctctgtt
aaagcggttctcatgttataataggcaaaagaagagtagtggtg
```

[0233] A plasmid map of pNB200 is shown in Figure 26. The desired spacer array sequences can be cloned in the clockwise direction between two *BsaI* sites and two *SapI* sites independently, for each promoter respectively.

Construction of pNB202

[0234] The plasmid pNB201 contains the dual promoters of pNB200 from which it is derived but a spacer array sequence targeted to OXA-48, SHV, TEM and CTX-M beta lactamase gene families are expressed from the second promoter.

[0235] To construct pNB202, pNB200 was digested with *BsaI* followed by agarose gel purification. The concatenated spacer array sequence B was generated by PCR-mediated pair-wise oligo nucleotide concatenation. This four-spacer concatemer array B was cloned to the pCR Blunt II-TOPO vector, purchased from Life Technologies, and the sequence was confirmed. *SapI* cuts out spacer array sequence B as a subclone from the TOPO vector and yields 5' protruding three base compatible bases on both ends for the sites created on pNB200 by *SapI* digestion. This four-spacer concatemer B cassette was ligated to pNB200 by T4 DNA ligase and transformed to DH5α competent cells (purchased from New England Biolabs). The transformants were selected on chloramphenicol LB plate and were screened by PCR with the reverse primer NB021: 5'-GGTGACTGATGGCCACGT (SEQ ID NO: 149) and a forward primer NB020: 5'-CCAACTACCTCCCCTTGCTTAAC (SEQ ID NO: 148), which anneal at 6368-6385 region and 7307-7329 region, respectively on the recombinant plasmid to generate 962 bp PCR amplicon. PCR positive clones were sequenced to confirm the four-spacer concatemer B sequence and this recombinant clone is designated as pNB202 and used to demonstrate CRISPR/Cas9-mediated inactivation of targeted beta lactamase genes following DNA delivery to bacterial strains carrying such genes. A plasmid map of pNB202 is shown in Figure 27.

Construction of pNB203

[0236] The plasmid pNB203 contains the dual promoters of pNB200 but each promoter expresses four spacers. The first promoter expresses spacer sequence targeted to NDM, IMP, VIM and KPC, the second promoter expresses OXA, SHV, TEM and CTX-M beta lactamase genes. The plasmid pNB202 was digested with *BsaI* followed by agarose gel

purification. The concatenated spacer array sequence A was cut out from pCR Blunt II-TOPO vector harbouring spacer concatemer A with *Bsal*. *Bsal* cuts out spacer region, which contains 5' protruding four base compatible bases on both ends for the sites created on pNB202 by *Bsal* digestion. This four-spacer concatemer A cassette was ligated to pNB202 by T4 DNA ligase and transformed to DH5α competent cells (purchased from New England Biolabs). The transformants were selected on chloramphenicol LB plate and were screened by PCR with the reverse primer NB021: 5'-GGTGACTGATGGCCACGT and a forward primer NB020: 5'- CCAACTACCTCCCCTTGCTTAAC , which anneal at 6368-6385 region and 7479-7501 region, respectively on the recombinant plasmid to generate 1134 bp PCR amplicon. PCR positive clones were sequenced to confirm the four-spacer concatemer A and B sequence and this recombinant clone is designated as pNB203 and used to demonstrate CRISPR/Cas9-mediated inactivation of targeted beta lactamase genes following DNA delivery to bacterial strains carrying such genes. A plasmid map of pNB203 is shown in Figure 28.

Schematic representation of the structure of concatenated spacer arrays

[0237] Spacer sequences were determined to maximise the coverage of the target beta-lactamase gene family. Each unit oligo contains the direct repeat flanking the appropriate spacer sequence at each end. Concatenation reactions are performed between pairwise oligos, *i.e.* the nearest neighbour unit oligos are concatenated first to generate two unit length oligo, then two unit length oligos are concatenated to generate four unit length of oligo etc.

[0238] The schematic structure of tetramer and octamer spacer structures are shown in Figure 29. S: spacer, R: direct repeat, A and B contain *Bsal* site to create ligation compatible sites for cloning into pNB100 and downstream of the first promotor of pNB200. C and D contain a *SapI* site to create ligation a compatible site for cloning downstream of the second promotor of pNB200. In this example, we employed spacer sequence S1 targeting NDM, S2 targeting IMP, S3 targeting VIM, S4 targeting KPC, S5 targeting OXA, S6 targeting SHV, S7 targeting TEM and S8 targeting CTX-M.

Spacer concatenation reaction

[0239] Each oligo has overlapped sequence in the 3' and 5' end to anneal to the nearest neighbour oligo except the first and the last oligo. The first and the last oligo have the overlapping sequence to the second and the penultimate oligo in the 5' end only. In order to concatenate four spacers, four oligos are synthesised. In other words, oligo No.1 consists spacer 1 and 2 in the 5' and 3' ends. Oligo No.2 contains reverse complement of spacer 2 and 3 in the 3' and 5' ends. Oligo No.3 contains spacer 3 and 4 in the 5' and 3' ends. Oligo No.4 contains reverse complement of spacer 4 in the 3' end. Thus the oligo No.2 can link oligo No.1 and oligo No.3, oligo 4 anneals to 3' end of oligo No.3. Oligo No.1 and oligo No. 2, oligo No. 3 and oligo No. 4 are concatenated in a separate tube using the following PCR reaction conditions.

Component	A1	A2	B1	B2	x 4
Nuclease-Free water	33.5 µL	33.5 µL	33.5 µL	33.5 µL	134
5X Q5 Reaction Buffer	10 µL	10 µL	10 µL	10 µL	40
10 mM dNTPs	1 µL	1 µL	1 µL	1 µL	4
Q5 High-Fidelity DNA Polymerase	0.5 µL	0.5 µL	0.5 µL	0.5 µL	2
10 µM Forward Primer NB026	2.5 µL				
10 µM Reverse Primer NB027	2.5 µL				
10 µM Forward Primer NB028		2.5 µL			
10 µM Reverse Primer NB034		2.5 µL			
10 µM Forward Primer NB035			2.5 µL		
10 µM Reverse Primer NB031			2.5 µL		
10 µM Forward Primer NB032				2.5 µL	
10 µM Reverse Primer NB036				2.5 µL	

Cycle conditions

[0240]

STEP	TEMP	TIME
Initial Denat.	98°C	60 sec
35 cycles	98°C	10 sec
	55°C	10 sec
	72°C	20 sec
Final Extension	72°C	2 minutes
Hold	4°C	

[0241] In this example, NB026 and NB027, NB028 and NB034, NB035 and NB031, NB032 and NB036 are concatenated. Each concatenated product A1, A2, B1 and B2 was gel purified and set up the second concatenation reaction using the purified A1 and A2, B1 and B2 dimer product in the following PCR condition.

Component	A	B	x 2
Nuclease-Free water	35.75 µL	35.75 µL	71.5
10 X PCR Buffer	5 µL	5 µL	10
10 mM dNTPs	1 µL	1 µL	2
QIAGEN Hot Start Taq	0.25 µL	0.25 µL	0.5
Gel extracted A1	4 µL		
Gel extracted A2	4 µL		
Gel extracted B1		4 µL	
Gel extracted B2		4 µL	

Cycle conditions

[0242]

STEP	TEMP	TIME
Initial Denat.	95°C	15 min
35 Cycles	94°C	30 sec
	A: 55 °C	30 sec
	72°C	30 sec
Final Extension	72°C	10 min

[0243] These extention products were amplified by NB037 and NB038 with Q5 DNA polymerase. The final amplicons were cloned to pCR Blunt II TOPO vector and the concatemer sequences were confirmed.

[0244] In case of eight spacer concatenation, spacer concatemer A and spacer concatemer B on pCR Blunt II TOPO vector were amplified with primer pairs NB026 and NB029, NB030 and NB033, respectively and amplicons were gel purified. Purified spacer A and B were utilised as a long primer in the following cycle extension reaction.

Component	A
Nuclease-Free water	35.75 µL
10 X PCR Buffer	5 µL
10 mM dNTPs	1 µL
QIAGEN Hot Start Taq	0.25 µL
Gel extracted A	4 µL

Component	A
Gel extracted B	4 µL

Cycle conditions

[0245]

STEP	TEMP	TIME
Initial Denat.	95 °C	15 min
25 Cycles	94 °C	30 sec
	55 °C	30 sec
	72 °C	30 sec
Final Extension	72 °C	10 min
Hold	4 °C	o/n

[0246] These extention products were amplified by NB037 and NB038 with Q5 DNA polymerase. The final amplicons were cloned into pCR Blunt II TOPO vector and the concatemer sequences were confirmed.

Delivery of CRISPR-Cas9 constructs to bacteria

[0247] Constructs that are able to inactivate target genes, including antibiotic resistant genes, via the CRISPR-Cas system, and which are an aspect of the present invention are also referred to herein as "Nemesis symbiotics". The CRISPR-Cas9 plasmid derivatives, pNB104A, pNB104B, pNB202 and pNB203 all carry spacer insertions targeted against the selected families of beta-lactamase (*b/a*) genes described, and so provide exemplars to demonstrate that a single plasmid construct possesses Nemesis symbiotic activity (NSA) and is therefore able to inactivate representative genes from all 8 different families of beta-lactam antibiotics. The plasmid pNB104A (see Fig. 23) is tested for its ability to inactivate representative genes members of the NDM, IMP, VIM and KPC families; pNB104B (see Fig. 24) and pNB202 (ss Fig. 27) are tested for their ability to inactivate representative genes members of the OXA, SHV, TEM and CTX-M families; and pNB108 (see Fig. 25) and pNB203 (see Fig. 28) are tested for their ability to inactivate representative genes members of the SHV, CTX-M, TEM, KPC, VIM, IMP, NDM and OXA families.

Nemesis symbiotic activity (NSA) assay by plasmid transformation

[0248] The NSA assay described in Example 2 showed that DNA transformation of an *E. coli* strain, DH5α also carrying the TEM-3 beta lactamase gene on the plasmid pBR322, with plasmid pNB102 converts the transformant to ampicillin sensitivity (ApS). Here, the plasmid pNB102 encodes resistance to chloramphenicol and the DH5α (pBR322) transformants now carrying pNB102 were selected on LB Cm plates and then screened for ApS (see Fig. 14). Here, the plasmid pNB102, in expressing the CRISPR/Cas9 system with the spacer sequence encoding the gRNA targeting the TEM-3 gene, inactivated the TEM-3 gene. In contrast in a negative control experiment, when DH5α (pBR322) was transformed with the parental plasmid pNB100 carrying the expressing the CRISPR/Cas9 system but lacking the gRNA targeting the TEM-3 gene, no conversion to ApS occurred.

[0249] For exemplification purposes an equivalent experiment is described where plasmid derivatives of pBR322 are constructed where the TEM-3 is replaced by representative genes from the other 7 different families of beta-lactam antibiotics: SHV, CTX-M, KPC, VIM, IMP, NDM and OXA. Such genes are obtained from suitable bacterial strains carrying such genes. This allows a direct comparison to the proof of concept experiments described in Example 2 in isogenic genetic backgrounds.

[0250] A set of *E. coli* and *K. pneumoniae* strains carrying representative genes from these seven different families of

beta-lactam antibiotics were purchased from Culture Collections, Public Health England, Porton Down, Salisbury, SP4 0JG, UK. These are: NCTC13368, a *K. pneumoniae* strain carrying the SHV-18 gene; NCTC13353 an *E. coli* strain carrying the CTX-M-15 gene; NCTC13438 a *K. pneumoniae* strain carrying the KPC-3 gene; NCTC13440 a *K. pneumoniae* strain carrying the VIM-1 gene; NCTC13476 an *E. coli* strain carrying an uncharacterised IMP gene; NCTC13443 a *K. pneumoniae* strain carrying the NDM-1 gene and NCTC13442 a *K. pneumoniae* strain carrying the OXA-48 gene. All seven genes encode beta lactamases that are also able to degrade and inactivate the penam class of antibiotics (see Fig. 16, 17). All strains were tested and, as expected, found to be resistant to the penam class antibiotic, ampicillin.

[0251] Beta lactamase coding sequences are amplified from the cell with appropriate forward and reverse primer set shown below:

Strain	NCTC No.	Resistance gene	Forward primer 5' to 3'	Reverse primer 5' to 3'
NBKp001	13443	NDM-1	attgaaaaaggaagagtATGGAATTGCCC AATATTATGCACCC (SEQ ID NO: 152)	agtccegetaGGTCTCaACCGTCAGCGCA GCTTGTCGG (SEQ ID NO: 153)
NBKp002	13442	OXA-48	attgaaaaaggaagagtATGCGTGTATTA GCCTTATCGGCTG (SEQ ID NO: 154)	agtccegetaGGTCTCaACCGCTAGGGAA TAATTTTTTCCTGTTGAGCACTTCT (SEQ ID NO: 155)
NBKp003	13368	SHV-18	attgaaaaaggaagagtATGCGTTATTTT CGCCTGTGTATTATCTCC (SEQ ID NO: 156)	agtccegetaGGTCTCaACCGTTAGCGTT GCCAGTGCTCGA (SEQ ID NO: 157)
NBKp004	13440	VIM-1	attgaaaaaggaagagtATGTTAAAGTT ATTAGTAGTTTATGGTCTACATGACCG (SEQ ID NO: 158)	agtccegetaGGATGacctggctgACCGC TACTCGGCGACTGAGCGAT (SEQ ID NO: 159)
NBKp005	13438	KPC-3	attgaaaaaggaagagtATGTCACGTGTAT CGCCGTCTAGTTCT (SEQ ID NO: 160)	agtccegetaGGTCTCaACCGTTACTGCC CGTTGACGCC (SEQ ID NO: 161)
NBEc018	13476	IMP-4	attgaaaaaggaagagtATGAGCAASTTA TCTGTATTCTTTATATTTTGTGTTAG CA (SEQ ID NO: 162)	agtccegetaGGTCTCaACCGTTAGTTGC TTAGTTTTCATGGTTTTTACTTTCGTTT AAC (SEQ ID NO: 163)
NBEc019	13353	CTX-M-15	attgaaaaaggaagagtATGGTTAAAAA TCACTGCGCCAGTTC (SEQ ID NO: 164)	agtccegetaGGTCTCaACCGTTACAAAC CGTCGGTGACGATTTTAG (SEQ ID NO: 165)

[0252] Each forward primer contains a 17 base sequence to restore the beta-lactamase promoter on pBR322, and each reverse primer contains *Bsa*I site (for NDM-1, OXA-48, SHV-18, KPC-3, IMP-4 and CTX-M15) or *Fok*I site (for VIM-1) to create 5'-ACCG four base protruding 5' end. After amplifying each beta lactamase gene with high fidelity DNA polymerase such as Q5 DNA polymerase, the amplicon is digested with the appropriate restriction enzyme located in the reverse primer, described above. The digested amplicons are ready to ligate using T4 ligase between the *Ssp*I and *Bsa*I sites on the plasmid pBR322 (purchased from New England Biolabs), after removal of the TEM-3 fragment. *Ssp*I creates a blunt end and *Bsa*I creates a 5'-CGGT protruding end. The reverse complement of the coding sequences of the each amplicons after restriction digestion are shown below. The 5' protruding end is underlined and 3' end of the promotor sequence is in bold small letters. The reverse complement CAT of the methionine initiating codons ATG of these seven genes, also shown in bold, yields a precise fusion of the coding region of the seven other beta-lactamases to the translational signal sequences of the TEM-3 beta-lactamase of pBR322.

NDM-1 (SEQ ID NO: 166)
ACCGTCAGCGCAGCTTGTCGGCCATGCGGGCCGTATGAGTGATTGCGGCGCGGCTATCGGGGGCGGA
ATGGCTCATCACGATCATGCTGGCCTTGGGGAACGCCGACCAAAACGCGCGCGCTGACGCGGCGTAG
TGCTCAGTGTGCGGCATCACCGAGATTGCCGAGCGACTTGGCCTTGCTGTCCTTGATCAGGCAGCCAC
CAAAAGCGATGTCGGTGCCGTCGATCCCAACGGTGATATTGTCACTGGTGIGGCCGGGGCCGGGGTA
AAATACCTTGAGCGGGCCAAAGTTGGGGCGGCTTGTGCTTCCAGCCAGCCATTGGCGGCGAAAGTC

.....
AGGCTGTGTTGCGCCGCAACCATCCCCTCTTGCGGGGCAAGCTGGTTGACAACGCATTGGCATAAG
TCGCAATCCCCGCCGCATGCAGCGCGTCCATACCGCCCATCTTGTCTTGAIGCGCGTGAGTCACCAC
CGCCAGCGCGACCGGCAGGTTGATCTCCTGCTTGATCCAGTTGAGGATCTGGGCGGTCTGGTCATCG
GTCCAGGCGGTATCGACCACGACGCGGCGCCATCCCTGACGATCAAACCGTTGGAAGCGACTG
CCCCGAAACCCGGCATGTCGAGATAGGAAGTGTGCTGCCAGACATTGCGTGCGAGCTGGCGGAAAC
CAGATCGCCAAACCGTTGGTCGCCAGTTTCCATTTGCTGGCCAATCGTCGCGCGGATTTACCGGGC
ATGCACCCGCTCAGCATCAATGCAGCGGCTAATGCGGTGCTCAGCTTCGCACCGGGTGATAATAT
TGGGCAATT**CCATactcttcctttttcaat**

OXA-48 (SEQ ID NO: 167)

ACCGCTAGGGAACAATTTTTTCTTGTTTGAGCACTTCTTTTGTGATGGCTTGGCGCAGCCCTAAACC
ATCCGATGTGGGCATATCCATATTCATCGCAAAAAACACACATTATCATCAAGTTCAACCCAACCG
ACCCACCAGCCAATCTTAGGTTGATTCTAGTCAGTATCCAGTTTTAGCCCGAATAATATAGTCAC
CATTGGCTTCGGTCAGCATGGCTTGTTTGACAATACGCTGGCTGCGCTCCSATACTGTAACTTATT
GTGATACAGCTTCTTAAAAAGCTGATTTGCTCCGTGGCCGAAATTCGAATACCACCGTCGAGCCAG
AAACTGTCTACATTGCCCGAAATGTCTCATTACCATAATCGAAAGCATGTAGCATCTTGCTCATAC
GTGCTTCGCCAATTTGGCGGGCAAATTCTTGATAAACAGGCACAACCTGAATATTTTCATCGCGGTGAT
TAGATTATGATCGCGATTCCAAGTGGCGATATCGCGCGTCTGTCCATCCCACCTTAAAGACTTGGTGT
TCATCCTTAACCACGCCCAAATCGAGGGCGATCAAGCTATTGGGAATTTTAAAGGTAGATGCGGGTA
AAAAATGCTTGGTTCGCCCGTTTAAGATTATTGGTAAATCCTTGCTGCTTAATCTCATTCAGAGCAC
AACTACGCCCTGTGATTTATGTTTCAATAAGTGAGCATTCCAACCTTTTGTTTTCTTGCCATTCTTTT
GCTACCGCAGGCATTCCGATAATCGATGCCACCAAAACACAGCCGATAAGGCTAATACACG**CATac**
tcttcctttttcaat

SHV-18 (SEQ ID NO: 168)

ACCGTTAGCGTTGCCAGTGCTCGATCAGCGCCGCGCCGATCCCGGCGATTIGCTGATTTGCTCGGC
CATGCTCGCCGGCGTATCCCGCAGATAAAATCACCACAATCCGCTCTGCTTIGTTATTCGGGCCAAGC
AGGGCGACAATCCCGCGCGCACCCCGTTTTGGCAGCTCCGGTCTTATCGGCGATAAACAGCCCCCG
GCAGCACGGAGCGGATCAACGGTCCGGCGACCCGATCGTCCACCATCCACTGCAGCAGCTGCCGTTG
CGAACGGGCGCTCAGACGCTGGCTGGTCAGCAGCTTGCGCAGGGTCGCGGCCATGCTGGCCGGGGTA
GTGGTGTGCGGGGCGTCGCCGGGAAGCGCCTCATTAGTTCCGTTTTCCAGCGGTCAAGGCGGGTGA
CGTTGTGCGCGATCTGGCGCAAAAGGCAGTCAATCCTGCGGGGCGCGCGACGGTGGCCAGCAGCAG
ATTGGCGGCGCTGTTATCGCTCATGGTAATGGCGGCGGCACAGAGTTCGCCGACCGTCATGCCGTCG
GCAAGGTGTTTTTCGCTGACCGGCGAGTAGTCCACCAGATCCTGCTGGCGATAGTGGATCTTTGCT
CCAGCTGTTTCGTACCCGCGATCCACCCGCGCCAGCAGTTCGCGCGCAGAGCACTACTTTAAAGGTGCT
CATCATGGGAAAGCGTTTCATCGGCGCGCCAGGCGGTACAGCGTGGCGCGCTGGCCAGATCCATTTCT
ATCATGCCTACGCTGCCCGACAGCTGGCTTTTCGCTTAGTTTTAATTTGCTCAAGCGGCTGCGGGCTGG
CGGTACCGCGCAGCGGCGAGGTGGCTAACAGGGAGATAATACACAGGCGAAAATAACG**CATactctt**
cctttttcaat

VIM-1 (SEQ ID NO: 169)

ACCGCTACTCGGCGACTGAGCGATTTTTGTGTGCTTTGACAACGTTGCTGTGTGCTGGAGCAAGTC
TAGACCGCCCCGTAGACCGTGCCCGGAATGACGACCTCTGCTTCCGGGTAGTGTTTTGAATCCGC
TCAACGGAGGTGGGCCATTAGCCAGATCGGCATCGGCCACGTTCCCCGCAGACGTGCTTGACAACT
CATGAACGGGCACAACCACCGTATAGCACGTTGCTGACGGGACGTATACAACCAGATTGTCGGTCGA
ATGCGCAGCACCCAGGATAGAAGAGCTCTACTTGACCGAAGCGCACTGCGTCCCCGCTCGATGAGAGT
CCTTCTAGAGAAATGCGTGGGAATCTCGTTCCCTCTGCTCGGCTAGCCGCGTGTGACGCTGATG
CGTACGTTGCCACCCAGCCGCCGAAGGACATCAACGCCCGCGACGCGGTGCTCATGAAAGTGCGT
GGAGACTGCACGCGTTACGGGAAGTCCAATTTGCTTTTCAATCTCCGCGASAAGTGCCGCTGTGTTT
TTGCGACCCCCACGCTGTATCAATCAAAGCAACTCATCACCATCACGGACAATGAGACCATTGGACG
GGTAGACCGCGCCATCAAACGACTGCGTTGCGATATGCGACCAAAACACCATCGGCAATCTGGTAAAG
TCGGACCTCTCCGACCGGAATTTGTTGACTGTGCGGATACTCACCACCTCGGCTCCCCGGAATGGGCT
AACGGACTTGCGACAGCCATGACAGACGCGGTCTGTAGACCAATAAACTACTAATAACTTTTTAA**CA**
Tactcttcctttttcaat

KPC-3 (SEQ ID NO: 170)

ACCGTTACTGCCCCGTTGACGCCCAATCCCTCGAGCGCGAGTCTAGCCGCAGCGGCGATGACGGCCTC
GCTGTACTTGTATCCTTGTTAGGCGCCCCGGTGTAGACGGCCAACACAATAGGTGCGCGCCAGTG
GGCCAGACGACGGCATAGTCATTTGCCGTGCCATACACTCCGACAGTTCCGTTTTGTCCTCGACTG
CCCAGTCTGCCCCGACCGCGCGGATGCGGTGGTTGCCGGTCGTGTTTTCCCTTTAGCCAATCAAC
AAACTGCTGCCGCTGCGGCGCAGCCAGTGCAGAGCCCAGTGTGAGTTTTTGTAAAGCTTTCCGTACG
GCGCGCGCGGATGAGGTATCGCGCGCATCGCTGGGATGGCGGAGTTCAGCTCCAGCTCCAGCGGT
CCAGACGGAACGTGGTATCGCCGATAGAGCGCATGAAGGCCGTACGCCCGCGCGGGCGCCCAACTC
CTTCAGCAACAAATTGGCGCGGCGTTATCACTGTATTGCACGGCGCGCGGACAGCTCCGCCACC
GTCATGCTGTTGTGTCAGATATTTTTCCGAGATGGGTGACCAACGGAACAGCGCATTTTTGCGGTAAAC
GGATGGGTGTGTCCAGCAAGCCGGCCTGCTGCTGGCTGCGAGCCAGCACAGCGGCAGCAAGAAAGCC
CTTGAATGAGCTGCACAGTGGGAAGCGCTCCTCAGCGCGGTAACTTACAGTTGCGCCTGAGCCGGTA
TCCATCGCGTACACACCGATGGAGCCGCCAAAGTCTGTTTCGAGTTTAGCSAATGGTTCCGCGACGA
GGTTGGTCAGCGCGGTGGCAGAAAAGCCAGCCAGCGCCATGAGAGACAAGACAGCAGAACTAGACG
CGGATACAGTG**ACATactcttcctttttcaat**

IMP-4 (SEQ ID NO: 171)

ACCGTTAGTTGCTTAGTTTTGATGGTTTTTTACTTTTCGTTTAAACCCTTTAACCGCCTGCTCTAATGT
AAGTTTTCAAGAGTGATGCGTCTCCAGCTTCACTGTGACTTGGAACAACCAAGTTTTGCCTTACCATAT
TTGGATATTAATAATTTAGCGGACTTTGGCCAAGCTTCTAAATTTGCGTCACCCAAATTACCTAGAC
CGTAGCGTTTTAAATAAACCAACCACGAATAATATTTTCTTTTTCAGGCAGCCAACTACTAGGTTATC
TGGAGTGTGTCCTGGGCTTGGATAAAAAACTTCAATTTTATTTTAACTAGCCAATAGTTAAACCCG
CCAAATGAATTTTTTAGCTTGAACCTTACCGTCTTTTTTAAAGCAGCTCATTAGTTAATTCAGACGCAT
ACGTGGGGATGGATTGAGAATTAAGCCACTCTATTCGCCCGTGCTGTCACTATGAAATGAGAGGA
AATACTGCCTTTTATTTATAGCCACGTTCCACAAACCAAGTGACTAACTTTTCAGTATCTTTAGCC
GTAAATGGAGTGCAATTAGATAAGCTTCAGCATCTACAAGAACAAACCAACCATGTTTAGGAACAA
CGCCCCACCCGTAACTTCTTCAAACGAAGTATGAACATAAACGCCTTCATCAAGTTTTTCAATTTT
TAAATCTGGCAAAGACTCTGCTGCGGTAGCAATGCTACAAAACAAAAATAAAAGAATACAGATAAC
TTGCT**CATactcttcctttttcaat**

CTX-M-15 (SEQ ID NO: 172)

ACCGTTACAAACCGTCGGTGACGATTTTAGCCGCGCAGGCTAATACATCGCGACGGCTTTCTGCCTT
AGGTTGAGGCTGGGTGAAGTAAGTGACCAGAATCAGCGGCGCACGATCTTTTGGCCAGATCACCGCG
ATATCGTTGGTGGTGCCATAGCCACCGCTGCCGTTTTATCCCCCACAACCCAGGAAGCAGGCAGTC
CAGCCTGAATGCTCGCTGCACCGGTGGTATTGCCTTTCATCCATGTCACCAGCTGCGCCCGTTGGCT
GTCGCCCCAATGCTTTACCCAGCGTCAGATTCCGCAGAGTTTGGGCCATTGGCCGAGGTGAAGTGGTA
TCAGCGGATCGCCCGGAATGGCGGTGTTTAAAGTCCGCTCGGTACGGTCGAGACGGAACGTTTCGT
CTCCAGCTCTGCGGCAACCGGCTCAGCCTAGCCCGCGCGCAACCTCAGCAATCAGCTTATTCAT

```

CTCCAGCIGTCCGGGGAACGGGGTAGCGTAGCGGGGCGGCAAGGTGAGCAATCAGCTTATTCAT
CGCCACGTTATCGCTGTACTGTAGCGCGGGCGCGCTAAGCTCAGCCAGTGACATCGTCCCATTGACG
TGCTTTTCCGCAATCGGATTATAGTTAACAAGGTCAGATTTTTTGATCTCAACTCGCTGATTTAACA
GATTCGGTTTCGCTTTCACCTTTCTTCAGCACCGCGGGCGGGCCATCACTTTACTGGTGCTGCACAT
CGCAAAGCGCTCATCAGCACGATAAAGTATTTGCGAATTATCTGCTGTGTTAATCAATGCCACACCC
AGTCTGCTCCCGACTGCCGCTCTAATTCGGCAAGTTTTTGCTGTACGTCCGGCGTTTGCGCATACA

GCGGCACACTTCCTAACAAACAGCGTGACGGTTGCCGTCGCCATCAGCGTGAAGTGGCGCAGTGATTT
TTTAACCATactcttcctttttcaat

```

[0253] Then DH5α competent cells purchased from New England Biolabs are transformed with these ligations followed by selection for the desired recombinants on LB Ampicillin (100µg/mL) plates.

[0254] Plasmid DNA samples are isolated from these transformants and submitted to DNA sequence analysis to confirm that the correct sequence for each of the seven different beta lactamases genes is present in each construct giving the plasmids:

These pBR322 derivative plasmids so derived are named:

1. i. pNB010 carrying the SHV-18 gene;
2. ii. pNB011 carrying the CTX-M-15 gene;
3. iii. pNB012 carrying the KPC-3 gene;
4. iv. pNB013 carrying the VIM-1 gene;
5. v. pNB014 carrying the IMP gene;
6. vi. pNB015 carrying the NDM-1 gene;
7. vii. pNB016 carrying the OXA-48 gene; in addition to, as described,
8. viii. pBR322 carrying the TEM-3 gene

[0255] Then 7 recipient *E. coli* strains, DH5α, each carrying one of these seven beta lactamase genes on the plasmids pNB010-016 are subsequently transformed with the plasmids pNB104A, pNB104B, pNB108 and pNB203 and selected for chloramphenicol resistance to select for acquisition of these Nemesis symbiotic plasmids, along with the negative control pNB100 as well as with transformation of DH5α (pBR322) by pNB102 as the positive control, and then tested for conversion to ampicillin sensitivity as described in Example 2 (see Fig 14.)

"Nemesis symbiotic activity" (NSA) assay by plasmid conjugation to test activity of constructs carrying multiple spacers targeting beta lactamase gene families

[0256] The plasmid conjugation assay described in Example 2 may also be used to test the Nemesis symbiotic activity of the new CRISPR/Cas9 plasmid constructs carrying spacer sequences targeting multiple families of beta lactamase genes. The assay involves mating a donor cell carrying the beta lactamase gene on a conjugative plasmid, and hence ampicillin resistant, with a recipient cell carrying the Nemesis symbiotic on a non-mobilisable plasmid encoding chloramphenicol resistance. Exconjugants are selected on LB plates containing both 100µg/mL ampicillin and 35µg/mL chloramphenicol. Successful Nemesis symbiotic activity is seen in a reduction in the efficiency of transfer of the ampicillin resistance gene.

[0257] As donors, the same strain used in Example 2 was used. This strain, JA200 (F+ thr-1, leu-6, DE(trpE)5, recA, lacY, thi, gal, xyl, ara, mtl), also carries plasmid pNT3 as described by Saka et al. (DNA Research 12, 63-68, 2005). The plasmid pNT3 is a mobilisable plasmid carrying the TEM-1 beta lactamase gene of Tn1. Conjugation of pNT3 and hence transfer of ampicillin resistance is effected by the transfer functions of the co-resident F+ plasmid.

[0258] The other potential donors are the set of *E. coli* and *K. pneumoniae* strains carrying representative genes from these seven different families of beta-lactam antibiotics that were purchased from Culture Collections, Public Health England, as described above. These strains need to be chloramphenicol sensitive in order to allow selection for exconjugants and were tested for growth on LB chloramphenicol 35µg/mL plates. NCTC13368, a *K. pneumoniae* strain carrying the SHV-18 gene; NCTC13438 a *K. pneumoniae* strain carrying the KPC-3 gene; NCTC13476 an *E. coli* strain carrying an uncharacterised IMP gene; NCTC13443 a *K. pneumoniae* strain carrying the NDM-1 gene and NCTC13442

a *K. pneumoniae* strain carrying the OXA-48 gene were all found to be resistant to chloramphenicol, but NCTC13353, an *E. coli* strain carrying the CTX-M-15 gene, and NCTC13440, a *K. pneumoniae* strain carrying the VIM-1 gene, were found to be chloramphenicol sensitive and were taken forward to be tested in matings with the recipients.

[0259] As recipients, the strains used in Example 2 serve as controls for testing the new plasmid constructs. Thus the negative control is DH5 α (F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ 80dlacZ Δ M15 Δ (lacZYA-argF)U169, hsdR17(rK- mK+), λ with the plasmid pNB100 encoding the CRISPR/Cas9 cassette but no spacer sequence targeting any antibiotic resistance gene; and the positive control is DH5 α with the plasmid pNB102 encoding the CRISPR/Cas9 cassette as well as the spacer sequence targeting the TEM beta-lactamase family. To be tested are DH5 α strains with the plasmids pNB104A, pNB104B and pNB108. These plasmids also encode the CRISPR/Cas9 cassette in addition to the spacer sequences, all driven off one promotor in the following order, proximal to distal from the promotor (pNB104A): NDM-IMP-VIM-KPC; (pNB104B): OXA-48-SHV-TEM-CTX-M (pNB108): NDM-IMP-VIM-KPC-OXA-48-SHV-TEM-CTX-M.

[0260] To set up the matings, colonies of donors were picked from LB Ap100 (ampicillin 100 μ g/mL) and recipients from LB Cm35 (chloramphenicol 35 μ g/mL) plates into 200 μ L of LB and then mixed 100 μ L of recipients with 35 μ L of donors, then 5 μ L of the mixture were spotted onto LB plates and incubated at 37°C for 5 hours to allow mating.

[0261] Figure 30A shows the results from mating the donor carrying the TEM-1 beta lactamase (JA200 (F+ thr-1, leu-6, DE(trpE)5, recA, lacY, thi, gal, xyl, ara, mtl)), and designated (5) in the figure, with the recipients DH5 α pNB100, designated (-), DH5 α pNB102, designated (+). Here a loopful of each mating mixture was resuspended in 220 μ L of LB and 200 μ L of the cells were plated on LB Ap100Cm35 plates to select for exconjugants. As expected from Example 2, the cross between the donor of TEM-1 and the recipient with pNB100 gives efficient mating and a lawn of cells (Fig. 30A, top left, 5-), and mating the donor of TEM-1 with the recipient with pNB102 encoding the single TEM spacer shows strong inhibition of transfer of the TEM-1 gene (see Fig. 30A, 5+, top right, where only a few isolated colonies are seen). The mating of the donor carrying the TEM-1 gene with the recipient carrying pNB104 (see bottom plate, 5B, of the figure) also shows strong inhibition of transfer of the TEM-1 gene and demonstrates that in the pNB104B construct, carrying the four spacers OXA-48-SHV-TEM-CTX-M 4, the TEM spacer is active.

[0262] Figure 30B shows the results from mating the strain NCTC13440, a *K. pneumoniae* strain carrying the VIM-1, designated (2), and the strain NCTC13353, an *E. coli* strain carrying the CTX-M-15 gene, designated (4). Again a loopful of each such mating mixture was resuspended in 220 μ L of LB and 200 μ L of the cells were plated on LB Ap100Cm35 plates to select for exconjugants. The results show that these strains are able to act as donors and transfer the VIM-1 and the CTX-M-15 genes respectively to the DH5 α pNB100 negative control recipient lacking Nemesis symbiotic activity (see Fig. 30B, top left and top right respectively). However transfer of the VIM-1 and the CTX-M-15 genes was found to be strongly inhibited in matings with recipients carrying spacers targeted against these genes: pNB104A and pNB104B (see plates 2A and 4B, bottom left and right respectively).

[0263] In another experiment, an equivalent mating was done to test Nemesis symbiotic activity in recipients carrying all 8 spacer sequences in the plasmid pNB108. Here cells were picked directly from the mating mixture and streaked onto LB Ap100Cm35 plates. Figure 30C plate, top left, again shows successful mating of donors 2, 4 and 5 with the recipient carrying pNB100 (see 2-, 4- and 5- in Fig. 30C). In all cases, however, mating with the recipient carrying pNB108 (see Fig. 30C, plate top right, 2/8, 4/8 and 5/8) gives strong inhibition of transfer of ampicillin resistance gene. And for comparison to a positive control in this assay the bottom plate with 5+ (see Fig. 30C) shows strong inhibition of transfer of TEM-1 ampicillin resistance gene to the recipient carrying pNB102.

[0264] The experiments reported above provide the proof-of-concept that, in the model organism, *Escherichia coli*, DNA constructs carrying the Cas9 CRISPR region plus a spacer region with sequences directed against a target region of the beta-lactamase gene can inactivate ampicillin resistance when delivered by naked DNA transformation and bacteriophage infection as well as prevent transfer of ampicillin resistance by plasmid conjugation. It is apparent that Nemesis symbiotics of the invention can be applied to pathogenic bacteria and for other antibiotic resistance genes.

SEQUENCE LISTING

[0265]

<110> Nemesis Bioscience Ltd

<120> Therapeutic

<130> P/71337.WO01/MAR

<150> GB1406674.0

<151> 2014-04-14

<150> GB1413719.4

<151> 2014-08-01

<150> GB1418508.6

<151> 2014-10-17

<160> 172

<170> PatentIn version 3.5

<210> 1

<211> 12

<212> DNA

<213> Unknown

<220>

<223> CR05 bla gene sequence

<400> 1

gatacgggag gg 12

<210> 2

<211> 12

<212> DNA

<213> Unknown

<220>

<223> CR05 bla gene reverse strand

<400> 2

ccctcccgtg tc 12

<210> 3

<211> 10

<212> DNA

<213> Unknown

<220>

<223> CR05 short bacterial off-target sequence

<400> 3

cgatacggga 10

<210> 4

<211> 11

<212> DNA

<213> Unknown

<220>

<223> CR05 short bacterial off-target sequence

<400> 4

cgatacggga g 11

<210> 5
<211> 11
<212> DNA
<213> Unknown

<220>
<223> CR05 short bacterial off-target sequence

<400> 5
gatacgggag g 11

<210> 6
<211> 19
<212> DNA
<213> Unknown

<220>
<223> CR30 bla gene sequence

<400> 6
tgctcatcat tggaaaacg 19

<210> 7
<211> 19
<212> DNA
<213> Unknown

<220>
<223> CR30 bla gene sequence reverse strand

<400> 7
cgttttccaa tgatgagca 19

<210> 8
<211> 12
<212> DNA
<213> Unknown

<220>
<223> CR30 short bacterial off-target sequence

<400> 8
tcattggaaa ac 12

<210> 9
<211> 10
<212> DNA
<213> Unknown

<220>
<223> CR30 short bacterial off-target sequence

<400> 9
tgctcatcat 10

<210> 10
<211> 11
<212> DNA
<213> Unknown

<220>

<223> CR30 short bacterial off-target sequence - 3

<400> 10

gctcatcatt g 11

<210> 11

<211> 13

<212> DNA

<213> Unknown

<220>

<223> CR30 short bacterial off-target sequence

<400> 11

ctcatcattg gaa 13

<210> 12

<211> 17

<212> DNA

<213> Unknown

<220>

<223> CR30 short bacterial off-target sequence

<400> 12

ctcagcattg caaaacg 17

<210> 13

<211> 15

<212> DNA

<213> Unknown

<220>

<223> CR30 short bacterial off-target sequence

<400> 13

tcatcattga aaaac 15

<210> 14

<211> 12

<212> DNA

<213> Unknown

<220>

<223> CR30 short bacterial off-target sequence

<400> 14

tcattggaaa ac 12

<210> 15

<211> 19

<212> DNA

<213> Unknown

<220>

<223> CR70 bla gene sequence

<400> 15

tcgccagtta atagtttgc 19

<210> 16

<211> 19

<212> DNA
 <213> Unknown

<220>
 <223> CR70 bla sequence reverse strand

<400> 16
 agcgggtcaat tatcaaacg 19

<210> 17
 <211> 11
 <212> DNA
 <213> Unknown

<220>
 <223> CR30 short bacterial off-target sequence - 1

<400> 17
 tcgccagtta a 11

<210> 18
 <211> 12
 <212> DNA
 <213> Unknown

<220>
 <223> CR70 short bacterial off-target sequence

<400> 18
 tcgccagtta at 12

<210> 19
 <211> 11
 <212> DNA
 <213> Unknown

<220>
 <223> CR70 short bacterial off-target sequence

<400> 19
 cgccagttaa t 11

<210> 20
 <211> 12
 <212> DNA
 <213> Unknown

<220>
 <223> CR70 short bacterial off-target sequence

<400> 20
 cgccagttaa ta 12

<210> 21
 <211> 15
 <212> DNA
 <213> Unknown

<220>
 <223> CR70 short bacterial off-target sequence

<400> 21

cgccagctaa tagtt 15

<210> 22

<211> 11

<212> DNA

<213> Unknown

<220>

<223> CR70 short bacterial off-target sequence

<400> 22

ccagttaata g 11

<210> 23

<211> 11

<212> DNA

<213> Unknown

<220>

<223> CR70 short bacterial off-target sequence

<400> 23

taatagtttg c 11

<210> 24

<211> 20

<212> DNA

<213> Unknown

<220>

<223> CR90 bla sequence

<400> 24

ccgcgccaca tagcagaact 20

<210> 25

<211> 20

<212> DNA

<213> Unknown

<220>

<223> CR90 bla sequence reverse strand

<400> 25

agttctgcta tgtggcgcg 20

<210> 26

<211> 11

<212> DNA

<213> Unknown

<220>

<223> CR90 short bacterial off-target sequence

<400> 26

acatagcaga a 11

<210> 27

<211> 11

<212> DNA

<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 27
cgcgccacat a 11

<210> 28
<211> 13
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 28
cgcgccacat agc 13

<210> 29
<211> 11
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 29
gcgcccacata g 11

<210> 30
<211> 11
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 30
gccacatagc a 11

<210> 31
<211> 11
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 31
acatagcaga a 11

<210> 32
<211> 11
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 32
catagcagaa c 11

<210> 33
<211> 16
<212> DNA
<213> Unknown

<220>
<223> CR90 short bacterial off-target sequence

<400> 33
gcgccatata gcagaa 16

<210> 34
<211> 20
<212> RNA
<213> Artificial Sequence

<220>
<223> Artificial RNA sequence

<220>
<221> stem_loop
<222> (1)..(10)

<400> 34
uagauaacua cgauacggga 20

<210> 35
<211> 20
<212> RNA
<213> Artificial sequence

<220>
<223> Artificial RNA sequence

<220>
<221> stem_loop
<222> (1)..(11)

<400> 35
acuuuaaaag ugcucaucau 20

<210> 36
<211> 20
<212> RNA
<213> Artificial sequence

<220>
<223> Artificial RNA sequence

<220>
<221> stem_loop
<222> (3)..(13)

<400> 36
acguugcgca aacuaauaac 20

<210> 37
<211> 20
<212> RNA
<213> Artificial sequence

<220>

<223> Artificial RNA sequence

<220>

```
<221> stem_loop
```

<222> (9)..(17)

<400> 37

acuuuuuaag uucugcuaug 20

<210> 38

<211> 861

<212> DNA

<213> Unknown

<220>

<223> Beta-lactamase gene from pBR322

<400> 38

atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt ttgccttcct 60

gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca 120

cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag ttttcgcccc 180

gaagaacggtt ttccaatgat gagcactttt aaagtctctgc tatgtggcgc ggtattatcc 240

cgtgttgacg cggggaaga gcaactcggg cgccgcatac actattctca gaatgacttg 300

gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt aagagaatta 360

tgcagtgctg ccataaccat gaggataac actgcggcca acttacttct gacaacgata 420

ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgcctt 480

gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg 540

cctgcagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact tactctagct 600

tcccggaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc 660

tgggcccttc cggctggctg gtttattgct gataaatctg gagccggtga gcgtgggtct 720

cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt agttatctac 780

acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga gataagtgcc 840

tcactgatta agcattgqta a 861

<210> 39

$\langle 211 \rangle$ 20

<212> DNA

<213> Unknown

$\langle 220 \rangle$

<223> Spacer sequence

<400> 39

ccgcgtaggc atgatagaaa 20

<210> 40

$\langle 211 \rangle$ 20

<212> DNA

<213> Unknown

<220>

<223> Spacer sequence

<400> 40

acgttaaaca ccgccattcc 20

<210> 41
 <211> 20
 <212> DNA
 <213> Unknown

 <220>
 <223> Spacer sequence

 <400> 41
 gcgctggaga aaagcagcgg 20

 <210> 42
 <211> 20
 <212> DNA
 <213> Unknown

 <220>
 <223> Spacer sequence

 <400> 42
 aagctgattg cccatctggg 20

 <210> 43
 <211> 20
 <212> DNA
 <213> Unknown

 <220>
 <223> Spacer sequence

 <400> 43
 acgctcaaca ccgcgatccc 20

 <210> 44
 <211> 20
 <212> DNA
 <213> Unknown

 <220>
 <223> Spacer sequence

 <400> 44
 aactacttac tctagcttcc 20

 <210> 45
 <211> 20
 <212> DNA
 <213> Unknown

 <220>
 <223> Spacer sequence

 <400> 45
 ttgttgctga aggagttggg 20

 <210> 46
 <211> 20
 <212> DNA
 <213> Unknown

 <220>

<223> Spacer sequence

<400> 46
agcgaaaaac accttgccga 20

<210> 47
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 47
ctgggaaacg gcactgaatg 20

<210> 48
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 48
tgggtgttg gagagaaaac 20

<210> 49
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 49
aaacacagcg gcacttctcg 20

<210> 50
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 50
aaaattgaag tttttatcc 20

<210> 51
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 51
tggcagccgc agtgaagcc 20

<210> 52
<211> 20

<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 52
tcacagctac ttgaagggtc 20

<210> 53
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 53
atcaaaaactg gcagccgcaa 20

<210> 54
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 54
atcaaaaactg gcagccgcaa 20

<210> 55
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 55
cagtactcca accccagcat 20

<210> 56
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 56
tcacctggcc gcaaatagtc 20

<210> 57
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 57

acaacggatt aacagaagca	20
<210> 58	
<211> 20	
<212> DNA	
<213> Unknown	
<220>	
<223> Spacer sequence	
<400> 58	
agaacatcag cgcttgggtca	20
<210> 59	
<211> 20	
<212> DNA	
<213> Unknown	
<220>	
<223> Spacer sequence	
<400> 59	
ataacggctt gacccagtca	20
<210> 60	
<211> 20	
<212> DNA	
<213> Unknown	
<220>	
<223> Spacer sequence	
<400> 60	
ggcaaccaga atatcagtgg	20
<210> 61	
<211> 20	
<212> DNA	
<213> Unknown	
<220>	
<223> Spacer sequence	
<400> 61	
ggatgccggt gacgaacagc	20
<210> 62	
<211> 20	
<212> DNA	
<213> Unknown	
<220>	
<223> Spacer sequence	
<400> 62	
gctacagtac agcgataacg	20
<210> 63	
<211> 20	
<212> DNA	
<213> Unknown	

<220>
<223> Spacer sequence

<400> 63
gacgttgcgt cagcttacgc 20

<210> 64
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 64
aactacttac tctagcttcc 20

<210> 65
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 65
ttgttgctga aggagttggg 20

<210> 66
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 66
agcgaaaaac accttgccga 20

<210> 67
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 67
acctttaaag tgctgctgtg 20

<210> 68
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 68
tgggttgttg gagagaaaac 20

<210> 69
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 69
aaacacagcg gcacttctcg 20

<210> 70
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 70
aaaattgaag tttttatcc 20

<210> 71
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 71
ggtttgatcg tcagggatgg 20

<210> 72
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 72
gtggattaac gttccgaaag 20

<210> 73
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 73
cagcgacagc aaagtggcat 20

<210> 74
<211> 20
<212> DNA
<213> Unknown

<220>

<223> Spacer sequence

<400> 74
cttgccacct acagtgcggg 20

<210> 75
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 75
cccccaaagg aatggagatc 20

<210> 76
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 76
caccaagtct ttaagtggga 20

<210> 77
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 77
ataacggctt gaccagtc 20

<210> 78
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 78
ctgggaaacg gaactgaatg 20

<210> 79
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 79
acgttaaaca ccgccattcc 20

<210> 80
<211> 20

<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 80
aactacttac tctagcttcc 20

<210> 81
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 81
ttgttgctga aggagttggg 20

<210> 82
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 82
aaacacagcg gcacttctcg 20

<210> 83
<211> 34
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 83
ggctagttaa aaataaaatt gaagttttt atcc 34

<210> 84
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 84
ggtttgatcg tcagggatgg 20

<210> 85
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Spacer sequence

<400> 85

ataacggctt gacccagtca 20

<210> 86

<211> 195

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 86

ccaaaactga gacctgctgc ggacgtccaa aggtctcgtt ttagagctat gctgttttga 60

atgggcccaa aacttgccga tgataacttg agaaagaggg ttaataccag cagtcggata 120

ccttcctatt ctttctgtta aagcgttttc atgttataat aggcaaattt tagatgaaga 180

ttattttotta ataac 195

<210> 87

<211> 81

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 87

tctaaaacga agagcgctgc gtccgagacg ctcttcagtt ttgggaccat tcaaaacagc 60

atagctctaa aacctcgtag a 81

<210> 88

<211> 54

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 88

gggctggcaa gccacgtttg gtgggtctcg aaacggtttg atcgtcaggg atgg 54

<210> 89

$\langle 211 \rangle$ 90

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 89

ggataaaaaa cttcaatttt atttttaact agccgttttg ggaccattca aaacagcata 60

gctctaaaac ccattccctga cgatcaaacc 90

<210> 90

$\langle 211 \rangle$ 90

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 90

ggctagttaa aaataaaaatt gaagtttttt atccgtttta gagctatgct gttttgaatg 60

gtcccaaaac aaacacagcg gcacttctcg 90

<210> 91

<211> 76

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 91

cccaactcct tcagcaacaa gttttgggac cattcaaaac agcatagctc taaaaccgag 60

aagtgcogct gtgttt 76

<210> 92

<211> 76

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 92

ttgttgctga aggagttggg gttttagagc tatgctgttt tgaatgggcc caaaacgtcc 60

atccactta aagact 76

<210> 93

<211> 76

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 93

cattcagttc cgtttccag gttttgggac cattcaaaac agcatagctc taaaacagtc 60

tttaagtggg atggac 76

<210> 94

<211> 76

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 94

ctgggaaacg gaactgaatg gttttagagc tatgctgttt tgaatgggcc caaaacaact 60

acttactcta gcttcc 76

<210> 95

<211> 111

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 95

cggggagctg catgtgtcag aggggtctcc aaaacggaat ggcggtgttt aacgtgtttt 60

gggaccattc aaaacagcat agctctaaaa cggaagctag agtaagtagt t 111

<210> 96
<211> 111
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 96
ccgggagctg catgtgtcag aggggtctcc aaaaccccaa ctcttcagc aacaagtttt 60
gggaccattc aaaacagcat agctctaaaa ccgagaagtg ccgctgtgtt t 111

<210> 97
<211> 54
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 97
gggctggcaa gccacgtttg gtggctcttc aaacgtccat ccacttaaa gact 54

<210> 98
<211> 111
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 98
ccgggagctg catgtgtcag agggctcttc aaaacggaat ggcggtgttt aacgtgtttt 60
gggaccattc aaaacagcat agctctaaaa cggaagctag agtaagtagt t 111

<210> 99
<211> 1368
<212> PRT
<213> Streptococcus pyogenes M1 GAS

<400> 99
Met Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val
1 5 10 15

Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe
20 25 30

Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile
35 40 45

Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu
50 55 60

Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys
65 70 75 80

Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser
85 90 95

Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys
100 105 110

His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr
115 120 125

His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp
 130 135 140

Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His
 145 150 155 160

Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro
 165 170 175

Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr
 180 185 190

Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala
 195 200 205

Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn
 210 215 220

Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn
 225 230 235 240

Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe
 245 250 255

Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp
 260 265 270

Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp
 275 280 285

Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp
 290 295 300

Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser
 305 310 315 320

Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys
 325 330 335

Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe
 340 345 350

Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser
 355 360 365

Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp
 370 375 380

Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg
 385 390 395 400

Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu
 405 410 415

Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe
 420 425 430

Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile
 435 440 445

Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp
 450 455 460

Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu
 465 470 475 480

Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr
 485 490 495

Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser

500	505	510
Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys		
515	520	525
Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln		
530	535	540
Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr		
545	550	555
Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp		
565	570	575
Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly		
580	585	590
Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp		
595	600	605
Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr		
610	615	620
Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala		
625	630	635
His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr		
645	650	655
Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp		
660	665	670
Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe		
675	680	685
Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe		
690	695	700
Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu		
705	710	715
His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly		
725	730	735
Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly		
740	745	750
Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln		
755	760	765
Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile		
770	775	780
Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro		
785	790	795
Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu		
805	810	815
Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg		
820	825	830
Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys		
835	840	845
Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg		
850	855	860
Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys		
865	870	875
Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys		
885	890	895

Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp
 900 905 910

Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr
 915 920 925

Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp
 930 935 940

Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser
 945 950 955 960

Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg
 965 970 975

Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val
 980 985 990

Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe
 995 1000 1005

Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala
 1010 1015 1020

Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe
 1025 1030 1035

Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala
 1040 1045 1050

Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu
 1055 1060 1065

Thr Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val
 1070 1075 1080

Arg Lys Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr
 1085 1090 1095

Glu Val Gln Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys
 1100 1105 1110

Arg Asn Ser Asp Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro
 1115 1120 1125

Lys Lys Tyr Gly Gly Phe Asp Ser Pro Thr Val Ala Tyr Ser Val
 1130 1135 1140

Leu Val Val Ala Lys Val Glu Lys Gly Lys Ser Lys Lys Leu Lys
 1145 1150 1155

Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met Glu Arg Ser Ser
 1160 1165 1170

Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys Gly Tyr Lys
 1175 1180 1185

Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr Ser Leu
 1190 1195 1200

Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala Gly
 1205 1210 1215

Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val
 1220 1225 1230

Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser
 1235 1240 1245

Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys
1250 1255 1260

His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys
1265 1270 1275

Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala
1280 1285 1290

Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn
1295 1300 1305

Ile Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala
1310 1315 1320

Phe Lys Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser
1325 1330 1335

Thr Lys Glu Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr
1340 1345 1350

Gly Leu Tyr Glu Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp
1355 1360 1365

<210> 100
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Anti-protospacer sequence

<400> 100
tagataacta cgatacggga 20

<210> 101
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Anti-protospacer sequence

<400> 101
gatcgttgtc agaagtaagt 20

<210> 102
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Anti-protospacer sequence

<400> 102
actttaaaag tgctcatcat 20

<210> 103
<211> 20
<212> DNA
<213> Unknown

<220>
<223> Anti-protospacer sequence

<400> 103
 ttactttca ccagcgtttc 20

<210> 104
 <211> 20
 <212> DNA
 <213> Unknown

<220>
 <223> Anti-protospacer sequence

<400> 104
 attaatagac tggatggagg 20

<210> 105
 <211> 20
 <212> DNA
 <213> Unknown

<220>
 <223> Anti-protospacer sequence

<400> 105
 acaattaata gactggatgg 20

<210> 106
 <211> 20
 <212> DNA
 <213> Unknown

<220>
 <223> Anti-protospacer sequence

<400> 106
 gcaacaatta atagactgga 20

<210> 107
 <211> 20
 <212> DNA
 <213> Unknown

<220>
 <223> Anti-protospacer sequence

<400> 107
 cccggcaaca attaatagac 20

<210> 108
 <211> 20
 <212> DNA
 <213> Unknown

<220>
 <223> Anti-protospacer sequence

<400> 108
 aactacttac tctagcttcc 20

<210> 109
 <211> 20
 <212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 109

acgttgcgca aactattaac 20

<210> 110

<211> 20

<212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 110

tgtaactcgc cttgatcgtt 20

<210> 111

<211> 20

<212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 111

atgtaactcg ccttgatcgt 20

<210> 112

<211> 20

<212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 112

aacttacttc tgacaacgat 20

<210> 113

<211> 20

<212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 113

agtcacagaa aagcatctta 20

<210> 114

<211> 20

<212> DNA

<213> Unknown

<220>

<223> Anti-protospacer sequence

<400> 114

acttttaaag ttctgctatg 20

<210> 115
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 115
aaactagata actacgatac gggag 25

<210> 116
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 116
aaaactcccg tatcgtagtt atcta 25

<210> 117
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 117
aaacacttta aaagtgtca tcatg 25

<210> 118
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 118
aaaacatgat gagcactttt aaagt 25

<210> 119
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 119
aaacacgttg cgcaaactat taacg 25

<210> 120
<211> 25
<212> DNA
<213> Unknown

<220>

<223> Adaptor sequence

<400> 120
aaaacgttaa tagtttgcgc aacgt 25

<210> 121
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 121
aaacactttt aaagttctgc tatgg 25

<210> 122
<211> 25
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence

<400> 122
aaaaccatag cagaacttta aaagt 25

<210> 123
<211> 81
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence for dual targets

<400> 123
aaacacttta aaagtgtcca tcatgtttta gagctatgct gttttgaatg gtcccaaac 60
acttttaaag ttctgctatg g 81

<210> 124
<211> 81
<212> DNA
<213> Unknown

<220>
<223> Adaptor sequence for dual targets

<400> 124
aaaaccatag cagaacttta aaagtgtttt gggaccattc aaaacagcat agctctaaaa 60
catgatgagc acttttaaag t 81

<210> 125
<211> 9326
<212> DNA
<213> Artificial

<220>
<223> Plasmid sequence

<400> 125
gaattccgga tgagcattca tcaggcgggc aagaatgtga ataaaggccg gataaaactt 60
gtgcttattt ttctttacgg tctttaaaaa ggccgtaata tccagctgaa oggtctggtt 120

```

ataggtacat tgagcaactg actgaaatgc ctcaaaatgt totttacgat gccattggga      180
tatatcaacg gtggtatatc cagtgathtt ttctccatt ttagcttcct tagctcctga      240
aatctcgat aactcaaaaa atacgcccg tagtgatctt atttcattat ggtgaaagtt      300
ggaacctctt acgtgccgat caacgtctca ttttcgccaa aagttggccc agggcttccc      360
ggtatcaaca gggacaccag gatttathta ttctgcgaag tgatcttccg tcacaggtat      420

ttattcggcg caaagtgcgt cgggtgatgc tgccaactta ctgatttagt gtatgatggt      480
gtttttgagg tgctccagtg gcttctgttt ctatcagctg tccctcctgt tcagctactg      540
acgggggtggt gcgtaacggc aaaagcaccg ccggacatca gcgctagcgg agtgataact      600
ggcttactat gttggcactg atgagggtgt cagtgaagtg cttcatgtgg caggagaaaa      660
aaggctgcac cgtgctgca gcagaatatg tgatacagga tatattccgc ttctcgcctc      720
actgactcgc tacgctcggc cgttcgactg cggcgagcgg aaatggctta cgaacggggc      780
ggagatttcc tggaagatgc caggaagata cttacaggg aagtgaagg gccgcggcaa      840
agccgttttt ccataggctc cgcctccctg acaagcatca cgaaatctga cgtcaaatc      900
agtgtggcg aaacccgaca ggactataaa gataccaggc gtttccccct ggcggctccc      960
tcgtgcgctc tcctgttccg gcctttcggg ttaccgggtg cattccgctg ttatggccgc     1020
gtttgtctca ttccacgcct gacactcagt tccgggtagg cagttcgcct caagctggac     1080
tgtatgcacg aaccccccg tcagtccgac cgtgcgcct tatccggtaa ctatcgtctt     1140
gagtcacaac cggaaagaca tgcaaaagca ccactggcag cagccactgg taattgattt     1200
agaggagtta gtcttgaaat catgcgccgg ttaaggctaa actgaaagga caagttttgg     1260
tgactgcgct cctccaagcc agttacctg gttcaaagag ttggtagctc agagaacctt     1320
cgaaaaaccg cctgcgaagg cggttttttc gttttcagag caagagatta cgcgcagacc     1380
aaaacgatct caagaagatc atcttattaa tcagataaaa ttttctaga tttcagtgc     1440
atttatctct tcaaatgtag cacctgaagt cagcccata cgatataagt tgtaattctc     1500
atgtttgaca gcttatcatc gataagcttt aatgcggtag tttatcacag ttaaattgct     1560
aacgcagtca ggcacgtgt atgaaatcta acaatgcgct catcgtcatc ctgggcaccg     1620
tcacctgga tgctgtaggc ataggcttgg ttatgccggg actgccgggc ctcttgccgg     1680
attaagaaat catcctgtgg agcttagtag gtttagcaag atggcagcgc ctaaatgtag     1740
aatgataaaa ggattaagag attaatctcc ctaaaaatga taaaacaagc gttttgaaag     1800
cgcttgtttt tttggtttgc agtcagagta gaatagaagt atcaaaaaaa gcaccgactc     1860
ggtgccactt tttcaagttg ataacggact agccttattt taacttgcta tgctgttttg     1920
aatggttcca acaagattat tttataactt ttataacaaa taatcaagga gaaattcaaa     1980
gaaatttatc agccataaaa caatacttaa tactatagaa tgataacaaa ataaactact     2040
ttttaaaaga attttgtgtt ataactatatt tattattaag tattgggtaa tttttttga     2100
agagatattt tgaaaaagaa aaattaaagc atattaaact aatttcggag gtcattaaaa     2160
ctattattga aatcatcaaa ctcatatagg atttaattta aactttttat tttaggaggc     2220
aaaaatggat aagaaatact caataggctt agatatcggc acaaatagcg tcggatgggc     2280
ggtgatcact gatgaatata aggttccgct taaaagttc aaggttctgg gaaatacaga     2340

ccgccacagt atcaaaaaaa atcttatagg ggctctttta ttgacagtg gagagacagc     2400
ggaagcgact cgtctcaaac ggacagctcg tagaaggtag acacgtcggg agaatcgtat     2460
ttgttatcta caggagattt tttcaaatga gatggcgaaa gtagatgata gtttctttca     2520
tcgacttgaa gagtcttttt ttgtggaaga agacaagaag catgaacgct atcctatttt     2580
tggaatatata gtagatgaag ttgcttatca tgagaaatat ccaactatct atcatctgcg     2640
aaaaaaattg gtagattcta ctgataaagc ggatttgccg ttaatctatt tggccttagc     2700
gcatatgatt aagtttcgtg gtcatttttt gattgagggg gatttaaact ctgataatag     2760
tgatgtggac aaactattta tccagttggg acaaacctac aatcaattat ttgaagaaaa     2820
ccctattaac gcaagtggag tagatgctaa agcgattctt totgcacgat tgagtaaact     2880
aagacgatta gaaaatctca ttgctcagct ccccggtgag aagaaaaatg gcttatttgg     2940
aatatgactt gtttatgact tgggttttga ggttctttt ggttgcctt ttttttttga     3000

```

```

gaatctcatt gctttgcat tgggttcgac ccccaatttc aaatcaaatt ttgatttggc 3000
agaagatgct aaattacagc tttcaaaaga tacttacgat gatgatttag ataatttatt 3060
ggcgcaaatt ggagatcaat atgctgattt gtttttggca gctaagaatt tatcagatgc 3120
tattttactt tcagatatcc taagagtaaa tactgaaata actaaggctc ccctatcagc 3180
ttcaatgatt aaacgctacg atgaacatca tcaagacttg actcttttaa aagcttttagt 3240
tcgacaacaa cttccagaaa agtataaaga aatctttttt gatcaatcaa aaaacggata 3300
tgcaggttat attgatgggg gagctagcca agaagaattt tataaattta tcaaaccaat 3360
tttagaaaaa atggatggta ctgaggaatt attggtgaaa ctaaactcgt aagatttgct 3420
gcgcaagcaa cggacctttg acaacggctc tattcccatc caaattcact tgggtgagct 3480
gcatgctatt ttgagaagac aagaagactt ttatccattt ttaaaagaca atcgtgagaa 3540
gattgaaaaa atcttgactt ttogaattcc ttattatggt ggtccatttg cgcgtggcaa 3600
tagtcgtttt gcatggatga ctcggaagtc tgaagaaaca attaccccat ggaattttga 3660
agaagttgtc gataaaggtg cttcagctca atcatttatt gaacgcatga caaactttga 3720
taaaaatctt ccaaataaaa aagtactacc aaaacatagt ttgctttatg agtattttac 3780
ggttttataac gaattgacaa aggtcaaata tgttactgaa ggaatgcgaa aaccagcatt 3840
tctttcaggt gaacagaaga aagccattgt tgatttactc ttcaaaacaa atcgaaaagt 3900
aaccgttaag caattaaaag aagattatth caaaaaata gaatgttttg atagtgttga 3960
aatttcagga gttgaagata gatttaatgc ttcatlaggt acctaccatg atttgctaaa 4020
aattattaaa gataaagatt ttttgataa tgaagaaaat gaagatatct tagaggatat 4080
tgttttaaca ttgaccttat ttgaagatag ggagatgatt gaggaagac ttaaacata 4140
tgctcacctc tttgatgata aggtgatgaa acagcttaaa cgtcgccgtt atactggttg 4200

gggacgtttg tctcgaaaat tgattaatgg tattagggat aagcaatctg gcaaaacaat 4260
attagatttt ttgaaatcag atggttttgc caatcgcaat tttatgcagc tgatccatga 4320
tgatagtttg acattttaaag aagacattca aaaagcacaa gtgtctggac aaggcgatag 4380
tttcatgaa catattgcaa atttagctgg tagccctgct attaaaaag gtattttaca 4440
gactgtaaaa gtgttgatg aattggtaa agtaatgggg cggcataagc cagaaaatat 4500
cgttattgaa atggcacgtg aaatcagac aactcaaaag ggccagaaaa attcgcgaga 4560
gcgtatgaaa cgaatcgaag aaggtatcaa agaattagga agtcagattc ttaaagagca 4620
tcctgttgaa aataactaat tgcaaaatga aaagctctat ctctattatc tccaaatgg 4680
aagagacatg tatgtggacc aagaattaga tattaatcgt ttaagtgatt atgatgtcga 4740
tcacattggt ccacaaagtt tccttaaaga cgattcaata gacaataagg tcttaacgcg 4800
ttctgataaa aatcgtggta aatcggataa cgttccaagt gaagaagtag tcaaaaagat 4860
gaaaaactat tggagacaac ttctaaacgc caagttaatc actcaacgta agtttgataa 4920
tttaacgaaa gctgaacgtg gaggtttgag tgaacttgat aaagctgggt ttatcaaacg 4980
ccaattgggt gaaactcgcc aaatcactaa gcatgtggca caaattttgg atagtcgcat 5040
gaatactaaa tacgatgaaa atgataaact tattogagag gttaaagtga ttaccttaaa 5100
atctaaatta gtttctgact tccgaaaaga ttccaattc tataaagtac gtgagattaa 5160
caattaccat catgcccatg atgcgtatct aaatgccgtc gttggaactg ctttgattaa 5220
gaaatatcca aaacttgaat cggagtgtgt ctatggtgat tataaagttt atgatgttcg 5280
taaaatgatt gctaagtctg agcaagaaat aggcaaagca accgcaaat atttctttta 5340
ctctaataat atgaacttct tcaaaacaga aattacactt gcaaattggag agattcgcaa 5400
acgccctcta atcgaaacta atggggaaac tggagaaatt gtctgggata aagggcgaga 5460
ttttgccaca gtgcgcgaaag tattgtccat gccccagtc aatattgtca agaaaacaga 5520
agtacagaca ggcggattct ccaaggagtc aattttacca aaaagaaatt cggacaagct 5580
tattgctcgt aaaaaagact gggatccaaa aaaatatggt ggttttgata gtccaaacgt 5640
agcttattca gtccatgttg ttgctaaggt ggaaaaaggg aaatcgaaga agttaaaatc 5700
cgttaaagag ttactaggga tcacaattat ggaaagaagt tcctttgaaa aaaatccgat 5760
tgacttttta gaagctaaag gatataagga agttaaaaaa gacttaatca ttaaaactac 5820
taaatataat ctttttgact tagaaaaggg tccataaggg atgctgcta atgcgggaga 5880

```

attacaaaaa	ggaaatgagc	tggctctgcc	aagcaaatat	gtgaattttt	tatattttagc	5940
tagtcattat	gaaaagttda	agggtagtc	agaagataac	gaacaaaaac	aattgtttgt	6000
ggagcagcat	aagcattatt	tagatgagat	tattgagcaa	atcagtgaat	tttctaagcg	6060
tgttatttta	gcagatgcc	atttagataa	agttcttagt	gcatataaca	aacatagaga	6120
caaaccaata	cgtgaacaag	cagaaaatat	tattcattta	tttacgttga	cgaatcttgg	6180
agctcccgct	gcttttaaat	attttgatac	aacaattgat	cgtaaacgat	atacgtctac	6240
aaaagaagtt	ttagatgcc	ctottatcca	tcaatccatc	actggtcttt	atgaaacacg	6300
cattgatttg	agtcagctag	gaggtgactg	aagtataatt	tagatgaaga	ttattttctta	6360
ataactaaaa	atatggtata	atactcttaa	taaatgcagt	aatacagggg	cttttcaaga	6420
ctgaagtcta	gctgagacaa	atagtgcgat	tacgaaattt	tttagacaaa	aatagtctac	6480
gaggtttttag	agctatgctg	ttttgaatgg	tcccaaaact	gagaccagtc	tcggaagctc	6540
aaagggtctcg	tttttagagct	atgctgtttt	gaatggtccc	aaaacttcag	cacactgaga	6600
cttggtgagt	tccatgtttt	agagctatgc	tgttttgaat	ggactccatt	caacattgcc	6660
gatgataact	tgagaaagag	ggttaatacc	agcagtcgga	taccttcccta	ttctttctgt	6720
taaagcgttt	tcatgttata	ataggcaaaa	gaagagtagt	gtgatcgtcc	attccgacag	6780
catcgccagt	cactatggcg	tgctgctagc	gctatatgcg	ttgatgcaat	ttctatgcgc	6840
acccgttctc	ggagcactgt	ccgaccgctt	tggccgcgcg	ccagtcctgc	tcgcttcgct	6900
acttgagacc	actatcgact	acgcgatcat	ggcgaccaca	cccgctcctgt	ggatcctcta	6960
cgccggacgc	atcgtggccg	gcacaccggg	cgccacaggt	gcggttgctg	gcgcctatat	7020
cgccgacatc	accgatgggg	aagatcgggc	tcgccacttc	gggctcatga	gcgcttgttt	7080
cgcggtgggt	atggtggcag	gccccgtggc	cgggggactg	ttgggcgcga	tctccttgca	7140
tgcaccattc	cttgccggcg	cgggtgctcaa	cggcctcaac	ctactactgg	gctgcttcct	7200
aatgcaggag	tcgcataagg	gagagcgtcg	accgatgcc	ttgagagcct	tcaaccagct	7260
cagtccttc	cgggtgggcg	ggggcatgac	tatcgtcgcc	gcacttatga	ctgtcttctt	7320
tatcatgcaa	ctcgtaggac	aggtgcgggc	agcgcctcgg	gtcattttcg	gcgaggacgg	7380
ctttcgctgg	agcgcgacga	tgatcggcct	gtcgcttgcg	gtattcggaa	tcttgcacgc	7440
cctcgctcaa	gccttcgtca	ctggtcccgc	caccaaacgt	ttcggcgaga	agcaggccat	7500
tatcgccggc	atggcggccg	acgcgctggg	ctacgtcttg	ctggcgctcg	cgacgcgagg	7560
ctggatggcc	ttccccatta	tgattcttct	cgcttcgggc	ggcatcggga	tgcccgcggt	7620
gcaggccatg	ctgtccaggc	aggtagatga	cgaccatcag	ggacagcttc	aaggatcgct	7680
cgcggtctct	accagcctaa	cttcgatcat	tggaccgctg	atcgtcacgg	cgatttatgc	7740
cgctcggcg	agcacatgga	acgggttggc	atggattgta	ggcgccggcc	tataccttgt	7800
ctgcctcccc	gcgttgcgtc	gcggtgcatg	gagccggggc	acctcgacct	gaatggaagc	7860
cggcggcacc	tcgctaacgg	attcaccact	ccaagaattg	gagccaatca	attcttgcgg	7920
agaactgtga	atgcgcaaac	caacccttgg	cagaacatat	ccatcgcgtc	cgccatctcc	7980
agcagccgca	cgcggcgc	ctcgggcagc	gttgggtcct	ggccacgggt	gcgcatgac	8040
gtgctcctgt	cgttgaggac	ccggctaggc	tggcgggggt	gccttactgg	ttagcagaat	8100
gaatcacoga	tacgcgagcg	aacgtgaagc	gactgctgct	gcaaaacgtc	tgcgacctga	8160
gcaacaacat	gaatgggtct	cggtttcctg	gtttcgtaaa	gtctggaaac	gcggaagtcc	8220
cctacgtgct	gctgaagttg	cccgaacag	agagtggaac	caaccgggtga	taccacgata	8280
ctatgactga	gagtcaacgc	catgagcggc	ctcatttctt	attctgagtt	acaacagtcc	8340
gcaccgctgt	ccggtagctc	cttcgggtgg	gcgcggggca	tgaactatcg	cgccgcactt	8400
atgactgtct	tctttatcat	gcaactcgta	ggacagggtg	cggcagcgcc	caacagtccc	8460
ccggccacgg	ggcctgccac	catacccacg	ccgaacaag	cgccctgcac	cattatgttc	8520
cggatctgca	tcgcaggatg	ctgctggcta	ccctgtggaa	cacctacatc	tgtattaacg	8580
aagcgctaac	cgtttttatc	aggctctggg	aggcagaata	aatgatcata	tcgtcaatta	8640

ttacctccac ggggagagcc tgagcaaaact ggcctcaggc atttgagaag cacacggtca	8700
cactgcttcc ggtagtcaat aaaccggtaa accagcaata gacataagcg gctattttaac	8760
gacctgccc tgaaccgacg accgggtcga atttgctttc gaatttctgc cattcatccg	8820
cttattatca cttattcagg cgtagcacca ggcgtttaag ggcaccaata actgccttaa	8880
aaaaattacg ccccgccctg ccactcatcg cagtactgtt gtaattcatt aagcattctg	8940
ccgacatgga agccatcaca gacggcatga tgaacctgaa togccagcgg catcagcacc	9000
ttgtcgcctt gcgtataata tttgcccatg gtgaaaacgg gggcgaagaa gttgtccata	9060
ttggccacgt ttaaataaaa actggtgaaa ctccccagg gattggctga gacgaaaaac	9120
atattctcaa taaacccttt agggaaatag gccaggtttt caccgtaaca cgccacatct	9180
tgcgaaatata tgtgtagaaa ctgccggaaa tcgtcgtggt attcactcca gagcgatgaa	9240
aacgtttcag tttgctcatg gaaaacggtg taacaagggt gaacactatc ccataccacc	9300
agctcacctg ctttcattgc catacg	9326

<210> 126

<211> 4107

<212> DNA

<213> Artificial

<220>

<223> Cas9 coding sequence

<400> 126

atggataaga aatactcaat aggccttagat atcggcacaa atagcgtcgg atgggcggtg	60
atcactgatg aatataaggt tccttctaaa aagttcaagg ttctgggaaa tacagaccgc	120
cacagtatca aaaaaaatct tataggggct cttttatttg acagtggaga gacagcggaa	180
gggactcgtc tcaaacggac agctcgtaga aggtatacac gtcggaagaa tcgtatttgt	240
tatctacagg agattttttc aaatgagatg gcgaaagtag atgatagttt ctttcatcga	300
cttgaagagt cttttttggt ggaagaagac aagaagcatg aacgtcatcc tatttttgga	360
aatatagtag atgaagttgc ttatcatgag aaatatccaa ctatctatca tctgcgaaaa	420
aaattggtag attctactga taaagcggat ttgcgcttaa tctatttggc cttagcgcgt	480
atgattaagt ttctgtgtca ttttttgatt gagggagatt taaatcctga taatagtgat	540
gtggacaaac tatttatcca gttggtacaa acctacaatc aattatttga agaaaaccct	600
attaacgcaa gtggagtaga tgctaaagcg attctttctg cagcattgag taaatcaaga	660
cgattagaaa atctcattgc tcagctcccc ggtgagaaga aaaatggctt atttggaat	720
ctcattgctt tgtcattggg tttgacctct aattttaaat caaattttga tttggcagaa	780
gatgctaaat tacagctttc aaaagatact tacgatgatg atttagataa tttattggcg	840
caaattggag atcaatatgc tgatttggtt ttggcagcta agaatttatc agatgctatt	900
ttactttcag atatcctaag agtaaatact gaaataacta aggtccctct atcagcttca	960
atgattaaac gctacgatga acatcatcaa gacttgactc ttttaaaagc tttagtgcga	1020
caacaacttc cagaaaagta taaagaaatc ttttttgatc aatcaaaaaa cggatatgca	1080
ggttatatatg atgggggagc tagccaagaa gaattttata aatttatcaa accaatttta	1140
gaaaaaatgg atggtactga ggaattattg gtgaaactaa atcgtgaaga tttgctgcgc	1200
aagcaacgga cctttgacaa cggctctatt ccccatcaaa ttcacttggg tgagctgcat	1260
gctattttga gaagacaaga agacttttat ccatttttaa aagacaatcg tgagaagatt	1320
gaaaaaatct tgacttttgc aattccttat tatgttggtc cattggcgcg tggcaatagt	1380
cgttttgcat ggatgactcg gaagtctgaa gaaacaatta ccccatggaa ttttgaagaa	1440
gttgtcgata aagggtgctc agctcaatca tttattgaac gcatgacaaa ctttgataaa	1500
aatcttccaa atgaaaaagt actaccaaaa catagtttgc tttatgagta ttttacggtt	1560
tataacgaat tgacaaaggt caaatatgtt actgaaggaa tgcgaaaacc agcatttctt	1620
tcagggtgaac agaagaaagc cattgttgat ttactcttca aaacaaatcg aaaagtaacc	1680

gttaagcaat taaaagaaga ttattttcaaa aaaatagaat gttttgatag tggtgaaatt	1740
tcaggagttg aagatagatt taatgcttca ttaggtacct accatgattt gctaaaaatt	1800
attaaagata aagatttttt ggataatgaa gaaaatgaag atatcttaga ggatattgtt	1860
ttaacattga ccttatttga agatagggag atgattgagg aaagacttaa aacatatgct	1920
cacctctttg atgataaggt gatgaaacag cttaaacgtc gccgttatac tgggtgggga	1980
cgtttgtctc gaaaattgat taatggtatt agggataagc aatctggcaa aacaatatta	2040
gattttttga aatcagatgg ttttgccaat cgcaatttta tgcagctgat ccatgatgat	2100
agtttgacat ttaaagaaga cattcaaaaa gcacaagtgt ctggacaagg cgatagttta	2160
catgaacata ttgcaaattt agctggtagc cctgctatta aaaaaggtat tttacagact	2220
gtaaaagttg ttgatgaatt ggtcaaagta atggggcggc ataagccaga aaatatcgtt	2280
attgaaatgg cacgtgaaaa tcagacaact caaaagggcc agaaaaattc gcgagagcgt	2340
atgaaacgaa tcgaagaagg tatcaaagaa ttaggaagtc agattcttaa agagcatcct	2400
gttgaaaata ctcaattgca aaatgaaaag ctctatctct attatctcca aaatggaaga	2460
gacatgtatg tggaccaaga attagatatt aatcgtttta gtgattatga tgtcgatcac	2520
attgttccac aaagtcttct taaagacgat tcaatagaca ataagtcctt aacgcgttct	2580
gataaaaatc gtggtaaatc ggataacgtt ccaagtgaag aagtagtcaa aaagatgaaa	2640
aactattgga gacaacttct aaacgccaaag ttaatcactc aacgtaagtt tgataattta	2700
acgaaagctg aacgtggagg tttgagtga cttgataaag ctggttttat caaacgccaa	2760
ttggttgaaa ctgcgcaaat cactaagcat gtggcacaaa ttttggatag tcgcatgaat	2820
actaaatcag atgaaaatga taaacttatt cgagaggtta aagtgattac cttaaatct	2880
aaattagttt ctgacttccg aaaagatttc caattctata aagtacgtga gattaacaat	2940
taccatcatg cccatgatgc gtatctaaat gccgtcgttg gaactgcttt gattaagaaa	3000
tatccaaaac ttgaatcggg gtttgtctat ggtgattata aagtttatga tgttcgtaaa	3060
atgattgcta agtctgagca agaaataggc aaagcaaccg caaaatattt cttttactct	3120
aatatcatga acttcttcaa aacagaaatt acacttgcaa atggagagat tcgcaaacgc	3180
cctctaactg aaactaatgg ggaaactgga gaaattgtct gggataaagg gcgagatttt	3240
gccacagtgc gcaaagtatt gtccatgccc caagtcaata ttgtcaagaa aacagaagta	3300
cagacaggcg gattctccaa ggagtcaatt ttaccaaaaa gaaattcggg caagcttatt	3360
gctcgtaaaa aagactggga tccaaaaaaa tatggtggtt ttgatatgcc aacggtagct	3420
tattcagtc tagtggttgc taaggtggaa aaagggaaat ogaagaagtt aaaatccgtt	3480
aaagagttac tagggatcac aattatggaa agaagttcct ttgaaaaaaa tccgattgac	3540
tttttagaag ctaaaggata taaggaagtt aaaaaagact taatcattaa actacctaaa	3600
tatagtcttt ttgagttaga aaacggtcgt aaacggatgc tggctagtgc cggagaatta	3660
caaaaaggaa atgagctggc tctgccaaagc aaatatgtga attttttata tttagctagt	3720
cattatgaaa agttgaaggg tagtccagaa gataacgaac aaaaacaatt gtttgtggag	3780
cagcataagc attattttaga tgagattatt gagcaaatca gtgaattttc taagcgtgtt	3840
attttagcag atgccaatth agataaagtt cttagtgcac ataacaaca tagagacaaa	3900
ccaatacgtg aacaagcaga aaatattatt catthattta cgttgacgaa tcttgagct	3960
cccgtgctt ttaaatattt tgatacaaca attgatcgtg aacgatatac gtctacaaaa	4020
gaagtttttag atgccactct tatccatcaa tccatcactg gtcttttatga aacacgcatt	4080
gatttgagtc agctaggagg tgactga	4107

<210> 127

<211> 69

<212> DNA

<213> Artificial

<220>

<223> -10 promoter in pCas9

<400> 127	
agtatatattt agatgaagat tatttcttaa taactaaaaa tatggtataa tactcttaat	60
aaatgcagt	69
<210> 128	
<211> 80	
<212> DNA	
<213> Artificial	
<220>	
<223> Leader sequence in pCas9	
<400> 128	
aatacagggg cttttcaaga ctgaagtcta gctgagacaa atagtgcgat tacgaaattt	60
tttagacaaa aatagtctac	80
<210> 129	
<211> 194	
<212> DNA	
<213> Artificial	
<220>	
<223> Spacer sequence	
<400> 129	
aaaactgaga cggggcagtg agcgcaacgc aattaacatt aggcacccca ggcttgacaa	60
ttaatcatcg gctcgtataa tgtgtggaat tgtgagcgga taacaatttc acacggaggt	120
cacatatgag ataataataa ctagctgaat tccccagccc gctaatagag cgggcttttt	180
tttggctctg tttt	194
<210> 130	
<211> 86	
<212> RNA	
<213> Artificial	
<220>	
<223> tracrRNA	
<400> 130	
ggaaccauuc aaaacagcau agcaaguuaa aaauaggcua guccguuauc aacuugaaaa	60
aguggcaccg agucggugcu uuuuuu	86
<210> 131	
<211> 91	
<212> DNA	
<213> Artificial	
<220>	
<223> pre-crRNA	
<400> 131	
guuuuagagc uaugctguuu ugaauggucc caaacacuuu uaaaguucug cuaugguuuu	60
agagcuaugc tguuuugaau ggucccaaaa c	91
<210> 132	
<211> 11	
<212> RNA	
<213> Artificial	
<220>	
<223> Cleaved tracrRNA after first processing event	

<400> 132
ggaaccauuc a 11

<210> 133
<211> 75
<212> DNA
<213> Artificial

<220>
<223> Cleaved tracrRNA

<400> 133
aaacagcaua gcaaguuaaa auaaggcuag uccguauca acuugaaaaa guggcaccga 60
gucggugcuu uuuuu 75

<210> 134
<211> 55
<212> DNA
<213> Artificial

<220>
<223> cleaved pre-crRNA

<400> 134
aaugguccca aacacuuuuu aaguucugcu augguuuuag agcuaugctg uuuug 55

<210> 135
<211> 42
<212> DNA
<213> Artificial

<220>
<223> Cleaved pre-crRNA after 2nd processing event

<400> 135
acuuuuaaag uucugcuaug guuuuagagc uaugctguuu ug 42

<210> 136
<211> 20
<212> DNA
<213> Unknown

<220>
<223> crRNA complementary sequence within target beta-lactamase DNA sequence

<400> 136
acttttaaag ttctgctatg 20

<210> 137
<211> 38
<212> DNA
<213> Unknown

<220>
<223> CR90-containing target beta-lactamase DNA sequence anti-protospacer strand

<400> 137
ccaagtcaac ttttaaagtt ctgctatgtg gcgcggta 38

<210> 138
<211> 38

<212> DNA

<213> Unknown

<220>

<223> CR90-containing target beta-lactamase DNA sequence protospacer strand

<400> 138

taccgcgcca catagcagaa ctttaaaagt tgacttgg 38

<210> 139

<211> 20

<212> DNA

<213> Unknown

<220>

<223> crRNA complementary sequence within target beta-lactamase DNA sequence - reverse strand

<400> 139

catagcagaa ctttaaaagt 20

<210> 140

<211> 4758

<212> DNA

<213> Streptococcus pyogenes

<400> 140

atgccggtac tgcggggcct cttgcgggat ccagaagtct ttttcttgca ctgtttcctt 60

ttctttatga tagtttacga aatcatcctg tggagcttag taggtttagc aagatggcag 120

cgcctaaatg tagaatgata aaaggattaa gagattaatt tccctaaaaa tgataaaaca 180

agcgttttga aagcgcttgt ttttttggtt tgcagtcaga gtagaataga agtatcaaaa 240

aaagcaccga ctcggtgcca ctttttcaag ttgataacgg actagcctta ttttaacttg 300

ctatgctggt ttgaatgggt ccaacaagat tattttataa cttttataac aaataatcaa 360

ggagaaattc aaagaaattt atcagccata aaacaatact taatactata gaatgataac 420

aaaataaaact acttttttaa agaattttgt gttataatct atttattatt aagtattggg 480

taatatTTTT tgaagagata ttttgaaaaa gaaaaattaa agcatattaa actaatttcg 540

gaggtcatta aaactattat tgaaatcatc aaactcatta tggatttaat ttaacttttt 600

tatttttagga ggcaaaaatg gataagaaat actcaatagg cttagatata gccacaaata 660

gcgtcggatg ggcggtgatc actgatgaat ataaggttcc gtctaaaaag ttcaaggttc 720

tgggaaatac agaccgccac agtatcaaaa aaaatcttat aggggctctt ttatttgaca 780

gtggagagac agcgggaagc actcgtctca aacggacagc tcgtagaagg tatacacgtc 840

ggaagaatcg tatttgttat ctacaggaga ttttttcaaa tgagatggcg aaagtagatg 900

atagtttctt tcatcgactt gaagagtctt ttttggtgga agaagacaag aagcatgaac 960

gtcatcctat ttttggaat atagtagatg aagttgctta tcatgagaaa tatccaacta 1020

tctatcatct gcgaaaaaaa ttggtagatt ctactgataa agcggatttg cgcttaatct 1080

atttggcctt agcgcataatg attaagtttc gtggtcattt tttgattgag ggagatttaa 1140

atcctgataa tagtgatgtg gacaaaactat ttatccagtt ggtacaaacc tacaatcaat 1200

tatttgaaga aaaccctatt aacgcaagtg gagtagatgc taaagcgatt ctttctgcac 1260

gattgagtaa atcaagacga ttagaaaatc tcattgctca gctccccggt gagaagaaaa 1320

atggcttatt tgggaatctc attgctttgt cattgggttt gaccctaat tttaaatcaa 1380

attttgattt ggcagaagat gctaaattac agctttcaaa agatacttac gatgatgatt 1440

tagataattt attggcgcaa attggagatc aatatgctga tttgtttttg gcagctaaga 1500

atztatcaga tgctatttta ctttcagata tctaagagt aaatactgaa ataactaagg 1560

ctcccctatc agcttcaatg attaaacgct acgatgaaca tcatcaagac ttgactcttt 1620

taccgcgcca catagcagaa ctttaaaagt tgacttgg 1680

taaaagcttt agtccgacaa caactccag aaaagtataa agaaatcttt ttgatcaat	1680
caaaaaacgg atatgcaggt tatattgatg ggggagctag ccaagaagaa ttttataaat	1740
ttatcaaacc aatttttagaa aaaatggatg gtactgagga attattggtg aaactaaatc	1800
gtgaagatth gctgcgcaag caacggacct ttgacaacgg ctctattccc catcaaatto	1860
acttgggtga gctgcatgct attttgagaa gacaagaaga cttttatcca tttttaaaag	1920
acaatcgtga gaagattgaa aaaatcttga cttttcgaat tccttattat gttggtccat	1980
tggcgcgtgg caatagtcgt tttgcatgga tgactcggaa gtctgaagaa acaattaccc	2040
catggaatth tgaagaagtt gtcgataaag gtgcttcagc tcaatcattt attgaacgca	2100
tgacaaactt tgataaaaat cttccaaatg aaaaagtact accaaaacat agtttgcttt	2160
atgagtatth tacggthtat aacgaattga caaaggtaaa atatgttact gaaggaatgc	2220
gaaaaccagc atttctttca ggtgaacaga agaaagccat tgttgattta ctcttcaaaa	2280
caaatcgaaa agtaaccgtt aagcaattaa aagaagatta tttcaaaaaa atagaatgtt	2340
ttgatagtgt tgaattttca ggagttgaag atagatttaa tgcttcatta ggtacctacc	2400
atgatttgct aaaaattatt aaagataaag attttttgga taatgaagaa aatgaagata	2460
tcttagagga tattgtttta acattgacct tatttgaaga tagggagatg attgaggaaa	2520
gacttaaaac atatgctcac ctctttgatg ataaggatg gaaacagctt aaacgtcgcc	2580
gttatactgg ttggggacgt ttgtctcgaa aattgattaa tggattagg gataagcaat	2640
ctggcaaaac aatattgat tttttgaaat cagatggtht tgccaatcgc aattttatgc	2700
agctgatcca tgatgatagt ttgacattta aagaagacat tcaaaaagca caagtgtctg	2760
gacaaggcga tagtttacat gaacatattg caaatttagc tggtagccct gctattaaaa	2820
aaggatthtt acagactgta aaagtgttg atgaattggt caaagtaatg gggcggcata	2880
agccagaaaa tatcgttatt gaaatggcac gtgaaaatca gacaactcaa aaggggcaga	2940
aaaattcgcg agagcgtatg aaacgaatcg aagaaggat caaagaatta ggaagtcaga	3000
ttcttaaaga gcatcctgtt gaaaatactc aattgcaaaa tgaaaagctc tatctctatt	3060
atctccaaaa tggaagagac atgtatgtgg accaagaatt agatattaat cgtttaagtg	3120
attatgatgt cgtcacatt gttccacaaa gtttctttaa agacgattca atagacaata	3180
aggtcttaac gcgttctgat aaaaatcgtg gtaaactcga taacgttcca agtgaagaag	3240
tagtcaaaaa gatgaaaaac tattggagac aacttctaaa cgccaagtta atcactcaac	3300
gtaagtttga taatttaacg aaagctgaac gtggaggttt gagtgaactt gataaagctg	3360
gttttatcaa acgccaattg gttgaaactc gccaaatcac taagcatgtg gcacaaatth	3420
tggatagtcg catgaatact aaatacgtg aaaaatgata acttattcga gaggttaaa	3480
tgattacott aaaaatctaaa ttagttcttg acttcgaaa agatttccaa ttctataaag	3540
tacgtgagat taacaattac catcatgcc atgatgcgt tctaaatgcc gtcgttgga	3600
ctgctttgat taagaaatat ccaaaacttg aatcggagtt tgtctatggt gattataaag	3660
tttatgatgt tcgtaaaatg attgctaagt ctgagcaaga aataggcaaa gcaaccgcaa	3720
aatatttctt ttaactcta atcatgaact tcttcaaaa agaaattaca cttgcaaatg	3780
gagagattcg caaacgccct ctaatcgaaa ctaatggga aactggagaa attgtctggg	3840
ataaagggcg agattttgcc acagtgcgca aagtattgtc catgccccaa gtcaatattg	3900
tcaagaaaac agaagtacag acaggcggat tctccaagga gtcaatttta ccaaaaagaa	3960
attcggacaa gcttattgct cgtaaaaaag actgggatcc aaaaaaatat ggtggthttg	4020
atagtccaac ggtagcttat tcagtcctag tggttgctaa ggtggaaaaa gggaaatcga	4080
agaagttaaa atccgttaaa gagttactag ggatcacaat tatggaaaga agttcctttg	4140
aaaaaaatcc gattgactth ttagaagcta aaggatataa ggaagttaaa aaagacttaa	4200
tcattaaact acctaaatat agtctthttg agttagaaaa cggtcgtaaa cggatgctgg	4260
ctagtgccgg agaattacaa aaaggaaatg agctggctct gccaaagcaaa tatgtgaatt	4320
ttttatattt agctagtcat tatgaaaagt tgaagggtag tccagaagat aacgaacaaa	4380
aacaattgtt tgtggagcag cataagcatt atttagatga gattattgag caaatcagt	4440
aattttctaa gcgtgttatt ttagcagatg ccaatttaga taaagttctt agtgcataa	4500

acaaacatag agacaaacca atacgtgaac aagcagaaaa tattattcat ttatttacgt	4560
tgacgaatct tggagctccc gctgctttta aatattttga tacaacaatt gatcgtaaac	4620
gatatacgtc tacaaaagaa gttttagatg ccactcttat ccatcaatcc atcactggtc	4680
tttatgaaac acgcattgat ttgagtcagc taggaggtga ctgatggcca cgtgaactat	4740
atgattttcc gcagtata	4758

<210> 141
<211> 276
<212> DNA
<213> Streptococcus pyogenes

<400> 141	
attgatttga gtcagctagg aggtgactga tggccacgtg aactatatga ttttccgcag	60
tatatttttag atgaagatta tttcttaata actaaaaata tgggtataata ctcttaataa	120
atgcagtaat acaggggctt ttcaagactg aagtctagct gagacaaata gtgcgattac	180
gaaatttttt agacaaaaat agtctacgag gttttagagc tatgctgttt tgaatgggcc	240
caaaactgag accagtctcg gacgtccaaa ggtctc	276

<210> 142
<211> 10
<212> DNA
<213> Streptococcus pyogenes

<400> 142	
ggtctccatt	10

<210> 143
<211> 10
<212> DNA
<213> Streptococcus pyogenes

<400> 143	
ggtcccaaaa	10

<210> 144
<211> 452
<212> DNA
<213> Artificial

<220>
<223> Fragment 3, amplified from genomic DNA of S. pyogenes strain SF370

<400> 144	
gagaccagtc tgggacgtcc aaaggtctcg ttttagagct atgctgtttt gaatgggtccc	60
aaaacaacat tgccgatgat aacttgagaa agaggggttaa taccagcagt cggatacctt	120
cctattcttt ctgttaaagc gttttcatgt tataataggc aaaagaagag tagtgtgatg	180
gaacaaacat tttttatgat taagccatat ggggttaagc aaggggaggt agttggagag	240
gttttacggt ggattgaacg cctaagattt acgtttaagc gattcgagct aagacaagct	300
agttcgaaat acttggctaa gcacgacgag gccttgggtga taaacctttt gatcctaaac	360
ttaaagctta catgacaagt ggtcctgttt taattgggat aattcttggg gactaaggtg	420
gtatcggtcca ttccgacagc atcgccagtc ac	452

<210> 145
<211> 9578
<212> DNA
<213> Artificial

<220>

<223> Sequence of the final construct pNB100

<400> 145

gaattccgga tgagcattca tcagggcgggc aagaatgtga ataaaggccg gataaaactt	60
gtgcttattt ttctttacgg tctttaaaaa ggccgtaata tccagctgaa cggctctggt	120
ataggtacat tgagcaactg actgaaatgc ctcaaatgt tctttacgat gccattggga	180
tatatcaacg gtggtatata cagtgatatt tttctccatt ttagcttcct tagctcctga	240
aatctcogat aactcaaaaa atacgcccg tagtgatctt atttcattat ggtgaaagtt	300
ggaacctctt acgtgccgat caacgtctca ttttcgccaa aagttggccc agggcttccc	360
ggtatcaaca gggacaccag gatttattta ttctgcgaag tgatcttccg tcacaggtat	420
ttattcggcg caaagtgcgt cgggtgatgc tgccaaacta ctgatttagt gtatgatggt	480
gtttttgagg tgctccagtg gcttctgttt ctatcagctg tccctcctgt tcagctactg	540
acggggtggt gcgtaacggc aaaagcaccg ccggacatca gcgctagcgg agtgtatact	600
ggcttactat gttggcactg atgaggggtg cagtgaagtg cttcatgtgg caggagaaaa	660
aaggctgcac cggtgcgta gcagaatatg tgatacagga tatattccgc ttcctcgtc	720
actgactcgc tacgctcggc cgttcgactg cggcgagcgg aaatggctta cgaacggggc	780
ggagatttcc tggaagatgc caggaagata cttaacaggg aagtgagag gccgcggcaa	840
agccgttttt ccataggctc cgtcccccctg acaagcatca cgaaatctga cgctcaaatc	900
agtgggtggc aaacccgaca ggactataaa gataccaggc gtttccccct ggccgctccc	960
togtgcgctc tcctgttcct gcctttcggg ttaccgggtg cattccgctg ttatggccgc	1020
gtttgtctca ttccacgcct gacactcagt tccgggtagg cagttcgtc caagctggac	1080
tgtatgcacg aacccccgt tcagtcgcac cgtcgcgcct tatccggtaa ctatcgtctt	1140
gagtcgaacc cggaaagaca tgcaaaagca ccactggcag cagccactgg taattgattt	1200
agaggagtta gtcttgaaat catgcgccgg ttaaggctaa actgaaagga caagttttgg	1260
tgactgcgct cctccaagcc agttacctg gttcaaagag ttggtagctc agagaacctt	1320
cgaaaaaccg ccctgcaagg cggttttttc gttttcagag caagagatta cgcgcagacc	1380
aaaacgatct caagaagatc atcttattaa tcagataaaa tatttctaga tttcagtga	1440
atttatctct tcaaatgtag cacctgaagt cagccccata cgatataagt tgtaattctc	1500
atgtttgaca gcttatcatc gataagcttt aatgcggtag tttatcacag ttaaattgct	1560
aacgcagtca ggcaccgtgt atgaaatcta acaatgcgct catcgtcac ctcggcacccg	1620
tcaccctgga tgctgtaggc ataggcttgg ttatgccggc actgccgggc ctcttgccgg	1680
atccagaagt ctttttcttg cactgtttcc ttttctttat gatagtttac gaaatcatcc	1740
tgtggagctt agtaggttta gcaagatggc agcgccctaaa tgtagaatga taaaaggatt	1800
aagagattaa tttccctaaa aatgataaaa caagcgtttt gaaagcgctt gtttttttgg	1860
tttgagtcga gagtagaata gaagtatcaa aaaagcacc gactcgggtc cactttttca	1920
agttgataac ggactagcct tattttaact tgctatgctg ttttgaatgg ttccaacaag	1980
attattttat aacttttata acaaataatc aaggagaaat tcaaagaaat ttatcagcca	2040
taaaacaata cttaatacta tagaatgata acaaaataaa ctacttttta aaagaatttt	2100
gtgtttataat ctatttatta ttaagtattg ggtaatatat tttgaagaga tattttgaaa	2160
aagaaaaatt aaagcatatt aaactaattt cggaggtcat taaaactatt attgaaatca	2220
tcaaactcat tatggattta atttaaacct tttatttttag gaggcacaaa tggataagaa	2280
atactcaata ggcttagata tcggcacaaa tagcgtcggg tgggcgggtg tcaactgatg	2340
atataagggt ccgtctaaaa agttcaaggc tctgggaaat acagaccgcc acagtatcaa	2400
aaaaaatctt ataggggctc ttttatttga cagtggagag acagcggaag cgactcgtct	2460
caaacggaca gctcgtagaa ggtatacacg tcggaagaat cgtatttgtt atctacagga	2520
gattttttca aatgagatgg cgaaagtaga tgatagtttc tttcatcgac ttgaagagtc	2580
ttttttggtg gaagaagaca agaagcatga acgtcatcct atttttggaa atatagtaga	2640
tqaaqtqct tatcatqaga aatatccaac tatctatcat ctacqaaaa aattqqtaga	2700

```

ttctactgat aaagcggatt tgcgcttaat ctatttggcc ttagcgcata tgattaagtt 2760
tcgtgggcat tttttgattg agggagattt aaatcctgat aatagtgatg tggacaaact 2820
atztatccag ttggtacaaa cctacaatca attatttgaa gaaaacccta ttaacgcaag 2880
tggagtagat gctaaagcga ttctttctgc acgattgagt aaatcaagac gattagaaaa 2940
tctcattgct cagctccccg gtgagaagaa aaatggctta tttgggaatc tcattgcttt 3000
gtcattgggt ttgaccocct attttaaatc aaattttgat ttggcagaag atgctaaatt 3060
acagctttca aaagatactt acgatgatga tttagataat ttattggcgc aaattggaga 3120
tcaatatgct gatitgtttt tggcagctaa gaatttatca gatgctatit tactttcaga 3180
tatcctaaga gtaaatactg aaataactaa ggctccccta tcagcttcaa tgattaaacg 3240
ctacgatgaa catcatcaag acttgactct tttaaaagct ttagttcgac aacaacttcc 3300
agaaaagtat aaagaaatct tttttgatca atcaaaaaac ggatatgcag gttatattga 3360
tggggggagct agccaagaag aattttataa atttatcaaa ccaatttttag aaaaaatgga 3420
tgggtactgag gaattattgg tgaaactaaa tcgtgaagat ttgctgcgca agcaacggac 3480
ctttgacaac ggctctattc cccatcaaat tcacttgggt gagctgcatg ctattttgag 3540
aagacaagaa gactttttat cattttttaa agacaatcgt gagaagattg aaaaaatctt 3600
gacttttoga attccttatt atgttgggtc attggcgcgt ggcaatagtc gttttgcatg 3660
gatgactcgg aagtctgaag aaacaattac cccatggaat tttgaagaag ttgtcgataa 3720
aggtgcttca gctcaatcat ttattgaacg catgacaaac tttgataaaa atcttcctaaa 3780
tgaaaaagta ctacccaaaac atagtittgt ttatgagtat ttacggttt ataacgaatt 3840
gacaaaggtc aaatatgtta ctgaaggaat gcgaaaacca gcatttcttt cagggtgaaca 3900
gaagaaagcc attgttgatt tactcttcaa aacaaatcga aaagtaaccg ttaagcaatt 3960
aaaagaagat tatttcacaaa aaatagaatg ttttgatagt gttgaaattt caggagttga 4020
agatagattt aatgcttcat taggtacctc ccatgatttg ctaaaaatta ttaaagataa 4080
agattttttg gataatgaag aaaatgaaga tatcttagag gatattgttt taacattgac 4140
cttatttgaa gatagggaga tgattgagga aagacttaaa acatatgctc acctctttga 4200
tgataaaggc atgaaacagc ttaaacgctc ccgttatact ggttggggac gtttgtctcg 4260
aaaattgatt aatgggtatta gggataagca atctggcaaa acaatattag attttttgaa 4320
atcagatggg tttgccaatc gcaattttat gcagctgac catgatgata gtttgacatt 4380
taaagaagac attcaaaaag cacaagtgtc tggacaaggc gatagtttac atgaacatat 4440

tgcaaattta gctggtagcc ctgctattaa aaaagggtatt ttacagactg taaaagttgt 4500
tgatgaattg gtcaaagtaa tggggcggca taagccagaa aatatcgtta ttgaaatggc 4560
acgtgaaaat cagacaaactc aaaagggcca gaaaattcg cgagagcgta tgaaacgaat 4620
cgaagaaggt atcaaagaat taggaagtca gattcttaaa gagcatcctg ttgaaaatac 4680
tcaattgcaa aatgaaaagc tctatctcta ttatctccaa aatggaagag acatgtatgt 4740
ggaccaagaa ttagatatta atcgtttaag tgattatgat gtcgatcaca ttgttcacac 4800
aagtttcctt aaagacgatt caatagacaa taagggtctta acgcgttctg ataaaaatcg 4860
tggtaaatcg gataacgttc caagtgaaga agtagtcaaa aagatgaaaa actattggag 4920
acaacttcta aacgccaaat taatcactca acgtaagttt gataatttaa cgaaagctga 4980
acgtggaggt ttgagtgaac ttgataaagc tggttttatc aaacgccaat tggttgaaac 5040
tcgccaaatc actaagcatg tggcacaaat tttggatagt cgcataata ctaaatacga 5100
tgaaaatgat aaacttattc gagaggttaa agtgattacc ttaaaatcta aattagtttc 5160
tgacttccga aaagatttcc aattctataa agtacgtgag attaacaatt accatcatgc 5220
ccatgatgcg tatctaaatg ccgtcgttgg aactgctttg attaagaaat atccaaaact 5280
tgaatcggag tttgtctatg gtgattataa agtttatgat gttcgtaaaa tgattgctaa 5340
gtctgagcaa gaaataggca aagcaaccgc aaaatatttc ttttactcta atatcatgaa 5400
cttcttcaaa acagaaatta cacttgcaaa tggagagatt cgcaaacgcc ctctaatacga 5460
aactaatggg gaaactggag aaattgtctg ggataaaggc cgagattttg ccacagtgcg 5520
caaagtattg tccatgcccc aagtcaatat tgtcaagaaa acagaagtac agacaggcgg 5580

```

attctccaag gagtcaattt taccaaaaag aaattcggac aagcttattg ctcgtaaaaa	5640
agactgggat ccaaaaaaat atggtggttt tgatagtcca acggtagctt attcagtcct	5700
agtggttgct aaggtggaaa aagggaaatc gaagaagtta aaatccgtta aagagttact	5760
agggatcaca attatggaaa gaagttcctt tgaaaaaat ccgattgact ttttagaagc	5820
taaaggatat aaggaagtta aaaaagactt aatcattaaa ctacctaat atagtctttt	5880
tgagttagaa aacggtcgta aacggatgct ggctagtgcc ggagaattac aaaaaggaaa	5940
tgagctggct ctgccaagca aatatgtgaa ttttttatat ttagctagtc attatgaaaa	6000
gttgaagggt agtccagaag ataacgaaca aaaacaattg tttgtggagc agcataagca	6060
ttatttagat gagattattg agcaaatcag tgaattttct aagcgtgtta ttttagcaga	6120
tgccaattta gataaagttc ttagtgcata taacaaacat agagacaaac caatacgtga	6180
acaagcagaa aatattattc atttatttac gttgacgaat cttggagctc ccgctgcttt	6240
taaatatttt gatacaacaa ttgatcgtaa acgatatacg tctacaaaag aagttttaga	6300
tgccactcct atccatcaat ccatcactgg tctttatgaa acacgcattg atttgagtca	6360
gctaggaggt gactgatggc cacgtgaact atatgatttt ccgcagtata ttttagatga	6420
agattatttc ttaataacta aaaatatggt ataatactct taataaatgc agtaatacag	6480
gggcttttca agactgaagt ctagctgaga caaatagtgc gattacgaaa ttttttagac	6540
aaaaatagtc tacgaggttt tagagctatg ctattttgaa tggccccaa actgagacca	6600
gtctcggacg tccaaaggtc tcgttttaga gctatgctgt tttgaatggt cccaaaacaa	6660
cattgccgat gataaactga gaaagagggt taataaccagc agtcggatac cttcctattc	6720
tttctgttaa agcgttttca tggtataata ggcaaaagaa gagtagtggt atggaacata	6780
cattttttat gattaagcca tatgggttta agcaaggga ggtagttgga gaggttttac	6840
ggtggattga acgcctaaga tttacgttta agcgattcga gctaagacaa gctagttcga	6900
aatacttggc taagcacgac gaggccttgg tgataaacct tttgatccta aacttaaagc	6960
ttacatgaca agtggtcctg ttttaattgg gataattctt ggggactaag gtggtatcgt	7020
ccattccgac agcatcgcca gtcactatgg cgtgctgcta gcgctatatg cgttgatgca	7080
atttctatgc gcacccgttc tcggagcact gtccgaccgc tttggccgcc gccagtcct	7140
gctcgcttgc ctacttggag ccactatcga ctacgcgac atggcgacca caccgctcct	7200
gtggatcctc tacgcgggac gcatcgtggc cggcatcacc ggcgcacacag gtgcgggttc	7260
tggcgcttat atcgccgaca tcaccgatgg ggaagatcgg gctcgccact tcgggctcat	7320
gagcgcttgt ttggcggtgg gtatgggtgg aggccccgtg gccgggggac tgttgggcgc	7380
catctccttg catgcaccat tccttgcggc ggcggtgctc aacggcctca acctactact	7440
gggctgcttc ctaatgcagg agtcgcataa gggagagcgt cgaccgatgc ccttgagagc	7500
cttcaaccca gtcagctcct tcgggtgggc gcggggcatg actatcgctc ccgcacttat	7560
gactgtcttc tttatcatgc aactcgtagg acaggtgccg gcagcgcctt gggtcatttt	7620
cggcgaggac cgttttcgct ggagcgcgac gatgatcggc ctgtcgcttg cgttattcgg	7680
aatcttgca cccctcgctc aagccttctt cactgggtccc gccaccaaac gtttcggcga	7740
gaagcaggcc attatcgccg gcatggcggc cgacgcgctg ggctacgtct tgctggcgct	7800
cgcgacgca ggtgggatgg ccttcccat tatgattctt ctgccttccg gcggcatcgg	7860
gatgcccgcg ttgcaggcca tgctgtccag gcaggtagat gacgaccatc agggacagct	7920
tcaaggatcg ctgcgggctc ttaccagcct aacttcgac attggacgc tgatcgtcac	7980
ggcgatttat gccgcctcgg cgagcacatg gaacgggttg gcatggattg taggcgccgc	8040
cctatacctt gtctgcctcc ccgcgttgcg tcgcggtgca tggagccggg ccacctcgac	8100
ctgaatggaa gccggcgcca cctcgctaac ggattcacca ctccaagaat tggagccaat	8160
caattcttgc ggagaactgt gaatgcgcaa accaaccctt ggcagaacat atccatcgcg	8220
tccgccatct ccagcagccg cacgcggcgc atctcgggca gcgttgggtc ctggccacgg	8280
gtgcgcata tggtgtcct gtcttgagg acccggttag gctggcgggg ttgccttact	8340
ggttagcaga atgaatcacc gatacgcgag cgaacgtgaa gcgactgctg ctgcaaacgc	8400
tctccacct qaqaacaac atqaatqatc ttcaatttcc ctatttcata aaqtctqaa	8460

```

-----
acgcggaagt cccctacgtg ctgctgaagt tgcccgcaac agagagtgga accaaccggt      8520
gataccacga tactatgact gagagtcaac gccatgagcg gcctcatttc ttattctgag      8580
ttacaacagt ccgcaccgct gtccggtagc tccttccggt gggcgcgggg catgactatc      8640
gtcgccgcac ttatgactgt cttctttatc atgcaactcg taggacaggt gccggcagcg      8700
cccaacagtc ccccgccac ggggcctgcc accataccca cgccgaaaca agcgccctgc      8760
accattatgt tcggatctg catcgagga tgctgctggc taccctgtgg aacacctaca      8820
tctgtattaa cgaagcgcta accgttttta tcaggctctg ggaggcagaa taaatgatca      8880
tatcgtcaat tattacctcc acggggagag cctgagcaaa ctggcctcag gcatttgaga      8940
agcacacggt cacactgctt ccggtagtca ataaaccggt aaaccagcaa tagacataag      9000
cggctattta acgaccctgc cctgaaccga cgaccgggtc gaatttgctt tcgaatttct      9060
gccattcatc cgcttattat cacttattca ggcgtagcac caggcgttta agggcaccaa      9120
taactgcctt aaaaaaatta cggcccgccc tgccactcat cgcagtactg ttgtaattca      9180
ttaagcattc tgccgacatg gaagccatca cagacggcat gatgaacctg aatcgccagc      9240
ggcatcagca ccttgctgcc ttgctataa tatttgcca tggtgaaaac gggggcgaag      9300
aagttgtcca tattggccac gtttaaatca aaactgggta aactcaccca gggattggct      9360
gagacgaaaa acatattctc aataaaccct ttagggaaat aggccaggtt ttcaccgtaa      9420
cacgccacat cttgcgaata tatgtgtaga aactgccgga aatcgtcgtg gtattcactc      9480
cagagcgatg aaaacgtttc agtttgctca tggaaaacgg tgtaacaagg gtgaacacta      9540
tcccatatca ccagctcacc gtctttcatt gccatacg      9578

```

<210> 146

<211> 386

<212> DNA

<213> Artificial

<220>

<223> Amplified sequence with primer NB018 and NB019 from pNB100 as template

<400> 146

```

ccaaaactga gacctgctgc ggacgtccaa aggtctcgtt ttagagctat gctgttttga      60
atggtcccaa aacttgccga tgataacttg agaaagaggg ttaataccag cagtcggata      120
ccttcctatt ctttctgtta aagcgttttc atgttataat aggcaaattt tagatgaaga      180
ttattttctta ataactaaaa atatggtata atactcttaa taaatgcagt aatacagggg      240
cttttcaaga ctgaagtcta gctgagacaa atagtgcgat tacgaaattt tttagacaaa      300
aatagtctac gaggttttag agctatgctg ttttgaatgg tcccaaaact gaagagcgtc      360
tcggacgcag cgctcttcgt tttaga      386

```

<210> 147

<211> 744

<212> DNA

<213> Artificial

<220>

<223> Modified CRISPR array in pNB200

<400> 147

```

ggtgactgat ggccacgtga actatatgat tttccgcagt atattttaga tgaagattat      60
ttcttaataa ctaaaaatat ggtataatac tcttaataaa tgcagtaata caggggcttt      120
tcaagactga agtctagctg agacaaatag tgcgattacg aaatttttta gacaaaaata      180
gtctacgagg ttttagagct atgctatttt gaatggtccc aaaactgaga cctgctgcgg      240
acgtccaaag gtctcgtttt agagctatgc tgttttgaat ggtcccaaaa cttgccgatg      300
ataacttgag aaagagggtt aataccagca gtcggatacc ttcctattct ttctgttaaa      360

```

gcggttttcat gttataatag gcaaatttta gatgaagatt atttcttaat aactaaaaat	420
atggtataat actcttaata aatgcagtaa tacaggggct tttcaagact gaagtctagc	480
tgagacaaat agtgcgatta cgaaattttt tagacaaaaa tagtctacga ggtttttagag	540
ctatgctgtt ttgaatggc ccaaaactga agagcgtctc ggacgcagcg ctcttcgttt	600
tagagctatg ctgttttgaa tggccccaaa acaacattgc cgatgataac ttgagaaaga	660
gggttaatac cagcagtcgg ataccttcct attctttctg ttaaagcgtt ttcatgttat	720
aataggcaaa agaagagtag tgtg	744

<210> 148
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 148
ccaactacct ccccttgctt aac 23

<210> 149
<211> 18
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 149
ggtgactgat ggccacgt 18

<210> 150
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 150
gggctggcaa gccacgtttg gtg 23

<210> 151
<211> 23
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 151
ccgggagctg catgtgtcag agg 23

<210> 152
<211> 43
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 152
attgaaaaag gaagagtatg gaattgccca atattatgca ccc 43

<210> 153
<211> 38
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 153
agtcccgcta ggtctcaacc gtcagcgcag cttgtcgg 38

<210> 154
<211> 42
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 154
attgaaaaag gaagagtatg cgtgtattag ccttatcggc tg 42

<210> 155
<211> 55
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 155
agtcccgcta ggtctcaacc gctaggggaat aatttttcc tgttgagca cttct 55

<210> 156
<211> 47
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 156
attgaaaaag gaagagtatg cgttattttc gcctgtgtat tatctcc 47

<210> 157
<211> 41
<212> DNA
<213> Artificial

<220>
<223> Primer sequence

<400> 157
agtcccgcta ggtctcaacc gttagcgttg ccagtgcctcg a 41

<210> 158
<211> 57
<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 158

attgaaaaag gaagagtatg ttaaaagtta ttagtagttt attggtctac atgaccg 57

<210> 159

<211> 48

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 159

agtcccgccta ggaatgacctg gctgaccgct actcggcgac tgagcgat 48

<210> 160

<211> 43

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 160

attgaaaaag gaagagtatg tcactgtatc gccgtctagt tct 34

<210> 161

<211> 39

<212> DNA

<213> Artificial

<220>

<223> KPC-3 reverse primer

<400> 161

agtcccgccta ggtctcaacc gttactgcc gttgacgcc 39

<210> 162

<211> 60

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 162

attgaaaaag gaagagtatg agcaagttat ctgtattctt tatattttg tttgtagca 60

<210> 163

<211> 61

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 163

agtcccgccta ggtctcaacc gttagttgct tagttttgat ggttttttac tttcgtttaa 60

c 61

<210> 164

<211> 44

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 164

attgaaaaag gaagagtatg gttaaaaaat cactgcgcca gttc 44

<210> 165

<211> 47

<212> DNA

<213> Artificial

<220>

<223> Primer sequence

<400> 165

agtcccgccta ggtctcaacc gttacaaacc gtcggtgacg attttag 47

<210> 166

<211> 834

<212> DNA

<213> Unknown

<220>

<223> NDM-1 sequence

<400> 166

```

accgtcagcg cagcttgctcg gccatgcggg ccgatatgagt gattgcggcg cggctatcgg      60
gggcgggaatg gctcatcacg atcatgctgg ccttggggaa cgccgcacca aacgcgcgcg      120
ctgacgcggc gtagtgctca gtgtcggcat caccgagatt gccgagcgac ttggccttgc      180
tgtccttgat caggcagcca ccaaaagcga tgtcgggtgcc gtcgatccca acggtgatat      240
tgtcactggt gtggccgggg cgggggtaaa ataccttgag cggggccaaag ttgggcgcgg      300
ttgctgggtc gaccagcca ttggcggcga aagtcaggct gtgttgcgcc gcaaccatcc      360
cctcttgcgg ggcaagctgg ttcgacaacg cattggcata agtcgcaatc cccgccgcac      420
gcagcgcgtc cataccgcc atcttgtcct gatgcgcgtg agtcaccacc gccagcgoga      480
ccggcagggt gatctcctgc ttgatccagt tgaggatctg ggcggtctgg tcatcggtcc      540
aggcggatat gaccaccagc acgcggccgc catccctgac gatcaaaccg ttggaagcga      600
ctgccccgaa acccggcacg tcgagatagg aagtgtgctg ccagacattc ggtgcgagct      660
ggcggaaaac cagatcgcca aaccgttggt cgccagtttc catttgctgg ccaatcgctg      720
ggcggatttc accgggcacg caccgctca gcatcaatgc agcggctaata gcggtgctca      780
gcttcgcgac cgggtgcata atattgggca attccatact cttccttttt caat      834

```

<210> 167

<211> 819

<212> DNA

<213> Unknown

<220>

<223> OXA-48 sequence

<400> 167

accgctaggc aataattttt tctcttttga gcactttttt tctgatggct tggccagccg 60

```

accgctaggy aataatcccc cccgctccga gcaccccccc cgcgctggcc cggcgctagcc    00
ctaaaccatc cgatgtgggc atatccatat tcacgcgaaa aaaccacaca ttatcatcaa    120
gttcaaccca accgaccac cagccaatct taggttcgat tctagtcgag tatccagttt    180
tagcccgaat aatatagtca ccattggctt cggctcagcat ggcttgcttg acaatacgtc    240
ggctgcgctc cgatacgtgt aacttattgt gatacagctt tcttaaaaag ctgatttgct    300
ccgtggccga aattcgaata ccaccgtcga gccagaaact gtctacattg cccgaaatgt    360
cctcattacc ataatcgaaa gcatgtagca tcttgctcat acgtgcctcg ccaatttggc    420
gggcaaattc ttgataaaca ggcacaactg aatatttcat cgcggtgatt agattatgat    480
cgcgattcca agtggcgata tcgcgcgtct gtccatccca cttaaagact tgggtgttcat    540
ccttaaccac gcccaaatcg agggcgatca agctattggg aatttttaaag gtagatgcgg    600
gtaaaaatgc ttggttcgcc cgtttaagat tattggtaaa tccttgctgc ttattctcat    660
tcagagcac aactacgcc tgtgatttat gttcagtaaa gtgagcattc caacttttgt    720
tttcttgcca ttcttttgt accgcaggca ttccgataat cgatgccacc aaaaacacag    780
ccgataaggc taatacacgc atactcttcc tttttcaat    819

```

<210> 168

<211> 882

<212> DNA

<213> Unknown

<220>

<223> SHV-1 sequence

<400> 168

```

accgttagcg ttgccagtgc tcgatcagcg ccgcgcgat cccggcgatt tgctgatttc    60
gctcgcccat gctcgccggc gtatcccgca gataaatcac cacaatccgc tctgctttgt    120
tattcggggc aagcagggcg acaatcccg cgcaccccg tttggcagct ccggtcttat    180
cggcgataaa ccagcccgcc ggcagcacgg agcggatcaa cggtcggcg acccgatcgt    240
ccaccatcca ctgcagcagc tgccgttgcg aacgggcgct cagacgctgg ctggtcagca    300
gcttgcgagc ggtcgccggc atgctggccg gggtagtggg gtccggggcg tcgccgggaa    360
gogcctcatt cagttccgtt tccagcggg caaggcgggt gacgttgctc ccgatctggc    420
gcaaaaaggc agtcaatcct gcggggccgc cgacggtggc cagcagcaga ttggcggcgc    480
tggtatcgct catggtaatg gcggcgccac agagttcgcc gaccgtcatg ccgtcggcaa    540
gggtgttttc gctgaccggc gagtagtcca ccagatcctg ctggcgatag tggatctttc    600
gctccagctg ttcgtcaccg gcatccacc cgcgcagcac tgcccgcgag agcactactt    660
taaagggtgt catcatggga aagcgttcat cggcgcgcca ggcggtcagc gtgcggccgc    720
tgccagatc catttctatc atgcctacgc tgcccgacag ctggctttcg cttagtttaa    780
tttgctcaag cggctgcggg ctggcggtga ccgccagcgg cagggtggct aacagggaga    840
taatacacag gcgaaaataa cgcatactct tcctttttca at    882

```

<210> 169

<211> 822

<212> DNA

<213> Unknown

<220>

<223> VIM-1 sequence

<400> 169

```

accgttactc ggcgactgag cgatttttgt gtgctttgac aacgttcgct gtgtgctgga    60
gcaagtctag accgcccggg agaccgtgcc cgggaatgac gacctctgct tccgggtagt    120
gtttttgaat ccgctcaacg gaggtgggac attcagccag atcggcatcg gccacgttcc    180
ccgcagacgt gcttgacaac tcatgaacgg cacaaccacc gtatagcacg ttcgctgacg    240

```

```

ggacgtatac aaccagattg toggtcgaat ggcagcacc aggatagaag agctctactg 300
gaccgaagcg cactgcgtcc ccgctcgatg agagtccttc tagagaatgc gtgggaatct 360
cgttccctc tgcctcggct agccggcgtg tcgacggtga tgcgtacgtt gccacccag 420
ccgcccgaag gacatcaacg ccgccgacgc ggtcgtcatg aaagtgcgtg gagactgcac 480
gcgttacggg aagtccaatt tgcttttcaa tctccgcgag aagtgcgct gtgtttttcg 540
caccacacgc tgtatcaatc aaaagcaact catcaccatc accgacaatg agaccattgg 600
acgggtagac cgcgccatca aacgactgcg ttgcgatatg cgaccaaaca ccatcggcaa 660
tctggtaaag tcggacctct ccgaccgga tttcgttgac tgcggatac tcaccactcg 720
gctccccgga atgggctaac ggacttgca cagccatgac agacgcggtc atgtagacca 780
ataaactact aataactttt aacatactct tcttttttca at 822

```

<210> 170

<211> 903

<212> DNA

<213> Unknown

<220>

<223> KPC-3 sequence

<400> 170

```

accgttactg ccggttgacg cccaatccct cgagcgcgag tctagccgca gggcgatga 60
cggcctcgct gtacttgtca tcttgtag ggcgggggt gtagacggcc aacacaatag 120
gtgcgcgcc agtgggcccag acgacggcat agtcatttgc cgtgccatac actccgcagg 180
ttccggtttt gtctccgact gccagctctg ccggcaccgc cgcgcggatg cggtggttgc 240
cggtcgtgtt tccctttagc caatcaacaa actgctgccg ctgcggcgca gccagtgcag 300
agcccagtgt cagtttttgt aagctttccg tcacggcgcg cggcgatgag gtatcgcgcg 360
catcgctgg gatggcgag ttcagctcca gctccagcg gtccagacgg aacgtggtat 420
cgccgataga gcgcatgaag gccgtcagcc cggccgggccc gcccaactcc ttcagcaaca 480
aattggcggc ggcgttatca ctgtattgca cggcgccgc ggacagctcc gccaccgtca 540
tgctgttgt cagatatctt tccgagatgg gtgaccacgg aaccagcgca tttttgccgt 600
aacggatggg tgtgtccagc aagccggcct gctgctggct gcgagccagc acagcggcag 660
caagaaagcc cttgaatgag ctgcacagtg ggaagcgtc ctacgcgcg taacttacag 720
ttgcgcctga gcgggtatcc atcgctaca caccgatgga gccgccaaag tctgttoga 780
gttttagcaa tggttccgcg acgaggttg tcagcgcggt ggcagaaaag ccagccagcg 840
gccatgagag acaagacagc agaactagac ggcgatacag tgacatactc ttcctttttc 900
aat 903

```

<210> 171

<211> 762

<212> DNA

<213> Unknown

<220>

<223> IMP-4 sequence

<400> 171

```

accgttagtt gcttagtttt gatggttttt tactttcgtt taacccttta accgctgct 60
ctaagttaag tttcaagagt gatgcgtctc cagcttctact gtgacttggg acaaccagtt 120
ttgccttacc atatttgat attaataatt tagcggactt tggccaagct tctaaatttg 180
cgtcacccaa attacctaga ccgtacggtt taataaaaca accaccgaat aatattttcc 240
tttcaggcag ccaaactact aggttatctg gagtgtgtcc tgggcctgga taaaaactt 300
caattttatt ttttaactagc caatagttaa cccgcgcaaa tgaattttta gcttgaacct 360

```

taccgtcttt ttttaagcagc tcattagtta attcagacgc atacgtgggg atggattgag 420
aattaagcca ctctattccg cccgtgctgt cactatgaaa atgagaggaa atactgcctt 480
ttattttata gccacgttcc acaaaccaag tgactaactt ttcagtatct ttagccgtaa 540
atggagtgtc aattagataa gcttcagcat ctacaagaac aaccaaacca tgtttaggaa 600
caacgccccca cccgttaact tcttcaaacg aagtatgaac ataaacgcct tcatcaagtt 660
tttcaatttt taaatctggc aaagactctg ctgcggtagc aatgctacaa aacaaaaata 720
taaagaatac agataacttg ctcatactct tcctttttca at 762

<210> 172
<211> 897
<212> DNA
<213> Unknown

<220>
<223> CTX-M-15 sequence

<400> 172
accgttacaa accgtcgggtg acgatttttag ccgccgacgc taatacatcg cgacggccttt 60
ctgccttagg ttgaggctgg gtgaagtaag tgaccagaat cagcggcgca cgatcttttg 120
gccagatcac cgcatatcg ttggtggtgc catagccacc gctgccggtt ttatccccca 180
caaccagga agcaggcagt ccagcctgaa tgctcgctgc accggtggtta ttgcctttca 240
tccatgtcac cagctgcgcc cgttggctgt cgcctaatgc tttaccagc gtcagattcc 300
gcagagtttg cgccattgcc cgaggtgaag tggatcacg cggatcgccc ggaatggcgg 360
tgtttaacgt cggctcggta cggctcgagc ggaacgtttc gtctcccagc tgtcgggcga 420
acgcggtgac gctagccggg ccgccaacgt gagcaatcag cttattcatc gccacgttat 480
cgctgtactg tagcgcggcc gcgctaagct cagccagtga catcgtcca ttgacgtgct 540
tttccgcaat cggattatag ttaacaaggt cagatttttt gatctcaact cgctgattta 600
acagattcgg ttcgctttca cttttcttca gcaccgcggc cgcggccatc actttactgg 660
tgctgcacat cgcaaagcg tcatcagcac gataaagtat ttgcgaatta tctgctgtgt 720
taatcaatgc cacaccagc ctgcctcccg actgccgctc taattcggca agtttttgct 780
gtacgtccgc cgtttgcgca tacagcggca cacttcctaa caacagcgtg acggttgccg 840
tcgccatcag cgtgaactgg cgcagtgatt ttttaaccat actcttcctt tttcaat 897

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2007025097A \[0032\]](#)
- [WO2010075424A \[0032\]](#)
- [WO2012164565A \[0032\]](#)
- [GB1406674A \[0265\]](#)
- [GB1413719A \[0265\]](#)
- [GB1418508A \[0265\]](#)

Non-patent literature cited in the description

- **GRISSA et al.**BMC Informatics, 2007, vol. 8, 172- [0030]
- **HORVATHBARRANGOU**Science, 2010, vol. 327, 167-170 [0030]
- **GASIUNAS et al.**Proc. Natl Acad. Sci. USA, 2012, vol. 109, E2579- [0030]
- **MARRAFFINISONTHEIMER**Science, 2008, vol. 322, 1843-1845 [0030]
- **GARNEAU**Nature, 2010, vol. 468, 67- [0030]
- **SENGUPTAAUSTIN**Infect. Immun., 2011, vol. 79, 2502-2509 [0046]
- **Am J Epidemiol**, 2013, vol. 178, 4508-520 [0075]
- **Am J Epidemiol.**, 2013, vol. 178, 4508-520 [0075]
- **TSAI et al.**Nature Biotechnology, 2014, vol. 32, 569-576 [0075]
- **PROUDFOOT et al.**PLoS ONE, 2011, vol. 6, 4e19537- [0075]
- **FERRETTI et al.**PNAS, 2001, vol. 98, 84658-4663 [0078]
- **CAMPANELLA et al.**BMC Bioinformatics, 2003, vol. 4, 29- [0082]
- **NEEDLEMANWUNSCHJ.** Mol. Biol., 1970, vol. 48, 443-453 [0082]
- **ALTSCHUL et al.**J. Mol. Biol., 1990, vol. 215, 403-410 [0082]
- **LARKIN et al.**Bioinformatics, 2007, vol. 23, 2947-2948 [0082]
- **KRUSKAL**Time warps, string edits and macromolecules: the theory and practice of sequence comparison198300001-44 [0082]
- **PIEKAROWICZ et al.**J. Virol., 2014, vol. 88, 1002-1010 [0112]
- **JINEK et al.**Science, 2012, vol. 337, 816- [0131]
- **TENSON TVEGA-HERRERA JKLOSS PGUARNEROS GMANKIN ASJ.** Bacteriol., 1999, vol. 181, 1617-1622 [0143]
- **Nature**, 2011, vol. 471, 7340602-607 [0148]
- **GIBSON DG**Nature Methods, 2009, vol. 6, 343-345 [0155]
- **SAKA et al.**DNA Research, 2005, vol. 12, 63-68 [0172] [0257]
- **SAMBROOKRUSSELL**Molecular Cloning: A Laboratory Manual20010000 [0182]

P a t e n t k r a v

1. Indgivelsesvehikel til indføring af et polynukleotid i en antibiotikaresistent mikroorganisme, hvor indgivelsesvehiklen er udvalgt fra gruppen bestående af et plasmid (såsom et konjugativt plasmid eller andet plasmid-replikon), en nukleotidvektor, lineær dobbeltstrenget DNA, en ikke-virulent bakteriofag og en lysogen bakteriofag og omfatter en rekombinant polynukleotid til inaktivering af DNA, der bærer mindst et antibiotikaresistensgen, der koder for et enzym, som giver antibiotikaresistens til en mikroorganisme, hvor det rekombinante polynukleotid omfatter en CRISPR (clustered regularly interspaced short palindromic repeat)-array-nukleinsyresekvens, som har eller transkriberer multiple RNA-guidemolekyler, hvor hvert RNA-guidemolekyle:
- (i) er transkriberet fra sin egen promotersekvens;
 - (ii) medierer bindingen af et CRISPR-associeret (Cas) DNA-bindende polypeptid eller dets funktionelle ækvivalent eller dets modificerede version deraf til det mindst ene antibiotikaresistensgen; og
 - (iii) har en spacersekvens, der er tilstrækkeligt komplementær til en target-DNA-sekvens af det mindst ene antibiotikaresistensgen, til at det mindst ene antibiotikaresistensgen kan targeteres og inaktiveres i nærvær af et CRISPR-associeret (Cas) DNA-bindende polypeptid eller en funktionel ækvivalent eller en modificeret version deraf, og hvor:
enten det Cas DNA-bindende polypeptid eller en funktionel ækvivalent eller en modificeret version deraf er et modificeret Cas DNA-bindende polypeptid, som frembringer en deletion og genforsegler target-DNA-sekvensen til inaktivering af det mindst ene antibiotikaresistensgen til forhinding af dobbeltstrenget brud (DSB)-induceret drab af mikroorganismen, således at mikroorganismen bliver sensibiliseret over for et antibiotikum, eller
det Cas DNA-bindende polypeptid eller en funktionel ækvivalent eller en modificeret version deraf frembringer et DSB i target-DNA-sekvensen til inaktivering af det mindst ene antibiotikaresistensgen, og indgivelsesvehiklen yderligere omfatter en nukleotidsekvens, der koder for et genprodukt, som forhindrer direkte drab af mikroorganismen på grund af frembringelsen af DSB'et i det mindst ene antibiotikaresistensgen, således at mikroorganismen bliver sensibiliseret over for et antibiotikum.

- 5 **2.** Indgivelsesvehikel ifølge krav 1, yderligere omfattende en nukleinsyresekvens, der koder for det Cas DNA-bindende polypeptid eller dets funktionelle ækvivalent eller dets modificerede version.
- 10 **3.** Indgivelsesvehikel ifølge krav 1 eller krav 2, hvori det Cas DNA-bindende polypeptid er Cas9 eller en funktionel ækvivalent eller en modificeret version deraf.
- 15 **4.** Indgivelsesvehikel ifølge et hvilket som helst af de foregående krav, omfattende et yderligere RNA-guidemolekyle, som targeterer et gen, der er involveret i patogenicitet eller andre aspekter af mikrobiel metabolisme, f.eks. et gen, der er involveret i bakteriel metabolisme til biofilmproduktion.
- 20 **5.** Indgivelsesvehikel ifølge et hvilket som helst af de foregående krav, hvori det Cas DNA-bindende polypeptid omfatter et katalytisk rekombinasedomæne til genforsegling af target-DNA-sekvensen.
- 25 **6.** Indgivelsesvehikel ifølge et hvilket som helst af kravene 1 til 4, hvor genproduktet, som forhindrer direkte drab af mikroorganismen, er et protein, der kodes af et replikon, som er udsat for nedbrydning på grund af DSB'et forårsaget af det Cas DNA-bindende polypeptid eller et antitoksin, der neutraliserer virkningen af et toksin eller en dræberfunktion, der bæres af et replikon, hvorpå target-DNA-sekvensen befinder sig.
- 30 **7.** Indgivelsesvehikel ifølge et hvilket som helst af de foregående krav, hvori CRISPR-array-nukleinsyresekvensen har eller transkriberer et eller flere RNA-guidemolekyler, der hver omfatter en spacersekvens, der er tilstrækkeligt komplementær til en targetsekvens af et eller flere beta-lactamase-gener, f.eks. et eller flere af eller alle generne udvalgt fra gruppen bestående af: NDM, VIM, IMP, KPC, OXA, TEM, SHV, CTX, OKP, LEN, GES, MIR, ACT, ACC, CMY, LAT og FOX.

- 5 **8.** Sammensætning omfattende indgivelsesvehiklen ifølge et hvilket som helst af kravene 1 til 7.
- 5 **9.** Sammensætning ifølge krav 8, hvori sammensætningen er en farmaceutisk sammensætning, en ikke-patogen mikroorganisme, såsom en kommensal bakterie f.eks. i en probiotisk formulering, eller et kosttilskud.
- 10 **10.** Sammensætning ifølge krav 8 eller 9, formuleret til topisk, enteral eller parenteral indgivelse.
- 10 **11.** Sammensætning ifølge et hvilket som helst af kravene 8 til 10, til anvendelse som et medikament.
- 15 **12.** Sammensætning ifølge et hvilket som helst af kravene 8 til 11, til anvendelse ved behandling eller forebyggelse af en infektion forårsaget af en antibiotikaresistent mikroorganisme omfattende et eller flere antibiotikaresistensgener targeteret af RNA-guidemolekylerne af det rekombinante polynukleotid.
- 20 **13.** Fremgangsmåde til inaktivering af antibiotikaresistens i en antibiotikaresistent mikroorganisme, hvilken fremgangsmåde omfatter indføring i mikroorganismen af indgivelsesvehiklen ifølge et hvilket som helst af kravene 1 til 7.
- 25 **14.** Værtscelle omfattende det rekombinante polynukleotid ifølge et hvilket som helst af kravene 1 til 7.
- 25 **15.** Værtscelle ifølge krav 14, hvori værtscellen er en kommensal bakterie.




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6A




Fig. 6B




Fig. 7

CR05

SEQ ID No.		
1	2	3
5' C G A T A C G G G A G G G		
3' G C I A I G C C I C C C		
< C G A T A C G G G A G		
C	C G G G A G G G >	
G A T A C G G G A G >		
< G A T A C G G G A G G		
C G A T < G G A G G G		
C G	G G G >	
C G A T A C	G G	
C G A T >	< G G	
C G A T		
< C G A T A C G G		

CR30

SEQ ID No.		
663 664		
5' T G C T C A T C A T T G G A A A A C G		
3' A C G A G I A G I A A C C T T T G C		
T G C T	T C A T T G G A A A A C >	
T G C T C A T C A T >	< G A A A A C G	
< G C T C A T C A T T G	A A A C G	
< C T C A T C A T T G G A	< G	
< C T C A G C A T T G C A A A A C G		
T >	< T C A T C A T T G A A A A C	
T G C T >	T C A T T G G A A A A C >	
< T G C T C A T C A	G G A A A A C G >	
T G C T C A >	G G A A A A C G >	

CR70

SEQ ID No.		
286 287		
5' T C G C C A G I I A A I A G I I I G C		
3' A G C G G T C A A T T A T C A A A C G		
T C G C C A G T T A A >		
T C G C C A G T T A A T >		
< C G C C A G T T A A T		
< C G C C A G T T A A T		
C G C C A G T T A A T >		
C G C C A G T T A A T >		
< C G C C A G T T A A T A		
C G C C A G C T A A T A G T T >		
C C A G T T A A T A G >		
T A A T A G T T T G >		

CR90

SEQ ID No.		
640 641		
5' C C G C G C C A C A T A G C A G A A C T		
3' G G C G C G G T G T A T C G T C T T G A		
C C G	A C A T A G C A G A A >	
< C C G C G C C A C A < G C A G A A C T		
C G C G C C A C A T A >	< G A A C T	
< C G C G C C A C A T A G C	< A A C T	
< G C G C C A C A T A G	< A A C T	
C G C C A C A T A G C A >	A C T	
C C G C G C >	< A C A T A G C A G A A	
C C G C G C >	< A C A T A G C A G A A	
C C G C G C	C A T A G C A G A A C >	
< G C G C C A T A T A G C A G A A		

Fig. 8



Fig. 9

1 atgaatatttc aacatttccg tctggccctt attcccttt ttgggcatt ttgccttcc
 61 gttttttgc accagaaac gctggtgaaa gtaaaagatg ctgaagatca gttgggtgca
 121 cgagtgggtt acatcgaaact ggatctcaac agcggtaaga tcttgagag ttttcgcccc
 181 gaagaacgtt ttccatg*at gagc**actttt aaagttctgc t*atg**TGGcgc ggtattatcc
 241 cgtgttgacg ccgggcaaga gcaactcggg cgcgcatac actattctca gaatgacttg
 301 gttgagtact caccagtcac agaaaagcat cttacggatg gcattgacagt aagagaatta
 361 tgcagtgctg ccataaccat gagtgataac actgcggcca acttacttct gacaacgato
 421 ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt aactcgctt
 481 gatcgttggg aaccggagct gaatgaagcc ataccaaacg acgagcgtga caccacgatg
 541 cctgcagcaa tggcaaca**ac gtgcgc**aa**ctatt*aac**T GGcgaactact tactctagct
 601 tcccggaac aattaataga ctggatggag gcggataaag ttgcaggacc acttctgcgc
 661 tcggcccttc cggctggctg gtttatgtct gataaatctg gagccggtga gcgtgggtct
 721 cgcggtatca ttgcagcact ggggccagat ggtaagccct cc*cgtatcgt agttatctac
 781 acgacgggga gtcagggaac tatggatgaa cgaatagac agatcgctga gataagtgcc
 841 tcaatgatta agcattggta a

Fig. 10




Fig. 11




Fig. 12




Fig. 13





Fig. 14

**Fig. 15**

Class	Gene type	gene	Example of Required Spacers 5' to 3'	PAM	Penams	Amoxicillin																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
						e_Cephalosporin					Cefazolin																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																					
						Cephems porin	Cephems n_sporin	Cephems porin_i	Cephems sporin_ii	Cephems sporin_iii	Cephems Cepharmycin	Ceftazidime	Ertapenem	Carbapenem	Monobactam																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
A	bl2be _shv2	SHV-a	CCGCGTAGGCATGATAGAAA	TGG	R	R	R																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									

Fig. 16

Class	Gene type	gene	Example of Required Spacers 5' to 3'	PAM	Amoxicillin										Cephems				Aztreonam		
					Penams	e_Cephalo sporin				Cefazolin	Cephamycin	Ceftazidime	Ertapenem	Carbapenem	Monobactam						
						Cephems	Cephems	Cephems	Cephems							Cephems	Cephems				
A	b12be	SHV	GGATGCCGGTGACGAAC	TGG	R	R	R														R
A	b12be	CTXM	GCTACAGTACAGCGATA	TGG	R				R						R						R
A	b12be	CTXM	GACGTTGGCTCAGCTTA	TGG	R				R						R						R
A	b12	TEM	AACTACTTACTCTAGCT	CGG	R				R						R						R
A	b12	KPC	TTGTTGCTGAAGGAGTT	CGG	R				R						R						
A	b12a	OKP	AGCGAAAAACACCTTGC	CGG	R																
A	b12	LEN	ACCTTTAAAGTGCTGCT	CGG	R																
A	b1s	GES	TGGGTTGTTGGACAGAA	TGG	R				R						R						
B	b13	VIM	AAACACAGCGGCAC TTC	CGG	R				R						R						R
B	b13	IMP	AAAATTGAAGTTTTTTA	AGG	R				R						R						R
B	b13	NDM	GGTTTGATCGTCAGGGA	CG	R				R						R						R
C	b11	ACT	GTGGATTAAACGTTCCGA						R						R						R
C	b11	CMY	CAGCGACAGCAAAGTGG	TGG					R						R						R
C	b11	FOX	CTTGCCACCCTACAGTGC	TGG					R						R						R
D	b12d	OXA	CCCCCAAAGGAATGGAG	TGG	R																
D	b12d	OXA	CACCAAGTCTTTAAGTG	TGG	R																
D	b12d	OXA	ATAACGGCTTGACCCAG	TGG	R																

Fig. 17




Fig. 18




Fig. 19




Fig. 20

Class	Gene type	gene	Example of Required Spacer	PAM	Penams	Cephems	Cephems	Cephems	Cefazolin	Cephamsycin	Ceftazidime	Carbapenem	Monobactam
5' to 3'													
Amoxicillin													
A	b12be	SHV	CTGGGAAACGGAAC	AGG	R	R							R
		-a	TGAATG										
A	b12be	CTXM	ACGTTAAACACCGC	GGG	R				R	R	R		R
		-b	CATTCC										
A	b12	TEM	AAC TACTTACTCTA	CGG	R				R	R			R
		-f	GCTTCC										
A	b12	KPC	TTGTTGCTGAAGGA	CGG	R	R			R	R	R	R	
		-g	GTTGGG										
B	b13	VIM	AAACACAGCGGCAC	CGG	R	R			R	R	R	R	
		-a	TTC TCG										
B	b13	IMP	GGCTAGTTAAAAAT	AGG	R				R	R	R	R	
		-b	AAAATTGAAGTTT										
			TTATCC										
B	b13	NDM	GGTTTGATCGTCAG	CGG	R	R			R	R	R	R	
		-c	GGATGG										
D	b12	OXA	ATAACGGCTTGACC	TGG	R								
		-48	CAGTCA										

Fig. 21

Primer	Sequence 5' to 3'
NB018	ccaaaaactgagacctgctgctggacgtccaaaggctctcggttttagagctatgctggttttgaaatgggtccccaaaactttgcccga tgataacttgagaaaagagggttaataaccagcagtcggataaccttccctattcttttctgtttaaagcgtttttcattgattataat aggcaaatTTTAGATGAAGATTATTCTTAATAAC
NB019	TCtAAaACGAAGAGCGCTGCGTCCGAGACGCTCTTCaGTTTtGGGACCAATCaaaaCAGCATAGCTCTAAaACctcgtag a
NB026	GGGCTGGCAAGCCACGTTTGGTGGGTCtCgAAACGGTTTgATCGTCAGGGATGG
NB027	ggaataaaaaacttcaatttttatttttaactagccGTTTtGGGACCAATCaaaaCAGCATAGCTCTAAaACccatccctga cgatcaaaacc
NB028	GGCTAGTTAAAAATAAAAATTGAAGTTTtTATCCGTTTtTAGAGCTATGCTGTTTtGAAATGGTCCCCAAAAcAACACAGCG GCACTTCTCG
NB029	cccaactccttcagcaacaaGTTTtGGGACCAATCaaaaCAGCATAGCTCTAAaACcgagaagtgcgcgtgttt
NB030	TTGTTGCTGAAGAGTTGGGGTTTtTAGAGCTATGCTGTTTtGAAATGGTCCCCAAAAcGTCCATCCCCACTTAAAGACT
NB031	caattcagttccgtttcccagGTTTtGGGACCAATCaaaaCAGCATAGCTCTAAaACagtcctttaagtgggatggac
NB032	CTGGAAACGGAACTGAATGGTTTtTAGAGCTATGCTGTTTtGAAATGGTCCCCAAAAcACTACTTACTCTAGCTTCC
NB033	CCGGAGCTGCATGTGTCAGAGGggtctccaaaaCggaatggcgggtgtttaacgtGTTTtGGGACCATTCaaaaACAGCAT AGCTCTAAAAcggaaagctagagtaagtagtt
NB034	CCGGGAGCTGCATGTGTCAGAGGggtctccaaaaCcccaactccttcagcaacaaGTTTtGGGACCATTCaaaaACAGCAT AGCTCTAAAAcCgagaagtgcgcgtgtgttt
NB035	GGGCTGGCAAGCCACGTTTGGTGGCTCTTCAAACGTCCATCCCCACTTAAAGACT
NB036	CCGGGAGCTGCATGTGTCAGAGGggtcttcaaaaCggaatggcgggtgtttaacgtGTTTtGGGACCATTCaaaaACAGCAT AGCTCTAAAAcCGGAAGCTAGAGTAAGTAGTT

Fig. 22

pNB104A




Fig. 23

pNB104B




Fig. 24

pNB200




Fig. 26

pNB202




Fig. 27




Fig. 29A




Fig. 29B




Fig. 30A




Fig. 30B




Fig. 30C